AcronGenomics entwicklet SuperChips (Nano/Biotech) - 500 Beiträge pro Seite

[Inspektor_Clouseau]

Heute habe ich eine neue und, wie ich finde, hoch interessante Empfehlung erhalten vom HSt-K:

"Für eilige Leser
AcronGenomics Inc., OTC BB, Symbol: AGNM,
seit 2004 in Frankfurt unter WKN A0B9TS, Symbol: EQ9 gelistet,

hat mit der höchst innovativen Molecular Vision Ltd. eine ausgesprochen aussichtsreiche strategische Allianz geschmiedet, durch die revolutionäre und konkurrenzlose medizindiagnostische Geräte entwickelt und hergestellt werden sollen."

[Inspektor_Clouseau]

Als Kursziel werden 2,30 Euro ausgegeben auf Jahressicht!

[Inspektor_Clouseau]

Was den Wert so interessant macht, ist die Zusammenarbeit mit Molecular Vision.

Die haben einen neuen medizindiagnostischen Chip (POC) entwicklet zur "Sofortdiagnose von Diabetes, Geschlechtskrankheiten, kardiovaskulären Krankheiten (Herz und -Gefäße betreffende Kr.; Anm. d. Red.) und Drogenmissbrauch".

An der Spitze von Molecular Vision steht einer der renommiertesten Physiker der Welt: Prof. Donal Barney

[Inspektor_Clouseau]

Man muss den Namen einmal Googel: unglaublicher Typ.

Schaut mal hier: http://hcr3.isiknowledge.com/author.cgi?&link1=Browse&link2=…

[Inspektor_Clouseau]

"unter anderem Mitglied der Royal Society,
Leiter der physikalischen Abteilung der naturwissenschaftliche Fakultät des Imperial College,
Gewinner des Latsis-Preis für Nano-Technologie 2005 #
als auch im selben Jahr des Jan-Rajchman-Preis für seine Forschungen auf dem Gebiet des Flat Panel Displays (das ist ein Flachbildschirm wir etwa das TFT-Display eines Laptops; Anm. d. Red.)."

[Penny.Z]

Ja ein Super Wert !!!

Was schätzt du werden wir wie bei deinem Tiro Tip wieder 50 % verlieren oder werden es diesmal weniger???

[Inspektor_Clouseau]

Was ihn fpr AcronGenomics so interessant macht, ist seine Erfindung der BioLED-Technologie.


Ich finde, dass sieht auf den ersten Blick ziemlich kompliziert aus, scheint aber der Hit werden zu können.

So viele habe ich aber verstanden: dieser Chip, nicht größer als eine Checkkarte, ist ein medizinisches Diagnosegerät (Point-of-Care) "POC; Streifentests und Schnelltestgeräte etwa für Blutalkoholgehalt, Schwangerschaft, Diabetes usw.; Anm. d. Red."

[Inspektor_Clouseau]

Antwort auf Beitrag Nr.: 23.034.709 von Penny.Z am 25.07.06 10:02:41

StopLoss wird bei 1,10 Euro empfohlen!
Wer mehr verliert, ist selber Schuld

[Inspektor_Clouseau]

Die aktuelle Empfehlung macht auch keinen Hehl über die Risiken.
Finde ich gut.
Muss jeder, wie immer, selber entscheiden.

[Inspektor_Clouseau]

Ich schaue mir den Wert jedenfalls mal an

[Penny.Z]

Antwort auf Beitrag Nr.: 23.034.756 von Inspektor_Clouseau am 25.07.06 10:05:52

Ja sind dann ja nur 20 % Minus. Klar ist dann weniger als bei Tiro.

Ich kaufe so einen Dr... erst gar nicht denn dann kann ich auch nichts verlieren.

Falls du mal einen richtigen Tip hast der auch Kohle mal bringt anstatt nur Minus Bringer dann sag mir doch mal bescheid.
Alles was du bis Dato hattest waren Minus Bringer!!!

[Inspektor_Clouseau]

Antwort auf Beitrag Nr.: 23.034.822 von Penny.Z am 25.07.06 10:09:08

Was du nie verstehen wirst:

ich gebe hier keine Tipps ab, ich stelle zur kritischen Diskussion, was z.B. Börsenbriefe an Tipps abgeben.

Ich zwinge niemanden zu irgend etwas und bin nicht verantwortlich, wenn Kurse einbrechen.

Was willst du eigentlich von mir???

Tiro hat sich halbiert: na und. Ist doch mein Schaden, nicht deiner.

[trading2006]

sieht nicht übel aus, gehe mal auf die HP. solche schnelltests werden boomen, weil sie kosteneffizienter sind. man erinnere nur an die gesundheitsreform, unglaublich schlecht was unsere politiker da zustande bringen. wofür kriegen die ihr geld?!

[Inspektor_Clouseau]

Antwort auf Beitrag Nr.: 23.034.994 von trading2006 am 25.07.06 10:20:10

absolut!

Die HP ist übrigens klasse!
Da bleibt keine Frage offen (auch SEC-Filings)!

[Penny.Z]

Antwort auf Beitrag Nr.: 23.034.969 von Inspektor_Clouseau am 25.07.06 10:18:46

Dein Schaden ???

Nein hast ja bei über 90 Cent deine an die ??? gegeben.
Den Schaden haben die nun und nicht du.

Und wenn man deine ID anklickt und sich die Threads von dir so ansieht, sehe ich nur Minus Bringer. Du "pushst" immer einen Tag und dann "Tschüß".

Ein Schelm wer da böses denkt.

Also solltest nicht versuchen mich hier zu vera...... denn deine "Nummer" ist mehr als offensichtlich.

Wird hier nicht anderst laufen!!!

Ja Börsenbriefe, HAHAHA für welchen arbeitest du denn ???

[Inspektor_Clouseau]

Antwort auf Beitrag Nr.: 23.035.104 von Penny.Z am 25.07.06 10:26:59

Mein Lieber,
noch so eine wilde Unterstellung, und du fliegst hier raus.

[trading2006]

The global trend towards miniaturization of devices could not leave the Life Sciences sector unaffected. The bringing together of different technologies like microelectronics, optics, mechanics, physics and molecular biology along with the miniaturization of fluidic and sensing devices makes possible the development of fully integrated, miniaturized diagnostic systems.

Acrongenomics, Inc. and Molecular Vision, Ltd. introduce BioLED Technology, an innovative and patented combination of microfluidics with a state-of-the-art optical detection system based on pLED (polymer Light Emitting Diode) technology to deliver affordable, intelligent and readily portable Point-of-Care Medical Diagnostic devices. Science and technology team up to improve patients’ quality of life.

Our mission is to provide solutions for:

Faster and accurate diagnosis and treatment decisions
Reduced healthcare costs
Reduced visits to hospitals
Flexibility, versatility and reliability
Latest Events
June 8, 2006
Acrongenomics at Arch Investment Conference...


Latest News Releases
May 22, 2006
Acrongenomics Inc., signs a £3.45 Million (US $6.5 Million) Joint Development Agreement with Molecular Vision Ltd., to offer novel Point-Of-Care solutions through the unique BioLED technology.

[trading2006]

Corporate Profile

Acrongenomics, Inc. (OTCBB: AGNM) is a publicly traded company that focuses on investing and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, customer-orientated applications. The company has its international headquarters in Geneva, Switzerland.

As the global population escalates every year, medical providers are constantly seeking technologically advanced products and processes from diagnostics to treatment to monitoring patient diseases. We anticipate the technological changes we will inevitably encounter and strive to play an influential role in advancing medical technologies that will undoubtedly benefit the medical community around the world.

Acrongenomics is confident of its ability to satisfy its shareholders and employees by constantly evaluating its business strategy by collaborating with well-established research institutions and investing in innovative scientific projects, converting them into commercial opportunities.

[trading2006]

Vision and Goals

Acrongenomics' goal is to advance the Medical Diagnostics industry and accomplish industry-leading growth by establishing our technology platform worldwide. Through innovative and advanced medical diagnostic applications, we aim to provide the most efficient and sustainable means of delivering new value to the marketplace.

We are also committed to contribute to the human health and quality of life by exploring new scientific approaches and continuously considering:

Business
By sponsoring new innovative ideas and transforming them into commercial opportunities.

Social Welfare
By providing the market with superior technology designed to serve the common good.

Our People
By expanding our qualified team of business professionals to further support our technology pipeline.

Acrongenomics is dedicated to sustain a code of contact that is defined by a list of values like:

ACHIEVEMENT: We value the active pursuit of excellence, demonstrated by continuous improvement in standards, quality, speed and timeliness. Our collective ability to get results and accomplish our goals adds priceless value to the Company. We are committed to winning in today's competitive market.

INNOVATION: Innovation is fundamental for Acrongenomics’ success. We value creativity—the ability of people to develop new ways to identify opportunities and solve problems. We utilize our skills to search for and apply new technologies, approaches and business solutions which will contribute to the development of new diagnostic platforms.

INTEGRITY: At Acrongenomics we insist on applying the highest ethical standards and adherence to Company values. All employees have the responsibility to conduct their business relationships with the highest level of professionalism and integrity.

SCIENCE: We invest on ground-breaking technologies. We are committed to nurturing breakthrough technological platforms within our framework of focused strategic directions.

[trading2006]

Board of Directors

Constantine Poulios LL.M
President

Mr. Poulios, 36, was appointed to the Board of Directors as Vice President on July 7, 2004 and as President on February 14, 2006. He has extensive experience in serving multinational companies in the rigorous environment of the Sarbanes-Oxley legislation. An attorney by education and profession, he was part of the Corporate and Tax Advisory Services of Ernst & Young before joining Acrongenomics, Inc. Mr. Poulios was managing important accounts including that of Coca Cola, Halliburton, Hewlett Packard, ABN AMRO, Citigroup, Ciments Francais, Pfizer, GlaxoSmithKline and EMI Music for Ernst & Young Southeast Europe, while he has also worked for Ernst & Young LLP in the US. He obtained his Master's of Laws from Northwestern University School of Law in Chicago in 1997, while he is a 1995 graduate from the School of Law at the National University of Athens. Mr. Poulios has also been awarded with a Certificate in Law in 1993 from the School of Law at the University of Bordeaux in France and he has attended graduate courses in management from top US universities.


Platon Tzouvalis MSc
Vice President, Chief Operating Officer

Mr. Tzouvalis, 41, was appointed Vice President of Acrongenomics, Inc. on February 14th, 2006. As a Biochemist and ex-Abbott Laboratories Associate, he is an experienced pharmaceutical industry professional. He has been a member of Acrongenomics' Scientific Advisory Board since May 2004. His expertise lies in the areas of Quality Control, Operational Procedures as well as Pharmaceutical Product and Process Improvement. He received his B.Sc. Degree in Biochemistry from the University of Illinois in 1990 and his Master's Degree in the same field from DePaul University at Chicago in 1995. Mr. Tzouvalis' earlier career includes working as a Research Chemist in collaboration with the University of Illinois at Chicago, holding the position of Research and Development Chemist at SynQuest, Inc. and as Advanced Quality Assurance Specialist of Organic Operations and then Project Manager in Bioanalytical Quality Assurance for Abbott Laboratories. Mr. Tzouvalis has also been awarded with the Abbott Diagnostics Division Science Award of 2002 as part of the Organic Operation Remediation Team.


Ron Lizèe B.Comm. CGA. CFP
Chief Financial Officer

Mr. Lizèe, 52, was appointed Chief Financial Officer of Acrongenomics in 2004. Mr. Lizèe has over 25 years experience in the fields of tax, accounting and auditing.


Manos Topoglidis PhD
Chief Technology Officer

Dr. Topoglidis, 32, was appointed to the Board of Directors and Scientific Advisory Board on February 24, 2006 as Chief Technology Officer. He received his Bachelor’s of Science from King’s College (University of London) in 1996, his MSc in Biochemistry from Imperial College London in 1997 and his Ph.D. in Chemistry (Biosensors and Nanomaterials) from Imperial College London in 2001. His research interests and expertise lie in the areas of Biosensors, Nanomaterials, Biotechnology and Nanotechnology. He has worked as a research fellow at the Center of Electronic Materials and Devices of Imperial College London and as manager of European and National programs at the MESL laboratory of the National Centre for Scientific Research, Demokritos in Athens. He is a member of the Electrochemical and British Biochemical Societies. Dr. Topoglidis has impressive experience leading international research teams in academia to unlock nanotechnology solutions. He ranks among the first to extensively research the use of nanoporous surfaces for biosensing applications and has written numerous original nanotechnology-related publications, which have been cited worldwide.

[trading2006]

Scientific Advisory Board

Professor Donal Bradley is the head of the Physics Department at Imperial College London and enjoys an international reputation for his organic semiconductor research. He is the 3rd most cited scientist in the field of physical sciences. In 2005, he was awarded the prestigious Jan Rajchman Prize by the Society for Information Displays for outstanding scientific and technical research in the field of flat-panel displays. He also received the 2005 European Latsis Prize for Nano-Engineering, awarded by the European Science Foundation, for research on molecular-level control of the performance of organic semi-conducting materials and devices. This year he was a runner-up in the inaugural European Inventor of the Year Awards.

Professor Andrew de Mello is a professor of Chemical Nanosciences in the Department of Chemistry at Imperial College. He is a pioneer in the field of microfluidics. In 2002, he was awarded the SAC Silver Medal by the Royal Society of Chemistry for his contribution to the Analytical Sciences.

Dr. John de Mello is a senior lecturer in nanomaterials in the Department of Chemistry at Imperial College. His primary research interests include organic semiconductors, miniaturized devices for chemical and biological diagnostics, and intelligent synthesis techniques for the controlled production of nanoparticles. He serves on the Editorial Boards of Chemical Society Reviews and the Journal of Experimental Nanoscience.

Mr. Platon Tzouvalis MSc was appointed Vice President of Acrongenomics, Inc. on February 14th, 2006. As a Biochemist and ex-Abbott Laboratories Associate, he is an experienced pharmaceutical industry professional. He has been a member of Acrongenomics' Scientific Advisory Board since May 2004. His expertise lies in the areas of Quality Control, Operational Procedures as well as Medical Devices, Pharmaceutical Product and Process Improvement.

Dr. Manos Topoglidis was appointed to the Board of Directors and Scientific Advisory Board on February 23rd 2006 as Chief Technology Officer. His research interests and expertise lie in the areas of Biosensors, Nanomaterials, Biotechnology and Nanotechnology. Dr. Topoglidis has 15 scientific publications during his 8 years of research and has presented his work in 10 U.S./international conferences.

[trading2006]

Strategic Alliances

Acrongenomics utilizes its extensive international network and qualified management team to scout out and invest in dynamic research projects. To that extent Acrongenomics has established a Strategic Alliance with the UK based Molecular Vision Ltd.

Molecular Vision is a spin-out company of Imperial Innovations Ltd. The company was founded in 2002 in order to meet a clearly defined demand in the medical diagnostics, biosensors and analytical instrumentations markets: the need for miniaturized chemical and biological detectors offering high sensitivity and functionality at low cost. The company has directly addressed this market demand by inventing a novel method for optical detection based on recent advances in organic electronics and light emitting diodes combined with microfluidics technology. The company has mainly focused on applying its technology to the medical diagnostics markets.

[trading2006]

BioLED Technology

Terms like Lab-On-a-Chip (LOC), Point-of-Care (POC) testing and miniaturized Total Analysis Systems (μTAS) describe the same concept; specialized, light weight, readily portable and easy to use devices, designed to perform complex biological tests at the site where they are most needed. These tests normally require specialized laboratories equipped with bulky and expensive instruments. POC testing constitutes a “stand alone” new market with impressive growth potential that may/or may not complement the already established laboratory testing. The main market driving force is the enhanced portability and networking capabilities that lead to improved patient’s quality of life and increased independence from organized healthcare facilities.

So far, the realization of readily portable diagnostic devices for POC testing has been hampered by the lack of suitable miniaturized, low-power consumption, optical detection systems.

Low cost, organic semiconductor polymers with tunable optical properties is the answer provided by Acrongenomics and Molecular Vision. Optical detection is provided by polymer Light Emitting Diodes (pLEDs) which are fully compatible with microfluidic chip technology. The combination of the two technologies is used for the development of a "readily portable" microfluidic and pLED platform (BioLED technology) that is initially applied to the development of POC microchips for the quantitative and qualitative analysis of medical conditions with high sensitivity and functionality at low cost.

Acrongenomics’ and Molecular Vision’s BioLED technology operates with two interdependent components that combine to form a Lab-On-a-Chip cartridge:

Microfluidics - Processing and Reaction component
pLED (polymer Light Emitting Diode) - Detection Component

Microfluidics Integration on a monolithic chip pLED

How does it work?

Under electrical excitation the polymer emits light via radiative combination of injected electrons and holes and therefore may be used as a light source. The same structure can then be used in reverse as a photodetector by illuminating the polymer in order to generate a measurable electrical current.

The reagents of an assay will be mixed with the body fluid through the microfluidic network. The resulting mixture will be excited by the integrated, battery driven pLED and the resulting light-signal will be detected by the integrated photodetector which will generate an electrical current (electronic readout).


Schematic of pLED and photodetector integrated into microfluidic chip

We endeavor to possess a strong market position since our novel and patented technology does not face any immediate competition.

BioLED technology's prototypes will consist of a Lab-On-a-Chip cartridge and an (optional) commercially available PDA (Personal Digital Assistant) data collector. Two configurations will be offered:

The chip will plug into a PDA which will supply the power needed, display the result on screen and offer data management and enhanced networking possibilities (ideal for hospital + physician's office use).
Fully autonomous chips that do not require a PDA, with an integrated display and powered by lithium button batteries (ideal for a home-care environment).
Technology Advantages

BioLED Technology
Meets Market Requirements

Market Demands…
We provide…

Fast, Unambiguous diagnosis
Electronic readout gives clear answer in 2-3 minutes. Quantitative and qualitative analysis with accuracy comparable to standard lab tests. Data management and networking possibilities.

Miniaturized analysis of complex materials (blood, urine and saliva)
Microfluidics are designed to handle drops of such materials. Detection at the submicromolar level, aiming to increase sensitivity to picomolar levels.

Multiple testing
Ability to run multiple diagnostic tests on the same microchip at marginal additional cost compared to a single-test microchip.

Low unit cost
Components manufactured by in-house printing technologies; total cost of each microchip < $1

Ease of use
Simple device; no expert personnel required; ideal as over the counter (OTC) product.

Miniaturized biochemical reactors
Technology platform with potential applications that go beyond POC devices.


References

Lab Chip, 2005, 5, 863-868.
Lab Chip, 2004, 4, 136-140
Sensors and Actuators B, 2005, 106, 878-884.

[trading2006]

Current - POC Diagnostics

Following a primary market research, a number of potential POC diagnostic device applications were evaluated in terms of feasibility, market needs, revenue generating potential, market growth rate and competition. Among these, four disease areas were chosen to be our primary targets for BioLED device development. These POC devices will enable on-the-spot quantitative and qualitative diagnosis from a few drops of blood, urine or saliva for:

Diabetes Management (Kidney Markers):
The prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030 (Global Prevalence of Diabetes. Diabetes Care 27:1047-1053, 2004). Microalbuminuria (MAU), a well known diabetic nephropathy marker, is defined by increased urinary Human Serum Albumin (HSA) excretion. If diagnosed at an early stage, MAU can be treated before its progression to the development of diabetic nephropathy (kidney failure). Approximately 25 – 30% of all diabetics develop evidence of nephropathy.

Sexually Transmitted Diseases (STDs):
STDs remain a major public health challenge in both developed and developing countries. According to the World Health Organization (WHO), more than 340 million new cases of sexually transmitted infections occur every year, worldwide, in people aged 15-49 years.
These infections can be a major cause of illness, infertility and even death. Most of them, however, can be treated and cured easily and with low cost, if diagnosed early enough.

Cardiovascular Diseases (Cardiac Markers):
Cardiovascular diseases are responsible for the deaths of 17 milion people worldwide each year, making them the developed world’s leading cause of death according to the World Health Organization. 32 million heart attacks and strokes per year demonstrate the need for the development of accurate, cost efficient and accessible diagnostics. Conventional diagnostic techniques, however, are costly, time consuming and of limited predictive potential. A smarter diagnostic approach is the in vitro measurement of various cardiac biomarkers of high preventive value, using a POC device.

Substances of Abuse:
According to the World Drug Report 2005, 5% of the global population have consumed illicit drugs at least once in the last 12 months. This number (about 200 million people) illustrates the severity of substance abuse as a major healthcare and socioeconomic problem. Diagnosis of substances of abuse is imperative to the judicial system, professional, professional sports, large corporations and healthcare. Easy, fast, simple and on-site diagnosis has considerable commercial value and huge revenue generating potential.

[trading2006]

Future

BioLED Technology has the potential for the development of a vast spectrum of applications that may include:

Pharmaceutics
Drug discovery, drug testing (high throughput screening)
Environmental technology
Soil (also agriculture), water and air quality measurements
Veterinary Medicine
Early disease detection in animals and location of the source of pathogens of public health threats such as mad cow disease and avian flu
Biodefense - Homeland Security
Portable devices which sample the air for biowarfare agents e.g. anthrax spores etc.
Forensics
Automated processing of crime scene forensic evidence
Food industry
Food diagnostics, packaging (smart sensors), functional food testing

[trading2006]

What is Microfluidics?

Microfluidics refers to a set of technologies that control the flow of minute amounts of liquids or gases- typically measured in nano- and picoliters- in a miniaturized system. Designed in the nanometer scale, microfluidic chips incorporate pumps, valves, microchambers and microchannels (usually less than 100 nanometers wide) that direct samples from one compartment to the next on the chip.

Although the laws of physics do not change, as the scale at which fluids are studied decreases the effects driving and controlling fluid motion changes radically. This is because properties such as surface forces, surface tension, capillary effect, electronic charges, heat and mass transfer become dominant altering the system’s behavior dramatically. Microfluidics not only enable the very precise manipulation of minute amounts of fluids but may perform functions such as mixing, separating handling different components efficiently, rapidly and with little human intervention.

"Microfluidics is one of the 10 technologies
that will change the world"
(Microfluidics Technologies, BCC, March 2004)

Contrary to microelectronics, where miniaturization is achieved mainly by reducing in the size of the transistors, microfluidic devices require construction and design that differ from macroscale devices. More complex systems of channels with more sophisticated fluid-handling capabilities are necessary.

The advantages of such systems include:

Reduced size of devices ("readily portable" microfluidic chips)
Reduced fabrication cost.
Efficient use of expensive reagents.
Reduced volumes of rare samples.
Low fabrication cost allows disposability of the chips.
Multifuncionality and speed.
Ease of use and enhanced safety.
Precise volumetric control of samples and reagents leading to higher sensitivities in analytical applications.
High throughput biological screening made possible by faster sampling times through parallel processing of samples.
Low power consumption.
Can be combined or integrated with other systems like MEMS (Micro-Electro-Mechanical Systems), NEMS (Nano-Electro-Mechanical Systems) to produce highly efficient μTAS (Miniaturized Total Analysis Systems), LOC (Lab-On-a-Chip) or POC (Point-of-Care) devices to form portable "all-in-one" devices able to perform complex functions.
Applications

"As the number of experiments has grown, the devices used to carry them out have shrunk, and the strategy of "smaller is better" has begun to transform the world of fluidics as it transformed the world of electronics."
(G. Whitesides, Mallinckrodt Professor of Chemistry and Chemical Biology at Harvard University -The Industrial Physicist, Aug/Sept 2003)

Microfluidics, due to recent advances in fluidics, microelectronics and integrated system technologies has penetrated to a number of diverse markets including printing, industrial automation, power management systems and life sciences.

The Life Science segment of the microfluidics market demonstrates the largest and fastest growth rate and is divided into:

Drug Discovery (Combinatorial Chemistry, High Throughput Screening, Quality Control)
Medicine (Diagnostics, Therapeutics)
Biotechnology (Genomics, Proteomics, Cell Sorting and counting)
Ecology (Food, Air/Water)
Microfluidics delivers advanced flexibility. A conventional diagnostic test follows a protocol that involves a series of processes and utilizes a number of bulky and expensive instruments that may take up the space of an entire bench. Moreover, specialized laboratory technicians are needed to perform the test.

A microfluidics-based assay can perform the same diagnostic test in a space smaller than the size of a credit card, requiring minimum human intervention. The advantages of such systems are the reason for the continuous penetration of microfluidics in markets that were traditionally driven by other technologies.

Links:
MIFLUS – Microfluidics Terminology Tree

References:

"A New Wave of Microfluidic Devices" by Jennifer Ouellette, The Industrial Physicist, August/September 2003.
Global Watch Technology Partnering, Information Technology, Electronics & Communications Sector Report (November 2005)
"Microfluidics", P. Kallio and J. Kuncova, TEKES, National Technology Agency, Technological Review 158/2004.

[trading2006]

What is pLED

Successful Point-Of-Care (POC) device design has to incorporate 2 major components. A reaction component, responsible for the chemical/biological reactions of an assay and a detection component, that will sense and report the outcome of the assay. The development of novel optical detection techniques are crucial in modern day chemical and biological analysis due to a recognised need for rapid, on-line measurements at low concentrations in fields such as chemical production, DNA analysis, drug discovery, pharmaceutical screening medical diagnostics and environmental analysis.

A Light-Emitting Diode (LED) is a semiconductor device that emits light under electrical excitation. This phenomenon is called electroluminescence. The color of the emitted light is determined by the chemical composition of the semi-conducting material used, and may therefore be controlled using standard synthetic chemistry. If the light-emitting semi-conducting layer material of a LED is organic then the device is known as Organic Light Emitting Diode (OLED). The OLED’s emitting material can be small organic molecules in crystalline phase or flexible polymers (plastics), which are basically long chains of organic molecules. Such LEDs are known as polymer LEDs or pLEDs.

A typical OLED or pLED consists of one or more organic layers sandwiched between two electrodes. Application of an electric field between these two electrodes results in emission of light from the organic layers. At the same time, the organic layers can generate a measurable current when illuminated; therefore, OLEDs and pLEDs exhibit dual functionality (photoemittors and photodetectors).

OLED Technologies
There are currently 3 OLED technologies:

Light Emitting Polymers have been the subject of intense scientific and commercial interest since their discovery in 1990 by Molecular Vision co-founder Professor Donal Bradley and his colleagues (Dr Jeremy Burroughes and Professor Richard Friend) at the Cambridge University Cavendish Laboratory. The emissive materials can be applied on the substrate by a technique derived from inkjet printing making manufacturing flexible and inexpensive. Light Emitting Polymers are set to revolutionize the display market, allowing for wafer-thin television and computer screens at very low cost. The diagnostics market represents a new and important application of this disruptive technology.
Small Molecule OLED technology was developed by Easman-Kodak, usually referred to as "small-molecule" OLED or SM-OLED. The production of this type of devices requires vacuum deposition making manufacturing expensive and inflexible.
A third hybrid light emitting layer technology has been developed recently. This technology uses nonconductive polymers doped with light-emitting, conductive molecules.
Applications

To date, interest in semi-conducting polymers has been driven primarily by their applications in thin film displays and – to a lesser extent – as solar cells and transistors. One of the great benefits of OLED displays compared to traditional LCD displays is that OLEDs do not require a backlight to function. This means that they draw far less power and, when powered from a battery can operate longer on the same charge. However the favourable processing properties of polymeric semiconductors make them highly attractive for a broad range of additional applications.

Owing to their simple design, OLEDs have great potential for integration into microfluidic systems at marginal additional costs delivering state-of-the-art and inexpensive POC devices. The integration of such sensing systems within microfluidic devices is the area of particular interest for Acrongenomics and Molecular Vision.

References:

O. Hofmann et al, Sens. Act. B, 2004, in press.
J.B. Edel et al, Lab Chip, 2004, 4, 13

[trading2006]

What is POC/LOC?

The new trends in healthcare dictate the provision of laboratory testing at the point where patient care is rendered or what is commonly called Point-Of-Care (POC) testing. Initially, diagnostic tests used to require well organized laboratory facilities, staffed with experienced personnel. Over the past few years, however, technological advances have driven the development of Lab-On-a-Chip (LOC) technology and POC testing which in turn have revolutionised the way medical diagnostic tests are performed. New technological attributes have added speed, simplicity, automation and accessibility to the in vitro diagnostics sector. Large and expensive laboratory facilities, well trained personnel and time consuming procedures are no longer necessary.

LOC technology involves the performance of complex biological functions on a very small chip-like device, able to perform automated biological protocols with minimal human intervention. This technology has been implemented in both laboratory testing instrumentation and POC testing devices.

As the POC testing market evolves two main types of technology have been adopted:

a) Small bench top analysers (e.g., blood gas and electrolyte systems) and
b) Hand held devices, usually accompanied by disposable cassettes, cartridges or sticks.

Both types exhibit significant advantages over laboratory testing. The bench top systems are smaller versions of laboratory analysers in which vulnerable operator dependent steps have been automated. Hand held devices (internally complex devices) have been developed using microfabrication techniques, which makes medical testing more immediate and accessible even for less ideal situations.

The benefits of POC testing can be assessed in terms of the benefit to the diagnostic and/or treatment outcome, as well as the economic outcome. Some examples benefits to the clinical outcome are the faster treatment decision making, improved adherence to treatment, reduce incidence of complications, quicker optimization of treatment and patient satisfaction. The economic benefits involve reduced number of clinic visits and hospitalisation, earlier discharge from hospital, better optimized drug treatment, less inappropriate use of drugs, reduced requirements in staff, equipment and estate and improved quality of life.

References:

Christopher P Price, Regular review: “Point of care testing”, Volume 322, 26 May 2001
American Society for Clinical Laboratory Science, “Point of Care Testing”

[trading2006]

Targeted Diseases
Diabetes

Diabetes mellitus (DM) is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin secretion, insulin action, or both. Diabetes can be associated with serious complications, such as:

Cardiovascular disease- a major complication and the leading cause of premature death among people with diabetes (about 75 percent of people with diabetes die from heart disease or stroke).
Kidney disease- also called Nephropathy is a condition that affects one-third or more of people who have had Type 1 (juvenile) diabetes for at least 20 years. About 10 to 40 percent of people with Type 2 (adult onset) diabetes also have kidney disease.
Blindness- diabetes is a major cause of blindness in the U.S. Diabetic retinopathy alone accounts for at least 12 percent of new cases of blindness each year in the U.S. People with diabetes are 25 times more at risk for blindness than the general population.
Nervous system disease- around 60 to 70 percent of diabetics have some type of nervous system damage or neuropathy, which includes decrease sensation in feet or hands, slowed digestion in the stomach, or carpal tunnel syndrome.
Dental disease- almost one third of people with diabetes has severe periodontal or gum diseases with loss of attachment of the gums to the teeth measuring 5 millimeters or more.
There are currently more than 194 million people with diabetes worldwide according to the World Health Organization (WHO). The National Information Clearinghouse estimates that DM costs the United States US$132 billion every year.

Sexually Transmitted Diseases (STDs)

Sexually transmitted diseases (STDs) -also called Sexually Transmitted Infections (STIs) - are a major global cause of acute illness, infertility, long term disability and death, with severe medical and psychological consequences for millions of men, women and children. The general term sexually transmitted disease (STD) is applied to any of the group of diseases that can be spread by sexual contact. STDs are caused by viruses, bacteria and parasites. There are at least 25 different STDs. The most common ones are the Acquired Immune Deficiency Syndrome (AIDS), Herpes Virus, Chlamydia, Syphilis, Human Papillomavirus (HPV), Hepatitis and Gonorrhea. The Medical Institute for Sexual Health in Texas estimates that 1 in 5 Americans between the ages of 15 and 55 are currently infected with one or more STDs, and 12 million Americans are newly infected each year. Also, the World Health Organization (WHO) states that in developing countries, STDs and their complications are amongst the top five disease categories for which adults seek health care. Direct medical costs associated with STDs in the United States are estimated at US$ 13 billion annually.

Cardiovascular disease

Cardiovascular disease (CVD) refers to diseases of the heart and blood vessel system (arteries, capillaries, veins). CVD claims more lives each year that the next 4 leading causes of deaths combined, which are cancer, chronic lowers respiratory diseases, accidents and diabetes mellitus. According to the World Health Organization (WHO), 16.7 million of people around the globe die of CVD each year. This is over 29 percent of all deaths globally. Today, men, women and children are at risk, and 80 percent of the burden is in low- and middle income countries. It is estimated that by 2010, CVD will be the leading cause of death in developing countries, whereas by 2020 heart diseases and strokes will be the leading cause of death and disability worldwide, increasing fatalities to more than 20 million yearly and to more than 24 million by 2030. (Atlas of Heart Disease and Stroke, WHO, September 2004). In U.S. the direct and indirect cost of CVD for 2006 is estimated to be US$ 403.1 billion, according to the American Social Health Association.

Drug abuse

Drug abuse refers to the use of illegal drugs or the inappropriate use of legal drugs. There are many reasons for drug abuse, including producing pleasure, alleviating stress, altering or avoiding reality. The negative impacts of the illicit drug trade touch every society in the world. This year's World Drug Report estimates that 200 million people, or 5% of the global population age 15-64, have consumed illicit drugs at least once in the last 12 months. The medical cost of drug abuse was estimated by the National Centre for Health Statistics to be nearly $60 billion worldwide.

[trading2006]

Financial Information

AUDITORS
Amisano Hanson · Vancouver BC
LEGAL COUNSEL
Clark Wilson LLP, Vancouver, Canada
BANKERS
HSBC Bank Canada · Calgary, Alberta
REGISTRAR AND TRANSFER AGENT
Pacific Stock Transfer Company · Las Vegas, Nevada
STOCK EXCHANGE LISTING
AGNM · OTCBB
EQ9.F · Deutsche Borse AG
FULLY DILUTED
13,722,536 (As of April 13th 2005)
PRICE RANGE 52 WEEK
AGNM · OTCBB $ 2.40 - $ 6.16
EQ9.F · Deutsche Borse AG €2.08 - €4.80



SEC Filings

Fiscal Year 2006

Form 10 K Annual Report n/a
10 Q (3) Report n/a
10 Q (2) Report n/a
10 Q (1) Report

Fiscal Year 2005

Form 10 K Annual Report
10 Q (3) Report
10 Q (2) Report
10 Q (1) Report
Fiscal Year 2004

Form 10 K Annual Report
10 Q (3) Report
10 Q (2) Report
10 Q (1) Report
Fiscal Year 2003

Form 10 K Annual Report

[trading2006]

News Releases

22 05 2006 Acrongenomics Inc., signs a £3.45 Million (US $6.5 Million) Joint Development Agreement with Molecular Vision Ltd., to offer novel Point-Of-Care solutions through the unique BioLED technology.
29 03 2006 Acrongenomics Inc. Enters Into Memorandum of Understanding with Molecular Vision, an Imperial Innovations Spin-Out Company
24 02 2006 Acrongenomics, Inc. Appoints Chief Technology Officer
14 02 2006 Acrongenomics Inc. Explores Novel 'Nanoweapons' in Eliminating Hospital-Related Infections
22 12 2005 Acrongenomics, Inc. Announces Closing of $4,000,000 Private Placement to Fund Ongoing Operations

[trading2006]

Contact

14 Rue Kleberg
CH-1201
Geneva, Switzerland
Tel: [phone]
Fax: [phone]
[e-mail] Contact Person:
Angela Vernadaki
Business Development
US Toll Free - 1-800-689 8181

[trading2006]

hab mir mal einige sachen durchgelesen, oder eher gesagt, überflogen, ist einfach zuviel. die haben da ein tolles produkt, welches eine schnelle diagnose kostengünstig ermöglicht. das spart jede menge geld im gesundheitssystem

[trading2006]

http://www.acrongen.com/index.html

die hp ist klasse, sehr professionell. werde den wert mal beobachten

[trading2006]

24.07.2006 1,80 1,89 1,80 1,89 82
21.07.2006 1,90 1,90 1,90 1,90 71
20.07.2006 2,00 2,00 2,00 2,00 5
19.07.2006 2,00 2,00 2,00 2,00 5
18.07.2006 1,95 2,05 1,95 2,05 105
17.07.2006 1,90 1,95 1,95 1,95 3.5k
14.07.2006 1,90 1,95 1,80 1,95 3.5k
13.07.2006 2,05 2,05 1,88 1,95 82
12.07.2006 1,85 2,16 1,85 2,00 28
11.07.2006 2,02 2,03 1,90 2,00 108
10.07.2006 2,00 2,00 1,80 2,00 11.9k
07.07.2006 2,25 2,25 2,10 2,15 60
06.07.2006 2,20 2,38 2,20 2,38 2.3k
05.07.2006 2,30 2,40 2,25 2,35 51
04.07.2006 2,45 2,45 2,31 2,40 2.1k
03.07.2006 2,45 2,45 2,31 2,40 2.1k
30.06.2006 2,22 2,40 2,22 2,40 77
29.06.2006 2,22 2,30 2,22 2,30 26
28.06.2006 2,39 2,45 2,30 2,30 11.4k

[trading2006]

24.07.2006 1,52 1,52 1,41 1,41 2.0k
21.07.2006 1,52 1,52 1,52 1,52 0
20.07.2006 1,53 1,53 1,53 1,53 0
19.07.2006 1,58 1,58 1,58 1,58 0
18.07.2006 1,50 1,50 1,50 1,50 0
17.07.2006 1,49 1,49 1,49 1,49 0
14.07.2006 1,48 1,48 1,48 1,48 0
13.07.2006 1,52 1,52 1,52 1,52 0
12.07.2006 1,51 1,51 1,51 1,51 0
11.07.2006 1,51 1,51 1,51 1,51 0
10.07.2006 1,62 1,62 1,62 1,62 0
07.07.2006 1,80 1,80 1,80 1,80 0
06.07.2006 1,78 1,78 1,78 1,78 0
05.07.2006 1,80 1,80 1,80 1,80 0
04.07.2006 1,81 1,81 1,81 1,81 0
03.07.2006 1,80 1,80 1,80 1,80 0
30.06.2006 1,74 1,74 1,74 1,74 250
29.06.2006 1,77 1,87 1,77 1,87 1.5k
28.06.2006 1,84 1,84 1,84 1,84 0

deutschland

[trading2006]

umsatz mau, entweder es kommt jetzt durch die empfehlung dauerhaft mehr umsatz rein oder das wird nix

[trading2006]

Börse
Frankfurt

Aktuell
1,44 EUR

Zeit
25.07.06 09:00

Diff. Vortag
+2,13 %

Tages-Vol.
--

Gehandelte Stück
0

Geld
1,44

Brief
1,55

Zeit
25.07.06 09:00

Spread
--

Geld Stk.
695

Brief Stk.
695

[trading2006]

Börse
Berlin-Bremen

Aktuell
1,49 EUR

Zeit
25.07.06 09:09

Diff. Vortag
+4,20 %

Tages-Vol.
--

Gehandelte Stück
0

Geld
1,42

Brief
1,57

Zeit
25.07.06 09:09

Spread
9,55%

Geld Stk.
--

Brief Stk.
--

[trading2006]

mit der entwicklung sollen sogar drogentests möglich sein, das wäre interessant für die polizei z.b. oder den sportlichen bereich. nebenbei natürlich viele volkskrankheiten wie diabetes, welche immer weiter voran schreitet.

[trading2006]

sl setzen ist bei so einem engen wert sinnvoll, aber ncht zu eng

[trading2006]

Wertpapiertyp
Auslandsaktie

Marktsegment
Freiverkehr

Branche
--

Geschäftsjahr
--

Marktkapital.
20,60 Mio. EUR

Streubesitz
--

Nennwert
--

Stücke
14 Mio.

Symbol
EQ9.BER

ISIN
--

WKN
A0B9TS

[Penny.Z]

Antwort auf Beitrag Nr.: 23.035.126 von Inspektor_Clouseau am 25.07.06 10:28:15

Wer hier raus fliegen sollte das lasse ich mal dahin gestellt.

[trading2006]

sehe gerade die empfehlung oben. einige wissen irgendwie immer wann gerade was kommt.

[trading2006]

Ihre Chance
AcronGenomics, gegründet 2004 und ehemals selbst ein innovatives Hightechunternehmen aus dem Nanotech-Bereich mit jetzigem Hauptsitz in Genf (Schweiz), versteht sich nunmehr als ein Unternehmen, das sich auf die Finanzierung und Kommerzialisieren neuartiger Technologien im medizinischen Bereich konzentriert. Am 22. Mai 2006 hat man deshalb ein Joint Development Agreement mit Molecular Vision Ltd. im Wert von 6.5 Mio. US$ geschlossen, um medizindiagnostische Produkte basierend auf der sog. BioLED-Technologie, einer Kombination aus Nano- und Biotechnologie, gemeinsam zu entwickeln und zu kommerzialisieren.

Sitz in der Schweiz, das ist schonmal gut

[trading2006]

Was ist die BioLED-Technologie? Die BioLED-Technologie bezeichnet das gleiche Konzept wie Lab-On-a-Chip (LOC; Labor auf dem Chip, d.h. vollständige analytische Prozesse von Probenvorbereitung bis zur Auswertung sind auf einem scheckkartengroßen (Computer)Chip integriert, Anm. D. Red.), Point-of-Care (POC; Streifentests und Schnelltestgeräte etwa für Blutalkoholgehalt, Schwangerschaft, Diabetes usw.; Anm. D. Red.) und „miniaturized Total Analysis Systems“ (μTAS; miniaturisierte Komplettanalysesysteme; Anm. d. Red.). Die BioLED ist eine vollkommen neuartige Technologie, bei der durch die patentierte Kombination der Mikroströmungslehre (engl. microfluidics, das Strömungsverhalten von Flüssigkeiten in kleinsten Mengen; Anm. d. Red.) mit optischen Detektoren, basierend auf der organischen pLED (polymer Light Emitting Diode), eine Vielzahl von miniaturisierten tragbaren POC-Diagnose-geräten realisiert werden könne, die das Potential dazu hätten, medizinische Standarttests zu werden.

[trading2006]

Nach Angaben von AcronGenomics ist diese Technologie konkurrenzlos. Man ist bestrebt, zukünftig zwei Versionen dieses Chips anzubieten: einmal als Chip, der mit einem handelsüblichen PDA (Personal Digital Assistant) verbunden werden kann, wie sie schon heute zum Beispiel in Krankenhäusern und Arztpraxen eingesetzt werden, und einmal als eine Version, die ohne PDA, stattdessen aber mit Hilfe eines eingebauten minaturisierten LCD-Displays ausgelesen werden kann, was das POC-Gerät auch für den privaten häuslichen Einsatz kostengünstig einsetzbar machen würde.

sehr interessant, so erreicht man auch den endkunden direkt, also die breite masse, was höhere umsätze verspricht

[trading2006]

Fazit
Trotz des bilanziellen Defizits und der erst kurzfristigen geschäftlichen Umorientierung von AcronGenomics erscheint uns das Papier aus folgenden Gründen dennoch als ein hoch interessantes und spekulatives Investment:


Durch die Zusammenarbeit mit Molecular Vision eröffnet sich die Möglichkeit einer sehr engen und Erfolg versprechenden Zusammenarbeit mit höchst renommierten und innovativen Wissenschaftlern – vor allem mit Donal Barney und seinem Team), aus der
höchst innovative Produkte hervorgehen könnten, die auf
einem insgesamt auch zukünftig boomender Mega-Markt für Medizintechnik konkurrenzlos sein könnten.
Aus charttechnischer Sicht könnte sich das Papier in einer Bodenbildungsphase befinden.

[trading2006]

ob hier jemand einsteigt, muss jeder selber entscheiden. fakt ist, das dieser wert sehr markteng ist. es kann schnell rauf gehen, aber auch runter. wenn das teil jemand kauft, dann mit kleinem einsatz und liegen lassen. die technik hat beste aussichten ein blockbuster zu werden, fragt sich nur in welchem zeitraum

[trading2006]

http://www.acrongen.com/index.html

die hp ist auf jeden fall sehr schön gestaltet.

[trading2006]

Börse
Frankfurt

Aktuell
1,44 EUR

Zeit
25.07.06 09:00

Diff. Vortag
+2,13 %

Tages-Vol.
--

Gehandelte Stück
0

Geld
1,45

Brief
1,56

Zeit
25.07.06 10:47

Spread
--

Geld Stk.
690

Brief Stk.
690

[trading2006]

The global trend towards miniaturization of devices could not leave the Life Sciences sector unaffected. The bringing together of different technologies like microelectronics, optics, mechanics, physics and molecular biology along with the miniaturization of fluidic and sensing devices makes possible the development of fully integrated, miniaturized diagnostic systems.

Acrongenomics, Inc. and Molecular Vision, Ltd. introduce BioLED Technology, an innovative and patented combination of microfluidics with a state-of-the-art optical detection system based on pLED (polymer Light Emitting Diode) technology to deliver affordable, intelligent and readily portable Point-of-Care Medical Diagnostic devices. Science and technology team up to improve patients’ quality of life.

Our mission is to provide solutions for:

Faster and accurate diagnosis and treatment decisions
Reduced healthcare costs
Reduced visits to hospitals
Flexibility, versatility and reliability
Latest Events
June 8, 2006
Acrongenomics at Arch Investment Conference...


Latest News Releases
May 22, 2006
Acrongenomics Inc., signs a £3.45 Million (US $6.5 Million) Joint Development Agreement with Molecular Vision Ltd., to offer novel Point-Of-Care solutions through the unique BioLED technology

[trading2006]

Corporate Profile

Acrongenomics, Inc. (OTCBB: AGNM) is a publicly traded company that focuses on investing and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, customer-orientated applications. The company has its international headquarters in Geneva, Switzerland.

As the global population escalates every year, medical providers are constantly seeking technologically advanced products and processes from diagnostics to treatment to monitoring patient diseases. We anticipate the technological changes we will inevitably encounter and strive to play an influential role in advancing medical technologies that will undoubtedly benefit the medical community around the world.

Acrongenomics is confident of its ability to satisfy its shareholders and employees by constantly evaluating its business strategy by collaborating with well-established research institutions and investing in innovative scientific projects, converting them into commercial opportunities.

[trading2006]

Vision and Goals

Acrongenomics\' goal is to advance the Medical Diagnostics industry and accomplish industry-leading growth by establishing our technology platform worldwide. Through innovative and advanced medical diagnostic applications, we aim to provide the most efficient and sustainable means of delivering new value to the marketplace.

We are also committed to contribute to the human health and quality of life by exploring new scientific approaches and continuously considering:

Business
By sponsoring new innovative ideas and transforming them into commercial opportunities.

Social Welfare
By providing the market with superior technology designed to serve the common good.

Our People
By expanding our qualified team of business professionals to further support our technology pipeline.

Acrongenomics is dedicated to sustain a code of contact that is defined by a list of values like:

ACHIEVEMENT: We value the active pursuit of excellence, demonstrated by continuous improvement in standards, quality, speed and timeliness. Our collective ability to get results and accomplish our goals adds priceless value to the Company. We are committed to winning in today\'s competitive market.

INNOVATION: Innovation is fundamental for Acrongenomics’ success. We value creativity—the ability of people to develop new ways to identify opportunities and solve problems. We utilize our skills to search for and apply new technologies, approaches and business solutions which will contribute to the development of new diagnostic platforms.

INTEGRITY: At Acrongenomics we insist on applying the highest ethical standards and adherence to Company values. All employees have the responsibility to conduct their business relationships with the highest level of professionalism and integrity.

SCIENCE: We invest on ground-breaking technologies. We are committed to nurturing breakthrough technological platforms within our framework of focused strategic directions.

[trading2006]

Board of Directors

Constantine Poulios LL.M
President

Mr. Poulios, 36, was appointed to the Board of Directors as Vice President on July 7, 2004 and as President on February 14, 2006. He has extensive experience in serving multinational companies in the rigorous environment of the Sarbanes-Oxley legislation. An attorney by education and profession, he was part of the Corporate and Tax Advisory Services of Ernst & Young before joining Acrongenomics, Inc. Mr. Poulios was managing important accounts including that of Coca Cola, Halliburton, Hewlett Packard, ABN AMRO, Citigroup, Ciments Francais, Pfizer, GlaxoSmithKline and EMI Music for Ernst & Young Southeast Europe, while he has also worked for Ernst & Young LLP in the US. He obtained his Master\'s of Laws from Northwestern University School of Law in Chicago in 1997, while he is a 1995 graduate from the School of Law at the National University of Athens. Mr. Poulios has also been awarded with a Certificate in Law in 1993 from the School of Law at the University of Bordeaux in France and he has attended graduate courses in management from top US universities.


Platon Tzouvalis MSc
Vice President, Chief Operating Officer

Mr. Tzouvalis, 41, was appointed Vice President of Acrongenomics, Inc. on February 14th, 2006. As a Biochemist and ex-Abbott Laboratories Associate, he is an experienced pharmaceutical industry professional. He has been a member of Acrongenomics\' Scientific Advisory Board since May 2004. His expertise lies in the areas of Quality Control, Operational Procedures as well as Pharmaceutical Product and Process Improvement. He received his B.Sc. Degree in Biochemistry from the University of Illinois in 1990 and his Master\'s Degree in the same field from DePaul University at Chicago in 1995. Mr. Tzouvalis\' earlier career includes working as a Research Chemist in collaboration with the University of Illinois at Chicago, holding the position of Research and Development Chemist at SynQuest, Inc. and as Advanced Quality Assurance Specialist of Organic Operations and then Project Manager in Bioanalytical Quality Assurance for Abbott Laboratories. Mr. Tzouvalis has also been awarded with the Abbott Diagnostics Division Science Award of 2002 as part of the Organic Operation Remediation Team.


Ron Lizèe B.Comm. CGA. CFP
Chief Financial Officer

Mr. Lizèe, 52, was appointed Chief Financial Officer of Acrongenomics in 2004. Mr. Lizèe has over 25 years experience in the fields of tax, accounting and auditing.


Manos Topoglidis PhD
Chief Technology Officer

Dr. Topoglidis, 32, was appointed to the Board of Directors and Scientific Advisory Board on February 24, 2006 as Chief Technology Officer. He received his Bachelor’s of Science from King’s College (University of London) in 1996, his MSc in Biochemistry from Imperial College London in 1997 and his Ph.D. in Chemistry (Biosensors and Nanomaterials) from Imperial College London in 2001. His research interests and expertise lie in the areas of Biosensors, Nanomaterials, Biotechnology and Nanotechnology. He has worked as a research fellow at the Center of Electronic Materials and Devices of Imperial College London and as manager of European and National programs at the MESL laboratory of the National Centre for Scientific Research, Demokritos in Athens. He is a member of the Electrochemical and British Biochemical Societies. Dr. Topoglidis has impressive experience leading international research teams in academia to unlock nanotechnology solutions. He ranks among the first to extensively research the use of nanoporous surfaces for biosensing applications and has written numerous original nanotechnology-related publications, which have been cited worldwide.

[trading2006]

Scientific Advisory Board

Professor Donal Bradley is the head of the Physics Department at Imperial College London and enjoys an international reputation for his organic semiconductor research. He is the 3rd most cited scientist in the field of physical sciences. In 2005, he was awarded the prestigious Jan Rajchman Prize by the Society for Information Displays for outstanding scientific and technical research in the field of flat-panel displays. He also received the 2005 European Latsis Prize for Nano-Engineering, awarded by the European Science Foundation, for research on molecular-level control of the performance of organic semi-conducting materials and devices. This year he was a runner-up in the inaugural European Inventor of the Year Awards.

Professor Andrew de Mello is a professor of Chemical Nanosciences in the Department of Chemistry at Imperial College. He is a pioneer in the field of microfluidics. In 2002, he was awarded the SAC Silver Medal by the Royal Society of Chemistry for his contribution to the Analytical Sciences.

Dr. John de Mello is a senior lecturer in nanomaterials in the Department of Chemistry at Imperial College. His primary research interests include organic semiconductors, miniaturized devices for chemical and biological diagnostics, and intelligent synthesis techniques for the controlled production of nanoparticles. He serves on the Editorial Boards of Chemical Society Reviews and the Journal of Experimental Nanoscience.

Mr. Platon Tzouvalis MSc was appointed Vice President of Acrongenomics, Inc. on February 14th, 2006. As a Biochemist and ex-Abbott Laboratories Associate, he is an experienced pharmaceutical industry professional. He has been a member of Acrongenomics\' Scientific Advisory Board since May 2004. His expertise lies in the areas of Quality Control, Operational Procedures as well as Medical Devices, Pharmaceutical Product and Process Improvement.

Dr. Manos Topoglidis was appointed to the Board of Directors and Scientific Advisory Board on February 23rd 2006 as Chief Technology Officer. His research interests and expertise lie in the areas of Biosensors, Nanomaterials, Biotechnology and Nanotechnology. Dr. Topoglidis has 15 scientific publications during his 8 years of research and has presented his work in 10 U.S./international conferences.

[trading2006]

Strategic Alliances

Acrongenomics utilizes its extensive international network and qualified management team to scout out and invest in dynamic research projects. To that extent Acrongenomics has established a Strategic Alliance with the UK based Molecular Vision Ltd.

Molecular Vision is a spin-out company of Imperial Innovations Ltd. The company was founded in 2002 in order to meet a clearly defined demand in the medical diagnostics, biosensors and analytical instrumentations markets: the need for miniaturized chemical and biological detectors offering high sensitivity and functionality at low cost. The company has directly addressed this market demand by inventing a novel method for optical detection based on recent advances in organic electronics and light emitting diodes combined with microfluidics technology. The company has mainly focused on applying its technology to the medical diagnostics markets.

[trading2006]

BioLED Technology

Terms like Lab-On-a-Chip (LOC), Point-of-Care (POC) testing and miniaturized Total Analysis Systems (μTAS) describe the same concept; specialized, light weight, readily portable and easy to use devices, designed to perform complex biological tests at the site where they are most needed. These tests normally require specialized laboratories equipped with bulky and expensive instruments. POC testing constitutes a “stand alone” new market with impressive growth potential that may/or may not complement the already established laboratory testing. The main market driving force is the enhanced portability and networking capabilities that lead to improved patient’s quality of life and increased independence from organized healthcare facilities.

So far, the realization of readily portable diagnostic devices for POC testing has been hampered by the lack of suitable miniaturized, low-power consumption, optical detection systems.

Low cost, organic semiconductor polymers with tunable optical properties is the answer provided by Acrongenomics and Molecular Vision. Optical detection is provided by polymer Light Emitting Diodes (pLEDs) which are fully compatible with microfluidic chip technology. The combination of the two technologies is used for the development of a "readily portable" microfluidic and pLED platform (BioLED technology) that is initially applied to the development of POC microchips for the quantitative and qualitative analysis of medical conditions with high sensitivity and functionality at low cost.

Acrongenomics’ and Molecular Vision’s BioLED technology operates with two interdependent components that combine to form a Lab-On-a-Chip cartridge:

Microfluidics - Processing and Reaction component
pLED (polymer Light Emitting Diode) - Detection Component

Microfluidics Integration on a monolithic chip pLED

How does it work?

Under electrical excitation the polymer emits light via radiative combination of injected electrons and holes and therefore may be used as a light source. The same structure can then be used in reverse as a photodetector by illuminating the polymer in order to generate a measurable electrical current.

The reagents of an assay will be mixed with the body fluid through the microfluidic network. The resulting mixture will be excited by the integrated, battery driven pLED and the resulting light-signal will be detected by the integrated photodetector which will generate an electrical current (electronic readout).


Schematic of pLED and photodetector integrated into microfluidic chip

We endeavor to possess a strong market position since our novel and patented technology does not face any immediate competition.

BioLED technology\'s prototypes will consist of a Lab-On-a-Chip cartridge and an (optional) commercially available PDA (Personal Digital Assistant) data collector. Two configurations will be offered:

The chip will plug into a PDA which will supply the power needed, display the result on screen and offer data management and enhanced networking possibilities (ideal for hospital + physician\'s office use).
Fully autonomous chips that do not require a PDA, with an integrated display and powered by lithium button batteries (ideal for a home-care environment).
Technology Advantages

BioLED Technology
Meets Market Requirements

Market Demands…
We provide…

Fast, Unambiguous diagnosis
Electronic readout gives clear answer in 2-3 minutes. Quantitative and qualitative analysis with accuracy comparable to standard lab tests. Data management and networking possibilities.

Miniaturized analysis of complex materials (blood, urine and saliva)
Microfluidics are designed to handle drops of such materials. Detection at the submicromolar level, aiming to increase sensitivity to picomolar levels.

Multiple testing
Ability to run multiple diagnostic tests on the same microchip at marginal additional cost compared to a single-test microchip.

Low unit cost
Components manufactured by in-house printing technologies; total cost of each microchip < $1

Ease of use
Simple device; no expert personnel required; ideal as over the counter (OTC) product.

Miniaturized biochemical reactors
Technology platform with potential applications that go beyond POC devices.


References

Lab Chip, 2005, 5, 863-868.
Lab Chip, 2004, 4, 136-140
Sensors and Actuators B, 2005, 106, 878-884.

[trading2006]

Current - POC Diagnostics

Following a primary market research, a number of potential POC diagnostic device applications were evaluated in terms of feasibility, market needs, revenue generating potential, market growth rate and competition. Among these, four disease areas were chosen to be our primary targets for BioLED device development. These POC devices will enable on-the-spot quantitative and qualitative diagnosis from a few drops of blood, urine or saliva for:

Diabetes Management (Kidney Markers):
The prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030 (Global Prevalence of Diabetes. Diabetes Care 27:1047-1053, 2004). Microalbuminuria (MAU), a well known diabetic nephropathy marker, is defined by increased urinary Human Serum Albumin (HSA) excretion. If diagnosed at an early stage, MAU can be treated before its progression to the development of diabetic nephropathy (kidney failure). Approximately 25 – 30% of all diabetics develop evidence of nephropathy.

Sexually Transmitted Diseases (STDs):
STDs remain a major public health challenge in both developed and developing countries. According to the World Health Organization (WHO), more than 340 million new cases of sexually transmitted infections occur every year, worldwide, in people aged 15-49 years.
These infections can be a major cause of illness, infertility and even death. Most of them, however, can be treated and cured easily and with low cost, if diagnosed early enough.

Cardiovascular Diseases (Cardiac Markers):
Cardiovascular diseases are responsible for the deaths of 17 milion people worldwide each year, making them the developed world’s leading cause of death according to the World Health Organization. 32 million heart attacks and strokes per year demonstrate the need for the development of accurate, cost efficient and accessible diagnostics. Conventional diagnostic techniques, however, are costly, time consuming and of limited predictive potential. A smarter diagnostic approach is the in vitro measurement of various cardiac biomarkers of high preventive value, using a POC device.

Substances of Abuse:
According to the World Drug Report 2005, 5% of the global population have consumed illicit drugs at least once in the last 12 months. This number (about 200 million people) illustrates the severity of substance abuse as a major healthcare and socioeconomic problem. Diagnosis of substances of abuse is imperative to the judicial system, professional, professional sports, large corporations and healthcare. Easy, fast, simple and on-site diagnosis has considerable commercial value and huge revenue generating potential.

[trading2006]

Future

BioLED Technology has the potential for the development of a vast spectrum of applications that may include:

Pharmaceutics
Drug discovery, drug testing (high throughput screening)
Environmental technology
Soil (also agriculture), water and air quality measurements
Veterinary Medicine
Early disease detection in animals and location of the source of pathogens of public health threats such as mad cow disease and avian flu
Biodefense - Homeland Security
Portable devices which sample the air for biowarfare agents e.g. anthrax spores etc.
Forensics
Automated processing of crime scene forensic evidence
Food industry
Food diagnostics, packaging (smart sensors), functional food testing

[trading2006]

What is Microfluidics?

Microfluidics refers to a set of technologies that control the flow of minute amounts of liquids or gases- typically measured in nano- and picoliters- in a miniaturized system. Designed in the nanometer scale, microfluidic chips incorporate pumps, valves, microchambers and microchannels (usually less than 100 nanometers wide) that direct samples from one compartment to the next on the chip.

Although the laws of physics do not change, as the scale at which fluids are studied decreases the effects driving and controlling fluid motion changes radically. This is because properties such as surface forces, surface tension, capillary effect, electronic charges, heat and mass transfer become dominant altering the system’s behavior dramatically. Microfluidics not only enable the very precise manipulation of minute amounts of fluids but may perform functions such as mixing, separating handling different components efficiently, rapidly and with little human intervention.

"Microfluidics is one of the 10 technologies
that will change the world"
(Microfluidics Technologies, BCC, March 2004)

Contrary to microelectronics, where miniaturization is achieved mainly by reducing in the size of the transistors, microfluidic devices require construction and design that differ from macroscale devices. More complex systems of channels with more sophisticated fluid-handling capabilities are necessary.

The advantages of such systems include:

Reduced size of devices ("readily portable" microfluidic chips)
Reduced fabrication cost.
Efficient use of expensive reagents.
Reduced volumes of rare samples.
Low fabrication cost allows disposability of the chips.
Multifuncionality and speed.
Ease of use and enhanced safety.
Precise volumetric control of samples and reagents leading to higher sensitivities in analytical applications.
High throughput biological screening made possible by faster sampling times through parallel processing of samples.
Low power consumption.
Can be combined or integrated with other systems like MEMS (Micro-Electro-Mechanical Systems), NEMS (Nano-Electro-Mechanical Systems) to produce highly efficient μTAS (Miniaturized Total Analysis Systems), LOC (Lab-On-a-Chip) or POC (Point-of-Care) devices to form portable "all-in-one" devices able to perform complex functions.
Applications

"As the number of experiments has grown, the devices used to carry them out have shrunk, and the strategy of "smaller is better" has begun to transform the world of fluidics as it transformed the world of electronics."
(G. Whitesides, Mallinckrodt Professor of Chemistry and Chemical Biology at Harvard University -The Industrial Physicist, Aug/Sept 2003)

Microfluidics, due to recent advances in fluidics, microelectronics and integrated system technologies has penetrated to a number of diverse markets including printing, industrial automation, power management systems and life sciences.

The Life Science segment of the microfluidics market demonstrates the largest and fastest growth rate and is divided into:

Drug Discovery (Combinatorial Chemistry, High Throughput Screening, Quality Control)
Medicine (Diagnostics, Therapeutics)
Biotechnology (Genomics, Proteomics, Cell Sorting and counting)
Ecology (Food, Air/Water)
Microfluidics delivers advanced flexibility. A conventional diagnostic test follows a protocol that involves a series of processes and utilizes a number of bulky and expensive instruments that may take up the space of an entire bench. Moreover, specialized laboratory technicians are needed to perform the test.

A microfluidics-based assay can perform the same diagnostic test in a space smaller than the size of a credit card, requiring minimum human intervention. The advantages of such systems are the reason for the continuous penetration of microfluidics in markets that were traditionally driven by other technologies.

Links:
MIFLUS – Microfluidics Terminology Tree

References:

"A New Wave of Microfluidic Devices" by Jennifer Ouellette, The Industrial Physicist, August/September 2003.
Global Watch Technology Partnering, Information Technology, Electronics & Communications Sector Report (November 2005)
"Microfluidics", P. Kallio and J. Kuncova, TEKES, National Technology Agency, Technological Review 158/2004.

[trading2006]

News Releases

22 05 2006 Acrongenomics Inc., signs a £3.45 Million (US $6.5 Million) Joint Development Agreement with Molecular Vision Ltd., to offer novel Point-Of-Care solutions through the unique BioLED technology.
29 03 2006 Acrongenomics Inc. Enters Into Memorandum of Understanding with Molecular Vision, an Imperial Innovations Spin-Out Company
24 02 2006 Acrongenomics, Inc. Appoints Chief Technology Officer
14 02 2006 Acrongenomics Inc. Explores Novel \'Nanoweapons\' in Eliminating Hospital-Related Infections
22 12 2005 Acrongenomics, Inc. Announces Closing of $4,000,000 Private Placement to Fund Ongoing Operations

[trading2006]

Financial Information

AUDITORS
Amisano Hanson · Vancouver BC
LEGAL COUNSEL
Clark Wilson LLP, Vancouver, Canada
BANKERS
HSBC Bank Canada · Calgary, Alberta
REGISTRAR AND TRANSFER AGENT
Pacific Stock Transfer Company · Las Vegas, Nevada
STOCK EXCHANGE LISTING
AGNM · OTCBB
EQ9.F · Deutsche Borse AG
FULLY DILUTED
13,722,536 (As of April 13th 2005)
PRICE RANGE 52 WEEK
AGNM · OTCBB $ 2.40 - $ 6.16
EQ9.F · Deutsche Borse AG €2.08 - €4.80



SEC Filings

Fiscal Year 2006

Form 10 K Annual Report n/a
10 Q (3) Report n/a
10 Q (2) Report n/a
10 Q (1) Report

Fiscal Year 2005

Form 10 K Annual Report
10 Q (3) Report
10 Q (2) Report
10 Q (1) Report
Fiscal Year 2004

Form 10 K Annual Report
10 Q (3) Report
10 Q (2) Report
10 Q (1) Report
Fiscal Year 2003

Form 10 K Annual Report

[trading2006]

Targeted Diseases
Diabetes

Diabetes mellitus (DM) is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin secretion, insulin action, or both. Diabetes can be associated with serious complications, such as:

Cardiovascular disease- a major complication and the leading cause of premature death among people with diabetes (about 75 percent of people with diabetes die from heart disease or stroke).
Kidney disease- also called Nephropathy is a condition that affects one-third or more of people who have had Type 1 (juvenile) diabetes for at least 20 years. About 10 to 40 percent of people with Type 2 (adult onset) diabetes also have kidney disease.
Blindness- diabetes is a major cause of blindness in the U.S. Diabetic retinopathy alone accounts for at least 12 percent of new cases of blindness each year in the U.S. People with diabetes are 25 times more at risk for blindness than the general population.
Nervous system disease- around 60 to 70 percent of diabetics have some type of nervous system damage or neuropathy, which includes decrease sensation in feet or hands, slowed digestion in the stomach, or carpal tunnel syndrome.
Dental disease- almost one third of people with diabetes has severe periodontal or gum diseases with loss of attachment of the gums to the teeth measuring 5 millimeters or more.
There are currently more than 194 million people with diabetes worldwide according to the World Health Organization (WHO). The National Information Clearinghouse estimates that DM costs the United States US$132 billion every year.

Sexually Transmitted Diseases (STDs)

Sexually transmitted diseases (STDs) -also called Sexually Transmitted Infections (STIs) - are a major global cause of acute illness, infertility, long term disability and death, with severe medical and psychological consequences for millions of men, women and children. The general term sexually transmitted disease (STD) is applied to any of the group of diseases that can be spread by sexual contact. STDs are caused by viruses, bacteria and parasites. There are at least 25 different STDs. The most common ones are the Acquired Immune Deficiency Syndrome (AIDS), Herpes Virus, Chlamydia, Syphilis, Human Papillomavirus (HPV), Hepatitis and Gonorrhea. The Medical Institute for Sexual Health in Texas estimates that 1 in 5 Americans between the ages of 15 and 55 are currently infected with one or more STDs, and 12 million Americans are newly infected each year. Also, the World Health Organization (WHO) states that in developing countries, STDs and their complications are amongst the top five disease categories for which adults seek health care. Direct medical costs associated with STDs in the United States are estimated at US$ 13 billion annually.

Cardiovascular disease

Cardiovascular disease (CVD) refers to diseases of the heart and blood vessel system (arteries, capillaries, veins). CVD claims more lives each year that the next 4 leading causes of deaths combined, which are cancer, chronic lowers respiratory diseases, accidents and diabetes mellitus. According to the World Health Organization (WHO), 16.7 million of people around the globe die of CVD each year. This is over 29 percent of all deaths globally. Today, men, women and children are at risk, and 80 percent of the burden is in low- and middle income countries. It is estimated that by 2010, CVD will be the leading cause of death in developing countries, whereas by 2020 heart diseases and strokes will be the leading cause of death and disability worldwide, increasing fatalities to more than 20 million yearly and to more than 24 million by 2030. (Atlas of Heart Disease and Stroke, WHO, September 2004). In U.S. the direct and indirect cost of CVD for 2006 is estimated to be US$ 403.1 billion, according to the American Social Health Association.

Drug abuse

Drug abuse refers to the use of illegal drugs or the inappropriate use of legal drugs. There are many reasons for drug abuse, including producing pleasure, alleviating stress, altering or avoiding reality. The negative impacts of the illicit drug trade touch every society in the world. This year\'s World Drug Report estimates that 200 million people, or 5% of the global population age 15-64, have consumed illicit drugs at least once in the last 12 months. The medical cost of drug abuse was estimated by the National Centre for Health Statistics to be nearly $60 billion worldwide.

[trading2006]

What is POC/LOC?

The new trends in healthcare dictate the provision of laboratory testing at the point where patient care is rendered or what is commonly called Point-Of-Care (POC) testing. Initially, diagnostic tests used to require well organized laboratory facilities, staffed with experienced personnel. Over the past few years, however, technological advances have driven the development of Lab-On-a-Chip (LOC) technology and POC testing which in turn have revolutionised the way medical diagnostic tests are performed. New technological attributes have added speed, simplicity, automation and accessibility to the in vitro diagnostics sector. Large and expensive laboratory facilities, well trained personnel and time consuming procedures are no longer necessary.

LOC technology involves the performance of complex biological functions on a very small chip-like device, able to perform automated biological protocols with minimal human intervention. This technology has been implemented in both laboratory testing instrumentation and POC testing devices.

As the POC testing market evolves two main types of technology have been adopted:

a) Small bench top analysers (e.g., blood gas and electrolyte systems) and
b) Hand held devices, usually accompanied by disposable cassettes, cartridges or sticks.

Both types exhibit significant advantages over laboratory testing. The bench top systems are smaller versions of laboratory analysers in which vulnerable operator dependent steps have been automated. Hand held devices (internally complex devices) have been developed using microfabrication techniques, which makes medical testing more immediate and accessible even for less ideal situations.

The benefits of POC testing can be assessed in terms of the benefit to the diagnostic and/or treatment outcome, as well as the economic outcome. Some examples benefits to the clinical outcome are the faster treatment decision making, improved adherence to treatment, reduce incidence of complications, quicker optimization of treatment and patient satisfaction. The economic benefits involve reduced number of clinic visits and hospitalisation, earlier discharge from hospital, better optimized drug treatment, less inappropriate use of drugs, reduced requirements in staff, equipment and estate and improved quality of life.

References:

Christopher P Price, Regular review: “Point of care testing”, Volume 322, 26 May 2001
American Society for Clinical Laboratory Science, “Point of Care Testing”

[trading2006]

What is pLED

Successful Point-Of-Care (POC) device design has to incorporate 2 major components. A reaction component, responsible for the chemical/biological reactions of an assay and a detection component, that will sense and report the outcome of the assay. The development of novel optical detection techniques are crucial in modern day chemical and biological analysis due to a recognised need for rapid, on-line measurements at low concentrations in fields such as chemical production, DNA analysis, drug discovery, pharmaceutical screening medical diagnostics and environmental analysis.

A Light-Emitting Diode (LED) is a semiconductor device that emits light under electrical excitation. This phenomenon is called electroluminescence. The color of the emitted light is determined by the chemical composition of the semi-conducting material used, and may therefore be controlled using standard synthetic chemistry. If the light-emitting semi-conducting layer material of a LED is organic then the device is known as Organic Light Emitting Diode (OLED). The OLED’s emitting material can be small organic molecules in crystalline phase or flexible polymers (plastics), which are basically long chains of organic molecules. Such LEDs are known as polymer LEDs or pLEDs.

A typical OLED or pLED consists of one or more organic layers sandwiched between two electrodes. Application of an electric field between these two electrodes results in emission of light from the organic layers. At the same time, the organic layers can generate a measurable current when illuminated; therefore, OLEDs and pLEDs exhibit dual functionality (photoemittors and photodetectors).

OLED Technologies
There are currently 3 OLED technologies:

Light Emitting Polymers have been the subject of intense scientific and commercial interest since their discovery in 1990 by Molecular Vision co-founder Professor Donal Bradley and his colleagues (Dr Jeremy Burroughes and Professor Richard Friend) at the Cambridge University Cavendish Laboratory. The emissive materials can be applied on the substrate by a technique derived from inkjet printing making manufacturing flexible and inexpensive. Light Emitting Polymers are set to revolutionize the display market, allowing for wafer-thin television and computer screens at very low cost. The diagnostics market represents a new and important application of this disruptive technology.
Small Molecule OLED technology was developed by Easman-Kodak, usually referred to as "small-molecule" OLED or SM-OLED. The production of this type of devices requires vacuum deposition making manufacturing expensive and inflexible.
A third hybrid light emitting layer technology has been developed recently. This technology uses nonconductive polymers doped with light-emitting, conductive molecules.
Applications

To date, interest in semi-conducting polymers has been driven primarily by their applications in thin film displays and – to a lesser extent – as solar cells and transistors. One of the great benefits of OLED displays compared to traditional LCD displays is that OLEDs do not require a backlight to function. This means that they draw far less power and, when powered from a battery can operate longer on the same charge. However the favourable processing properties of polymeric semiconductors make them highly attractive for a broad range of additional applications.

Owing to their simple design, OLEDs have great potential for integration into microfluidic systems at marginal additional costs delivering state-of-the-art and inexpensive POC devices. The integration of such sensing systems within microfluidic devices is the area of particular interest for Acrongenomics and Molecular Vision.

References:

O. Hofmann et al, Sens. Act. B, 2004, in press.
J.B. Edel et al, Lab Chip, 2004, 4, 13

[trading2006]

What is Microfluidics?

Microfluidics refers to a set of technologies that control the flow of minute amounts of liquids or gases- typically measured in nano- and picoliters- in a miniaturized system. Designed in the nanometer scale, microfluidic chips incorporate pumps, valves, microchambers and microchannels (usually less than 100 nanometers wide) that direct samples from one compartment to the next on the chip.

Although the laws of physics do not change, as the scale at which fluids are studied decreases the effects driving and controlling fluid motion changes radically. This is because properties such as surface forces, surface tension, capillary effect, electronic charges, heat and mass transfer become dominant altering the system’s behavior dramatically. Microfluidics not only enable the very precise manipulation of minute amounts of fluids but may perform functions such as mixing, separating handling different components efficiently, rapidly and with little human intervention.

"Microfluidics is one of the 10 technologies
that will change the world"
(Microfluidics Technologies, BCC, March 2004)

Contrary to microelectronics, where miniaturization is achieved mainly by reducing in the size of the transistors, microfluidic devices require construction and design that differ from macroscale devices. More complex systems of channels with more sophisticated fluid-handling capabilities are necessary.

The advantages of such systems include:

Reduced size of devices ("readily portable" microfluidic chips)
Reduced fabrication cost.
Efficient use of expensive reagents.
Reduced volumes of rare samples.
Low fabrication cost allows disposability of the chips.
Multifuncionality and speed.
Ease of use and enhanced safety.
Precise volumetric control of samples and reagents leading to higher sensitivities in analytical applications.
High throughput biological screening made possible by faster sampling times through parallel processing of samples.
Low power consumption.
Can be combined or integrated with other systems like MEMS (Micro-Electro-Mechanical Systems), NEMS (Nano-Electro-Mechanical Systems) to produce highly efficient μTAS (Miniaturized Total Analysis Systems), LOC (Lab-On-a-Chip) or POC (Point-of-Care) devices to form portable "all-in-one" devices able to perform complex functions.
Applications

"As the number of experiments has grown, the devices used to carry them out have shrunk, and the strategy of "smaller is better" has begun to transform the world of fluidics as it transformed the world of electronics."
(G. Whitesides, Mallinckrodt Professor of Chemistry and Chemical Biology at Harvard University -The Industrial Physicist, Aug/Sept 2003)

Microfluidics, due to recent advances in fluidics, microelectronics and integrated system technologies has penetrated to a number of diverse markets including printing, industrial automation, power management systems and life sciences.

The Life Science segment of the microfluidics market demonstrates the largest and fastest growth rate and is divided into:

Drug Discovery (Combinatorial Chemistry, High Throughput Screening, Quality Control)
Medicine (Diagnostics, Therapeutics)
Biotechnology (Genomics, Proteomics, Cell Sorting and counting)
Ecology (Food, Air/Water)
Microfluidics delivers advanced flexibility. A conventional diagnostic test follows a protocol that involves a series of processes and utilizes a number of bulky and expensive instruments that may take up the space of an entire bench. Moreover, specialized laboratory technicians are needed to perform the test.

A microfluidics-based assay can perform the same diagnostic test in a space smaller than the size of a credit card, requiring minimum human intervention. The advantages of such systems are the reason for the continuous penetration of microfluidics in markets that were traditionally driven by other technologies.

Links:
MIFLUS – Microfluidics Terminology Tree

References:

"A New Wave of Microfluidic Devices" by Jennifer Ouellette, The Industrial Physicist, August/September 2003.
Global Watch Technology Partnering, Information Technology, Electronics & Communications Sector Report (November 2005)
"Microfluidics", P. Kallio and J. Kuncova, TEKES, National Technology Agency, Technological Review 158/2004.

[trading2006]

hab mir mal einige sachen durchgelesen, oder eher gesagt, überflogen, ist einfach zuviel. die haben da ein tolles produkt, welches eine schnelle diagnose kostengünstig ermöglicht. das spart jede menge geld im gesundheitssystem

[trading2006]

http://www.acrongen.com/index.html

die hp ist klasse, sehr professionell. werde den wert mal beobachten

[trading2006]

News Releases

22 05 2006 Acrongenomics Inc., signs a £3.45 Million (US $6.5 Million) Joint Development Agreement with Molecular Vision Ltd., to offer novel Point-Of-Care solutions through the unique BioLED technology.
29 03 2006 Acrongenomics Inc. Enters Into Memorandum of Understanding with Molecular Vision, an Imperial Innovations Spin-Out Company
24 02 2006 Acrongenomics, Inc. Appoints Chief Technology Officer
14 02 2006 Acrongenomics Inc. Explores Novel \'Nanoweapons\' in Eliminating Hospital-Related Infections
22 12 2005 Acrongenomics, Inc. Announces Closing of $4,000,000 Private Placement to Fund Ongoing Operations

[trading2006]

Financial Information

AUDITORS
Amisano Hanson · Vancouver BC
LEGAL COUNSEL
Clark Wilson LLP, Vancouver, Canada
BANKERS
HSBC Bank Canada · Calgary, Alberta
REGISTRAR AND TRANSFER AGENT
Pacific Stock Transfer Company · Las Vegas, Nevada
STOCK EXCHANGE LISTING
AGNM · OTCBB
EQ9.F · Deutsche Borse AG
FULLY DILUTED
13,722,536 (As of April 13th 2005)
PRICE RANGE 52 WEEK
AGNM · OTCBB $ 2.40 - $ 6.16
EQ9.F · Deutsche Borse AG €2.08 - €4.80

[trading2006]

24.07.2006 1,52 1,52 1,41 1,41 2.0k
21.07.2006 1,52 1,52 1,52 1,52 0
20.07.2006 1,53 1,53 1,53 1,53 0
19.07.2006 1,58 1,58 1,58 1,58 0
18.07.2006 1,50 1,50 1,50 1,50 0
17.07.2006 1,49 1,49 1,49 1,49 0
14.07.2006 1,48 1,48 1,48 1,48 0
13.07.2006 1,52 1,52 1,52 1,52 0
12.07.2006 1,51 1,51 1,51 1,51 0
11.07.2006 1,51 1,51 1,51 1,51 0
10.07.2006 1,62 1,62 1,62 1,62 0
07.07.2006 1,80 1,80 1,80 1,80 0
06.07.2006 1,78 1,78 1,78 1,78 0
05.07.2006 1,80 1,80 1,80 1,80 0
04.07.2006 1,81 1,81 1,81 1,81 0
03.07.2006 1,80 1,80 1,80 1,80 0
30.06.2006 1,74 1,74 1,74 1,74 250
29.06.2006 1,77 1,87 1,77 1,87 1.5k
28.06.2006 1,84 1,84 1,84 1,84 0

deutschland

[trading2006]

24.07.2006 1,80 1,89 1,80 1,89 82
21.07.2006 1,90 1,90 1,90 1,90 71
20.07.2006 2,00 2,00 2,00 2,00 5
19.07.2006 2,00 2,00 2,00 2,00 5
18.07.2006 1,95 2,05 1,95 2,05 105
17.07.2006 1,90 1,95 1,95 1,95 3.5k
14.07.2006 1,90 1,95 1,80 1,95 3.5k
13.07.2006 2,05 2,05 1,88 1,95 82
12.07.2006 1,85 2,16 1,85 2,00 28
11.07.2006 2,02 2,03 1,90 2,00 108
10.07.2006 2,00 2,00 1,80 2,00 11.9k
07.07.2006 2,25 2,25 2,10 2,15 60
06.07.2006 2,20 2,38 2,20 2,38 2.3k
05.07.2006 2,30 2,40 2,25 2,35 51
04.07.2006 2,45 2,45 2,31 2,40 2.1k
03.07.2006 2,45 2,45 2,31 2,40 2.1k
30.06.2006 2,22 2,40 2,22 2,40 77
29.06.2006 2,22 2,30 2,22 2,30 26
28.06.2006 2,39 2,45 2,30 2,30 11.4k

[trading2006]

umsätze sind hier wie drüben nicht gerade der reißer. sieht mir so aus, als wenn viele shares in festen händen wären.

[trading2006]

Börse
Frankfurt

Aktuell
1,44 EUR

Zeit
25.07.06 09:00

Diff. Vortag
+2,13 %

Tages-Vol.
--

Gehandelte Stück
0

Geld
1,45

Brief
1,56

Zeit
25.07.06 10:47

Spread
--

Geld Stk.
690

Brief Stk.
690

[trading2006]

Wertpapiertyp
Auslandsaktie

Marktsegment
Freiverkehr

Branche
--

Geschäftsjahr
--

Marktkapital.
19,91 Mio. EUR

Streubesitz
--

Nennwert
--

Stücke
14 Mio.

Symbol
EQ9.FSE

ISIN
--

WKN
A0B9TS

[trading2006]

die mk ist sehr gering bei den aussichten, dennoch darf man nicht vergessen, das vorerst noch keine gewine erwirtschaftet werden/umsätze.

[trading2006]

gewinne

[trading2006]

Antwort auf Beitrag Nr.: 23.035.965 von trading2006 am 25.07.06 11:16:49

oder der wert einfach noch unentdeckt ist

[trading2006]

Acrongenomics, Inc. and Molecular Vision, Ltd. introduce BioLED Technology, an innovative and patented combination of microfluidics with a state-of-the-art optical detection system based on pLED (polymer Light Emitting Diode) technology to deliver affordable, intelligent and readily portable Point-of-Care Medical Diagnostic devices. Science and technology team up to improve patients’ quality of life.

Our mission is to provide solutions for:

Faster and accurate diagnosis and treatment decisions
Reduced healthcare costs
Reduced visits to hospitals
Flexibility, versatility and reliability

[trading2006]

Fazit
Trotz des bilanziellen Defizits und der erst kurzfristigen geschäftlichen Umorientierung von AcronGenomics erscheint uns das Papier aus folgenden Gründen dennoch als ein hoch interessantes und spekulatives Investment:


Durch die Zusammenarbeit mit Molecular Vision eröffnet sich die Möglichkeit einer sehr engen und Erfolg versprechenden Zusammenarbeit mit höchst renommierten und innovativen Wissenschaftlern – vor allem mit Donal Barney und seinem Team), aus der
höchst innovative Produkte hervorgehen könnten, die auf
einem insgesamt auch zukünftig boomender Mega-Markt für Medizintechnik konkurrenzlos sein könnten.
Aus charttechnischer Sicht könnte sich das Papier in einer Bodenbildungsphase befinden.

[trading2006]

Nach Angaben von AcronGenomics ist diese Technologie konkurrenzlos. Man ist bestrebt, zukünftig zwei Versionen dieses Chips anzubieten: einmal als Chip, der mit einem handelsüblichen PDA (Personal Digital Assistant) verbunden werden kann, wie sie schon heute zum Beispiel in Krankenhäusern und Arztpraxen eingesetzt werden, und einmal als eine Version, die ohne PDA, stattdessen aber mit Hilfe eines eingebauten minaturisierten LCD-Displays ausgelesen werden kann, was das POC-Gerät auch für den privaten häuslichen Einsatz kostengünstig einsetzbar machen würde.

[trading2006]

Was ist die BioLED-Technologie? Die BioLED-Technologie bezeichnet das gleiche Konzept wie Lab-On-a-Chip (LOC; Labor auf dem Chip, d.h. vollständige analytische Prozesse von Probenvorbereitung bis zur Auswertung sind auf einem scheckkartengroßen (Computer)Chip integriert, Anm. D. Red.), Point-of-Care (POC; Streifentests und Schnelltestgeräte etwa für Blutalkoholgehalt, Schwangerschaft, Diabetes usw.; Anm. D. Red.) und „miniaturized Total Analysis Systems“ (μTAS; miniaturisierte Komplettanalysesysteme; Anm. d. Red.). Die BioLED ist eine vollkommen neuartige Technologie, bei der durch die patentierte Kombination der Mikroströmungslehre (engl. microfluidics, das Strömungsverhalten von Flüssigkeiten in kleinsten Mengen; Anm. d. Red.) mit optischen Detektoren, basierend auf der organischen pLED (polymer Light Emitting Diode), eine Vielzahl von miniaturisierten tragbaren POC-Diagnose-geräten realisiert werden könne, die das Potential dazu hätten, medizinische Standarttests zu werden.

[trading2006]

Ihre Chance
AcronGenomics, gegründet 2004 und ehemals selbst ein innovatives Hightechunternehmen aus dem Nanotech-Bereich mit jetzigem Hauptsitz in Genf (Schweiz), versteht sich nunmehr als ein Unternehmen, das sich auf die Finanzierung und Kommerzialisieren neuartiger Technologien im medizinischen Bereich konzentriert. Am 22. Mai 2006 hat man deshalb ein Joint Development Agreement mit Molecular Vision Ltd. im Wert von 6.5 Mio. US$ geschlossen, um medizindiagnostische Produkte basierend auf der sog. BioLED-Technologie, einer Kombination aus Nano- und Biotechnologie, gemeinsam zu entwickeln und zu kommerzialisieren.

[trading2006]

sl setzen ist bei so einem engen wert sinnvoll, aber nicht zu eng

[trading2006]

mit der entwicklung sollen sogar drogentests möglich sein, das wäre interessant für die polizei z.b. oder den sportlichen bereich. nebenbei natürlich viele volkskrankheiten wie diabetes, welche immer weiter voran schreitet.

[Projektbaum]

Antwort auf Beitrag Nr.: 23.036.184 von trading2006 am 25.07.06 11:26:33

Hallo scheint ja interresaant zu sein.............

[trading2006]

The global trend towards miniaturization of devices could not leave the Life Sciences sector unaffected. The bringing together of different technologies like microelectronics, optics, mechanics, physics and molecular biology along with the miniaturization of fluidic and sensing devices makes possible the development of fully integrated, miniaturized diagnostic systems.

Acrongenomics, Inc. and Molecular Vision, Ltd. introduce BioLED Technology, an innovative and patented combination of microfluidics with a state-of-the-art optical detection system based on pLED (polymer Light Emitting Diode) technology to deliver affordable, intelligent and readily portable Point-of-Care Medical Diagnostic devices. Science and technology team up to improve patients’ quality of life.

Our mission is to provide solutions for:

Faster and accurate diagnosis and treatment decisions
Reduced healthcare costs
Reduced visits to hospitals
Flexibility, versatility and reliability
Latest Events
June 8, 2006
Acrongenomics at Arch Investment Conference...


Latest News Releases
May 22, 2006
Acrongenomics Inc., signs a £3.45 Million (US $6.5 Million) Joint Development Agreement with Molecular Vision Ltd., to offer novel Point-Of-Care solutions through the unique BioLED technology.

[trading2006]

Corporate Profile

Acrongenomics, Inc. (OTCBB: AGNM) is a publicly traded company that focuses on investing and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, customer-orientated applications. The company has its international headquarters in Geneva, Switzerland.

As the global population escalates every year, medical providers are constantly seeking technologically advanced products and processes from diagnostics to treatment to monitoring patient diseases. We anticipate the technological changes we will inevitably encounter and strive to play an influential role in advancing medical technologies that will undoubtedly benefit the medical community around the world.

Acrongenomics is confident of its ability to satisfy its shareholders and employees by constantly evaluating its business strategy by collaborating with well-established research institutions and investing in innovative scientific projects, converting them into commercial opportun

[trading2006]

Vision and Goals

Acrongenomics\' goal is to advance the Medical Diagnostics industry and accomplish industry-leading growth by establishing our technology platform worldwide. Through innovative and advanced medical diagnostic applications, we aim to provide the most efficient and sustainable means of delivering new value to the marketplace.

We are also committed to contribute to the human health and quality of life by exploring new scientific approaches and continuously considering:

Business
By sponsoring new innovative ideas and transforming them into commercial opportunities.

Social Welfare
By providing the market with superior technology designed to serve the common good.

Our People
By expanding our qualified team of business professionals to further support our technology pipeline.

Acrongenomics is dedicated to sustain a code of contact that is defined by a list of values like:

ACHIEVEMENT: We value the active pursuit of excellence, demonstrated by continuous improvement in standards, quality, speed and timeliness. Our collective ability to get results and accomplish our goals adds priceless value to the Company. We are committed to winning in today\'s competitive market.

INNOVATION: Innovation is fundamental for Acrongenomics’ success. We value creativity—the ability of people to develop new ways to identify opportunities and solve problems. We utilize our skills to search for and apply new technologies, approaches and business solutions which will contribute to the development of new diagnostic platforms.

INTEGRITY: At Acrongenomics we insist on applying the highest ethical standards and adherence to Company values. All employees have the responsibility to conduct their business relationships with the highest level of professionalism and integrity.

SCIENCE: We invest on ground-breaking technologies. We are committed to nurturing breakthrough technological platforms within our framework of focused strategic directions.

[trading2006]

Board of Directors

Constantine Poulios LL.M
President

Mr. Poulios, 36, was appointed to the Board of Directors as Vice President on July 7, 2004 and as President on February 14, 2006. He has extensive experience in serving multinational companies in the rigorous environment of the Sarbanes-Oxley legislation. An attorney by education and profession, he was part of the Corporate and Tax Advisory Services of Ernst & Young before joining Acrongenomics, Inc. Mr. Poulios was managing important accounts including that of Coca Cola, Halliburton, Hewlett Packard, ABN AMRO, Citigroup, Ciments Francais, Pfizer, GlaxoSmithKline and EMI Music for Ernst & Young Southeast Europe, while he has also worked for Ernst & Young LLP in the US. He obtained his Master\'s of Laws from Northwestern University School of Law in Chicago in 1997, while he is a 1995 graduate from the School of Law at the National University of Athens. Mr. Poulios has also been awarded with a Certificate in Law in 1993 from the School of Law at the University of Bordeaux in France and he has attended graduate courses in management from top US universities.


Platon Tzouvalis MSc
Vice President, Chief Operating Officer

Mr. Tzouvalis, 41, was appointed Vice President of Acrongenomics, Inc. on February 14th, 2006. As a Biochemist and ex-Abbott Laboratories Associate, he is an experienced pharmaceutical industry professional. He has been a member of Acrongenomics\' Scientific Advisory Board since May 2004. His expertise lies in the areas of Quality Control, Operational Procedures as well as Pharmaceutical Product and Process Improvement. He received his B.Sc. Degree in Biochemistry from the University of Illinois in 1990 and his Master\'s Degree in the same field from DePaul University at Chicago in 1995. Mr. Tzouvalis\' earlier career includes working as a Research Chemist in collaboration with the University of Illinois at Chicago, holding the position of Research and Development Chemist at SynQuest, Inc. and as Advanced Quality Assurance Specialist of Organic Operations and then Project Manager in Bioanalytical Quality Assurance for Abbott Laboratories. Mr. Tzouvalis has also been awarded with the Abbott Diagnostics Division Science Award of 2002 as part of the Organic Operation Remediation Team.


Ron Lizèe B.Comm. CGA. CFP
Chief Financial Officer

Mr. Lizèe, 52, was appointed Chief Financial Officer of Acrongenomics in 2004. Mr. Lizèe has over 25 years experience in the fields of tax, accounting and auditing.


Manos Topoglidis PhD
Chief Technology Officer

Dr. Topoglidis, 32, was appointed to the Board of Directors and Scientific Advisory Board on February 24, 2006 as Chief Technology Officer. He received his Bachelor’s of Science from King’s College (University of London) in 1996, his MSc in Biochemistry from Imperial College London in 1997 and his Ph.D. in Chemistry (Biosensors and Nanomaterials) from Imperial College London in 2001. His research interests and expertise lie in the areas of Biosensors, Nanomaterials, Biotechnology and Nanotechnology. He has worked as a research fellow at the Center of Electronic Materials and Devices of Imperial College London and as manager of European and National programs at the MESL laboratory of the National Centre for Scientific Research, Demokritos in Athens. He is a member of the Electrochemical and British Biochemical Societies. Dr. Topoglidis has impressive experience leading international research teams in academia to unlock nanotechnology solutions. He ranks among the first to extensively research the use of nanoporous surfaces for biosensing applications and has written numerous original nanotechnology-related publications, which have been cited worldwide.

[trading2006]

Scientific Advisory Board

Professor Donal Bradley is the head of the Physics Department at Imperial College London and enjoys an international reputation for his organic semiconductor research. He is the 3rd most cited scientist in the field of physical sciences. In 2005, he was awarded the prestigious Jan Rajchman Prize by the Society for Information Displays for outstanding scientific and technical research in the field of flat-panel displays. He also received the 2005 European Latsis Prize for Nano-Engineering, awarded by the European Science Foundation, for research on molecular-level control of the performance of organic semi-conducting materials and devices. This year he was a runner-up in the inaugural European Inventor of the Year Awards.

Professor Andrew de Mello is a professor of Chemical Nanosciences in the Department of Chemistry at Imperial College. He is a pioneer in the field of microfluidics. In 2002, he was awarded the SAC Silver Medal by the Royal Society of Chemistry for his contribution to the Analytical Sciences.

Dr. John de Mello is a senior lecturer in nanomaterials in the Department of Chemistry at Imperial College. His primary research interests include organic semiconductors, miniaturized devices for chemical and biological diagnostics, and intelligent synthesis techniques for the controlled production of nanoparticles. He serves on the Editorial Boards of Chemical Society Reviews and the Journal of Experimental Nanoscience.

Mr. Platon Tzouvalis MSc was appointed Vice President of Acrongenomics, Inc. on February 14th, 2006. As a Biochemist and ex-Abbott Laboratories Associate, he is an experienced pharmaceutical industry professional. He has been a member of Acrongenomics\' Scientific Advisory Board since May 2004. His expertise lies in the areas of Quality Control, Operational Procedures as well as Medical Devices, Pharmaceutical Product and Process Improvement.

Dr. Manos Topoglidis was appointed to the Board of Directors and Scientific Advisory Board on February 23rd 2006 as Chief Technology Officer. His research interests and expertise lie in the areas of Biosensors, Nanomaterials, Biotechnology and Nanotechnology. Dr. Topoglidis has 15 scientific publications during his 8 years of research and has presented his work in 10 U.S./international conferences.

[trading2006]

Strategic Alliances

Acrongenomics utilizes its extensive international network and qualified management team to scout out and invest in dynamic research projects. To that extent Acrongenomics has established a Strategic Alliance with the UK based Molecular Vision Ltd.

Molecular Vision is a spin-out company of Imperial Innovations Ltd. The company was founded in 2002 in order to meet a clearly defined demand in the medical diagnostics, biosensors and analytical instrumentations markets: the need for miniaturized chemical and biological detectors offering high sensitivity and functionality at low cost. The company has directly addressed this market demand by inventing a novel method for optical detection based on recent advances in organic electronics and light emitting diodes combined with microfluidics technology. The company has mainly focused on applying its technology to the medical diagnostics markets.

[trading2006]

BioLED Technology

Terms like Lab-On-a-Chip (LOC), Point-of-Care (POC) testing and miniaturized Total Analysis Systems (μTAS) describe the same concept; specialized, light weight, readily portable and easy to use devices, designed to perform complex biological tests at the site where they are most needed. These tests normally require specialized laboratories equipped with bulky and expensive instruments. POC testing constitutes a “stand alone” new market with impressive growth potential that may/or may not complement the already established laboratory testing. The main market driving force is the enhanced portability and networking capabilities that lead to improved patient’s quality of life and increased independence from organized healthcare facilities.

So far, the realization of readily portable diagnostic devices for POC testing has been hampered by the lack of suitable miniaturized, low-power consumption, optical detection systems.

Low cost, organic semiconductor polymers with tunable optical properties is the answer provided by Acrongenomics and Molecular Vision. Optical detection is provided by polymer Light Emitting Diodes (pLEDs) which are fully compatible with microfluidic chip technology. The combination of the two technologies is used for the development of a "readily portable" microfluidic and pLED platform (BioLED technology) that is initially applied to the development of POC microchips for the quantitative and qualitative analysis of medical conditions with high sensitivity and functionality at low cost.

Acrongenomics’ and Molecular Vision’s BioLED technology operates with two interdependent components that combine to form a Lab-On-a-Chip cartridge:

Microfluidics - Processing and Reaction component
pLED (polymer Light Emitting Diode) - Detection Component

Microfluidics Integration on a monolithic chip pLED

How does it work?

Under electrical excitation the polymer emits light via radiative combination of injected electrons and holes and therefore may be used as a light source. The same structure can then be used in reverse as a photodetector by illuminating the polymer in order to generate a measurable electrical current.

The reagents of an assay will be mixed with the body fluid through the microfluidic network. The resulting mixture will be excited by the integrated, battery driven pLED and the resulting light-signal will be detected by the integrated photodetector which will generate an electrical current (electronic readout).


Schematic of pLED and photodetector integrated into microfluidic chip

We endeavor to possess a strong market position since our novel and patented technology does not face any immediate competition.

BioLED technology\'s prototypes will consist of a Lab-On-a-Chip cartridge and an (optional) commercially available PDA (Personal Digital Assistant) data collector. Two configurations will be offered:

The chip will plug into a PDA which will supply the power needed, display the result on screen and offer data management and enhanced networking possibilities (ideal for hospital + physician\'s office use).
Fully autonomous chips that do not require a PDA, with an integrated display and powered by lithium button batteries (ideal for a home-care environment).
Technology Advantages

BioLED Technology
Meets Market Requirements

Market Demands…
We provide…

Fast, Unambiguous diagnosis
Electronic readout gives clear answer in 2-3 minutes. Quantitative and qualitative analysis with accuracy comparable to standard lab tests. Data management and networking possibilities.

Miniaturized analysis of complex materials (blood, urine and saliva)
Microfluidics are designed to handle drops of such materials. Detection at the submicromolar level, aiming to increase sensitivity to picomolar levels.

Multiple testing
Ability to run multiple diagnostic tests on the same microchip at marginal additional cost compared to a single-test microchip.

Low unit cost
Components manufactured by in-house printing technologies; total cost of each microchip < $1

Ease of use
Simple device; no expert personnel required; ideal as over the counter (OTC) product.

Miniaturized biochemical reactors
Technology platform with potential applications that go beyond POC devices.


References

Lab Chip, 2005, 5, 863-868.
Lab Chip, 2004, 4, 136-140
Sensors and Actuators B, 2005, 106, 878-884.

[trading2006]

Current - POC Diagnostics

Following a primary market research, a number of potential POC diagnostic device applications were evaluated in terms of feasibility, market needs, revenue generating potential, market growth rate and competition. Among these, four disease areas were chosen to be our primary targets for BioLED device development. These POC devices will enable on-the-spot quantitative and qualitative diagnosis from a few drops of blood, urine or saliva for:

Diabetes Management (Kidney Markers):
The prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030 (Global Prevalence of Diabetes. Diabetes Care 27:1047-1053, 2004). Microalbuminuria (MAU), a well known diabetic nephropathy marker, is defined by increased urinary Human Serum Albumin (HSA) excretion. If diagnosed at an early stage, MAU can be treated before its progression to the development of diabetic nephropathy (kidney failure). Approximately 25 – 30% of all diabetics develop evidence of nephropathy.

Sexually Transmitted Diseases (STDs):
STDs remain a major public health challenge in both developed and developing countries. According to the World Health Organization (WHO), more than 340 million new cases of sexually transmitted infections occur every year, worldwide, in people aged 15-49 years.
These infections can be a major cause of illness, infertility and even death. Most of them, however, can be treated and cured easily and with low cost, if diagnosed early enough.

Cardiovascular Diseases (Cardiac Markers):
Cardiovascular diseases are responsible for the deaths of 17 milion people worldwide each year, making them the developed world’s leading cause of death according to the World Health Organization. 32 million heart attacks and strokes per year demonstrate the need for the development of accurate, cost efficient and accessible diagnostics. Conventional diagnostic techniques, however, are costly, time consuming and of limited predictive potential. A smarter diagnostic approach is the in vitro measurement of various cardiac biomarkers of high preventive value, using a POC device.

Substances of Abuse:
According to the World Drug Report 2005, 5% of the global population have consumed illicit drugs at least once in the last 12 months. This number (about 200 million people) illustrates the severity of substance abuse as a major healthcare and socioeconomic problem. Diagnosis of substances of abuse is imperative to the judicial system, professional, professional sports, large corporations and healthcare. Easy, fast, simple and on-site diagnosis has considerable commercial value and huge revenue generating potential.

[trading2006]

Future

BioLED Technology has the potential for the development of a vast spectrum of applications that may include:

Pharmaceutics
Drug discovery, drug testing (high throughput screening)
Environmental technology
Soil (also agriculture), water and air quality measurements
Veterinary Medicine
Early disease detection in animals and location of the source of pathogens of public health threats such as mad cow disease and avian flu
Biodefense - Homeland Security
Portable devices which sample the air for biowarfare agents e.g. anthrax spores etc.
Forensics
Automated processing of crime scene forensic evidence
Food industry
Food diagnostics, packaging (smart sensors), functional food testing

[trading2006]

What is Microfluidics?

Microfluidics refers to a set of technologies that control the flow of minute amounts of liquids or gases- typically measured in nano- and picoliters- in a miniaturized system. Designed in the nanometer scale, microfluidic chips incorporate pumps, valves, microchambers and microchannels (usually less than 100 nanometers wide) that direct samples from one compartment to the next on the chip.

Although the laws of physics do not change, as the scale at which fluids are studied decreases the effects driving and controlling fluid motion changes radically. This is because properties such as surface forces, surface tension, capillary effect, electronic charges, heat and mass transfer become dominant altering the system’s behavior dramatically. Microfluidics not only enable the very precise manipulation of minute amounts of fluids but may perform functions such as mixing, separating handling different components efficiently, rapidly and with little human intervention.

"Microfluidics is one of the 10 technologies
that will change the world"
(Microfluidics Technologies, BCC, March 2004)

Contrary to microelectronics, where miniaturization is achieved mainly by reducing in the size of the transistors, microfluidic devices require construction and design that differ from macroscale devices. More complex systems of channels with more sophisticated fluid-handling capabilities are necessary.

The advantages of such systems include:

Reduced size of devices ("readily portable" microfluidic chips)
Reduced fabrication cost.
Efficient use of expensive reagents.
Reduced volumes of rare samples.
Low fabrication cost allows disposability of the chips.
Multifuncionality and speed.
Ease of use and enhanced safety.
Precise volumetric control of samples and reagents leading to higher sensitivities in analytical applications.
High throughput biological screening made possible by faster sampling times through parallel processing of samples.
Low power consumption.
Can be combined or integrated with other systems like MEMS (Micro-Electro-Mechanical Systems), NEMS (Nano-Electro-Mechanical Systems) to produce highly efficient μTAS (Miniaturized Total Analysis Systems), LOC (Lab-On-a-Chip) or POC (Point-of-Care) devices to form portable "all-in-one" devices able to perform complex functions.
Applications

"As the number of experiments has grown, the devices used to carry them out have shrunk, and the strategy of "smaller is better" has begun to transform the world of fluidics as it transformed the world of electronics."
(G. Whitesides, Mallinckrodt Professor of Chemistry and Chemical Biology at Harvard University -The Industrial Physicist, Aug/Sept 2003)

Microfluidics, due to recent advances in fluidics, microelectronics and integrated system technologies has penetrated to a number of diverse markets including printing, industrial automation, power management systems and life sciences.

The Life Science segment of the microfluidics market demonstrates the largest and fastest growth rate and is divided into:

Drug Discovery (Combinatorial Chemistry, High Throughput Screening, Quality Control)
Medicine (Diagnostics, Therapeutics)
Biotechnology (Genomics, Proteomics, Cell Sorting and counting)
Ecology (Food, Air/Water)
Microfluidics delivers advanced flexibility. A conventional diagnostic test follows a protocol that involves a series of processes and utilizes a number of bulky and expensive instruments that may take up the space of an entire bench. Moreover, specialized laboratory technicians are needed to perform the test.

A microfluidics-based assay can perform the same diagnostic test in a space smaller than the size of a credit card, requiring minimum human intervention. The advantages of such systems are the reason for the continuous penetration of microfluidics in markets that were traditionally driven by other technologies.

Links:
MIFLUS – Microfluidics Terminology Tree

References:

"A New Wave of Microfluidic Devices" by Jennifer Ouellette, The Industrial Physicist, August/September 2003.
Global Watch Technology Partnering, Information Technology, Electronics & Communications Sector Report (November 2005)
"Microfluidics", P. Kallio and J. Kuncova, TEKES, National Technology Agency, Technological Review 158/2004.

[trading2006]

Future

BioLED Technology has the potential for the development of a vast spectrum of applications that may include:

Pharmaceutics
Drug discovery, drug testing (high throughput screening)
Environmental technology
Soil (also agriculture), water and air quality measurements
Veterinary Medicine
Early disease detection in animals and location of the source of pathogens of public health threats such as mad cow disease and avian flu
Biodefense - Homeland Security
Portable devices which sample the air for biowarfare agents e.g. anthrax spores etc.
Forensics
Automated processing of crime scene forensic evidence
Food industry
Food diagnostics, packaging (smart sensors), functional food testing


das ist doch mal was, schafft große umsatzerwartungen. leider erst in einigen jahren so wie ich das sehe

[trading2006]

Targeted Diseases
Diabetes

Diabetes mellitus (DM) is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin secretion, insulin action, or both. Diabetes can be associated with serious complications, such as:

Cardiovascular disease- a major complication and the leading cause of premature death among people with diabetes (about 75 percent of people with diabetes die from heart disease or stroke).
Kidney disease- also called Nephropathy is a condition that affects one-third or more of people who have had Type 1 (juvenile) diabetes for at least 20 years. About 10 to 40 percent of people with Type 2 (adult onset) diabetes also have kidney disease.
Blindness- diabetes is a major cause of blindness in the U.S. Diabetic retinopathy alone accounts for at least 12 percent of new cases of blindness each year in the U.S. People with diabetes are 25 times more at risk for blindness than the general population.
Nervous system disease- around 60 to 70 percent of diabetics have some type of nervous system damage or neuropathy, which includes decrease sensation in feet or hands, slowed digestion in the stomach, or carpal tunnel syndrome.
Dental disease- almost one third of people with diabetes has severe periodontal or gum diseases with loss of attachment of the gums to the teeth measuring 5 millimeters or more.
There are currently more than 194 million people with diabetes worldwide according to the World Health Organization (WHO). The National Information Clearinghouse estimates that DM costs the United States US$132 billion every year.

Sexually Transmitted Diseases (STDs)

Sexually transmitted diseases (STDs) -also called Sexually Transmitted Infections (STIs) - are a major global cause of acute illness, infertility, long term disability and death, with severe medical and psychological consequences for millions of men, women and children. The general term sexually transmitted disease (STD) is applied to any of the group of diseases that can be spread by sexual contact. STDs are caused by viruses, bacteria and parasites. There are at least 25 different STDs. The most common ones are the Acquired Immune Deficiency Syndrome (AIDS), Herpes Virus, Chlamydia, Syphilis, Human Papillomavirus (HPV), Hepatitis and Gonorrhea. The Medical Institute for Sexual Health in Texas estimates that 1 in 5 Americans between the ages of 15 and 55 are currently infected with one or more STDs, and 12 million Americans are newly infected each year. Also, the World Health Organization (WHO) states that in developing countries, STDs and their complications are amongst the top five disease categories for which adults seek health care. Direct medical costs associated with STDs in the United States are estimated at US$ 13 billion annually.

Cardiovascular disease

Cardiovascular disease (CVD) refers to diseases of the heart and blood vessel system (arteries, capillaries, veins). CVD claims more lives each year that the next 4 leading causes of deaths combined, which are cancer, chronic lowers respiratory diseases, accidents and diabetes mellitus. According to the World Health Organization (WHO), 16.7 million of people around the globe die of CVD each year. This is over 29 percent of all deaths globally. Today, men, women and children are at risk, and 80 percent of the burden is in low- and middle income countries. It is estimated that by 2010, CVD will be the leading cause of death in developing countries, whereas by 2020 heart diseases and strokes will be the leading cause of death and disability worldwide, increasing fatalities to more than 20 million yearly and to more than 24 million by 2030. (Atlas of Heart Disease and Stroke, WHO, September 2004). In U.S. the direct and indirect cost of CVD for 2006 is estimated to be US$ 403.1 billion, according to the American Social Health Association.

Drug abuse

Drug abuse refers to the use of illegal drugs or the inappropriate use of legal drugs. There are many reasons for drug abuse, including producing pleasure, alleviating stress, altering or avoiding reality. The negative impacts of the illicit drug trade touch every society in the world. This year\'s World Drug Report estimates that 200 million people, or 5% of the global population age 15-64, have consumed illicit drugs at least once in the last 12 months. The medical cost of drug abuse was estimated by the National Centre for Health Statistics to be nearly $60 billion worldwide.


das verspricht das größte umsatzpotential: diabetes, eine immer weiter fortschreitende krankheit, die sogar schon jugendliche trifft.

[trading2006]

ob hier jemand einsteigt, muss jeder selber entscheiden. fakt ist, das dieser wert sehr markteng ist. es kann schnell rauf gehen, aber auch runter. wenn das teil jemand kauft, dann mit kleinem einsatz und liegen lassen. die technik hat beste aussichten ein blockbuster zu werden, fragt sich nur in welchem zeitraum

[MaatMod]

Antwort auf Beitrag Nr.: 23.036.325 von trading2006 am 25.07.06 11:35:27

@trading2006

w-o freut sich über jeden fleissigen User

Aber bitte, welcher interessierte User
kann hier die Übersicht behalten ?

MfG
MaatMOD

[AMERIBULL]

Guten Morgen !!!

[AMERIBULL]

Ist ACRONGENOMICS eine neue Tradingchance?

Meinungen bitte...

[Cpt_Tenbagger]

hi an alle!

Liebe Leserinnen und Leser!



Für eilige Leser
Der Uranexplorer AcronGenomics Inc., OTC BB, Symbol: AGNM,
seit 2004 in Frankfurt unter WKN A0B9TS , Symbol: EQ9 gelistet, hat mit der höchst innovativen Molecular Vision Ltd. eine ausgesprochen aussichtsreiche strategische Allianz geschmiedet, durch die revolutionäre und konkurrenzlose medizindiagnostische Geräte entwickelt und hergestellt werden sollen.

Quelle: hot-stock kurier

hab ich irgendwas verpasst?

acron und uranexplorer?

[AMERIBULL]

Aktueller Ticker bei WO:

http://www.wallstreet-online.de/adserver/code.php?bid=8682

[AMERIBULL]

Liebe Leserinnen und Leser!



Für eilige Leser

Der Uranexplorer AcronGenomics Inc., OTC BB, Symbol: AGNM,
seit 2004 in Frankfurt unter WKN A0B9TS , Symbol: EQ9 gelistet, hat mit der höchst innovativen Molecular Vision Ltd. eine ausgesprochen aussichtsreiche strategische Allianz geschmiedet, durch die revolutionäre und konkurrenzlose medizindiagnostische Geräte entwickelt und hergestellt werden sollen.



Unserer Kursziel auf Jahressicht: 2,30 Euro (aktueller Stand: 1,41 Euro). StopLoss bei 1,10 Euro. Sehr spekulativer Kauf!




Ihre Chance
AcronGenomics, gegründet 2004 und ehemals selbst ein innovatives Hightechunternehmen aus dem Nanotech-Bereich mit jetzigem Hauptsitz in Genf (Schweiz), versteht sich nunmehr als ein Unternehmen, das sich auf die Finanzierung und Kommerzialisieren neuartiger Technologien im medizinischen Bereich konzentriert. Am 22. Mai 2006 hat man deshalb ein Joint Development Agreement mit Molecular Vision Ltd. im Wert von 6.5 Mio. US$ geschlossen, um medizindiagnostische Produkte basierend auf der sog. BioLED-Technologie, einer Kombination aus Nano- und Biotechnologie, gemeinsam zu entwickeln und zu kommerzialisieren.

Die Molecular Vision Ltd.
Molecular Vision ist ein noch relativ junges und höchst innovatives Spin-Off-Unternehmen, das sich aus der Imperial Innovations Ltd. heraus entwickelt hat. Die Aufgabe dieser Firma wiederum besteht darin, die zahlreichen Innovationen des auf den Gebieten der Naturwissenschaften, Ingenieurwissenschaften und Medizin überaus renommierten Imperial College in London durch die Bildung entsprechender Firmen zu vermarkten. An der Spitze von Molecular Vision Ltd. steht seit 2001 Prof. Donal Barney, ein international äußerst renommierter Physiker, unter anderem Mitglied der Royal Society, Leiter der physikalischen Abteilung der naturwissenschaftliche Fakultät des Imperial College, Gewinner des Latsis-Preis für Nano-Technologie 2005 als auch im selben Jahr des Jan-Rajchman-Preis für seine Forschungen auf dem Gebiet des Flat Panel Displays (das sind Flachbild-schirme wir etwa das TFT-Display eines Laptops; Anm. d. Red.). Die Enge des Agreements zwischen AcronGenomics und Molecular Vision dokumentiert sich unter anderem darin, dass Donal Barney dem wissenschaftlichen Beratungsgremium von AcronGenomics vorsitzt. Zusammen will man neue und revolutionäre POC-Geräte zur Sofortdiagnose von Diabetes, Geschlechtskrankheiten, kardiovaskulären Krankheiten (Herz und -Gefäße betreffende Kr.; Anm. d. Red.) und Drogenmissbrauch entwickeln. Was ist die BioLED-Technologie? Die BioLED-Technologie bezeichnet das gleiche Konzept wie Lab-On-a-Chip (LOC; Labor auf dem Chip, d.h. vollständige analytische Prozesse von Probenvorbereitung bis zur Auswertung sind auf einem scheckkartengroßen (Computer)Chip integriert, Anm. D. Red.), Point-of-Care (POC; Streifentests und Schnelltestgeräte etwa für Blutalkoholgehalt, Schwangerschaft, Diabetes usw.; Anm. D. Red.) und „miniaturized Total Analysis Systems“ (μTAS; miniaturisierte Komplettanalysesysteme; Anm. d. Red.). Die BioLED ist eine vollkommen neuartige Technologie, bei der durch die patentierte Kombination der Mikroströmungslehre (engl. microfluidics, das Strömungsverhalten von Flüssigkeiten in kleinsten Mengen; Anm. d. Red.) mit optischen Detektoren, basierend auf der organischen pLED (polymer Light Emitting Diode), eine Vielzahl von miniaturisierten tragbaren POC-Diagnose-geräten realisiert werden könne, die das Potential dazu hätten, medizinische Standarttests zu werden.

Genauer: Die Reagenzien (Prüfflüssigkeiten oder Indikatoren) einer Feinprobe werden mit der Körperflüssigkeit – Blut, Urin oder Speichel - durch das Mikroflüssigkeitsnetz gemischt. Diese Mischung wird durch die integrierte, batteriegetriebene pLED dazu angeregt, ein Lichtsignal auszusenden, das wiederum vom integrierten Photodetektor aufgefangen wird und das Lichtsignal umwandelt in einen elektrischen Strom, dessen Spezifik einen medizindiagnostischen Aufschluss über die Struktur der Körperflüssigkeit gibt.
Nach Angaben von AcronGenomics ist diese Technologie konkurrenzlos. Man ist bestrebt, zukünftig zwei Versionen dieses Chips anzubieten: einmal als Chip, der mit einem handelsüblichen PDA (Personal Digital Assistant) verbunden werden kann, wie sie schon heute zum Beispiel in Krankenhäusern und Arztpraxen eingesetzt werden, und einmal als eine Version, die ohne PDA, stattdessen aber mit Hilfe eines eingebauten minaturisierten LCD-Displays ausgelesen werden kann, was das POC-Gerät auch für den privaten häuslichen Einsatz kostengünstig einsetzbar machen würde.

Ihr Risiko
Seit Januar/Februar 2006 hat sich der Kurs der Aktie von ca. 4 US$ bis auf aktuell ca. 1,90 US$ halbiert. Grund hierfür dürfte der Rücktritt von Dr. Leftheris Georgakopoulos als Präsident und Chefwissenschaftler von AcronGenomics am 13.02.2006 gewesen sein. Dr. Georgakopoulos stand für die viel versprechende Nano-JETA-Technologie. Mit dem Wechsel an der Firmenspitze hat sich auch das Geschäftsmodell verändert. Am 13.02.2006 wurde zwischen AcronGenomics und dem ausgeschiedenen Präsidenten ein Agreement geschlossen, die 4 Mio. Stammaktien von Dr. Georgakopoulos gegen 50 Prozent der Einnahmen aus dem Nano-Jeta Patent zu tauschen. Demnach werden alle möglichen zukünftigen Gewinne aus diesem Patent durch das Agreement geschmälert.
Darüber hinaus wies AcronGenomics im März 2006 ein akkumuliertes bilanzielles Defizit von insgesamt ca. 16 Mio. US$ für 2005 aus, von dem ein Löwenanteil auf Entwicklungskosten zurück zu führen ist. Am 22.05.2006 wies AcronGenomics einen Cashbestand von ca. US$ 1,279 Mio. US$ aus, der für die Finanzierung des operativen Geschäfts der nächsten sechs Monate ausreiche. Eine Kapitalerhöhung von US$ 1.12 Mio. zur Deckung der Betriebskosten in 2006 ist geplant und erscheint von Firmenseite als notwendig; vor allem im Hinblick auf die Finanzierung der Entwicklungskosten in der Zusammenarbeit mit Molecular Vision, die das einzige aktuelle Standbein von AcronGenomics zu sein scheint.
Hinzu kommt, dass bisher noch keine Umsätze generiert wurden und noch nicht abgesehen werden kann, wann das der Fall sein wird. Alles in allem keine ungewöhnliche finanzielle Situation für ein Early–Stage-Unternehmen, die einmal mehr das extreme Chance-Risiko-Verhältnis der am OTC BB gelisteten Firmen dokumentiert.

Fazit
Trotz des bilanziellen Defizits und der erst kurzfristigen geschäftlichen Umorientierung von AcronGenomics erscheint uns das Papier aus folgenden Gründen dennoch als ein hoch interessantes und spekulatives Investment:


Durch die Zusammenarbeit mit Molecular Vision eröffnet sich die Möglichkeit einer sehr engen und Erfolg versprechenden Zusammenarbeit mit höchst renommierten und innovativen Wissenschaftlern – vor allem mit Donal Barney und seinem Team), aus der
höchst innovative Produkte hervorgehen könnten, die auf
einem insgesamt auch zukünftig boomender Mega-Markt für Medizintechnik konkurrenzlos sein könnten.
Aus charttechnischer Sicht könnte sich das Papier in einer Bodenbildungsphase befinden.

Ein Kursziel von 2,30 Euro erscheint uns als möglich auf eine Sicht von zwölf Monaten. Ein StopLoss sollte aber konservativ bei 1,10 Euro gesetzt werden.
Ein sehr spekulativer Kauf!

Ihr Team vom
www.HotStock-Kurier.de










Sichern Sie sich den entscheidenden Vorteil der kostenlosen Expressbelieferung mit unseren aktuellsten Informationen.
Sie erhalten den kostenlosen HotStock-Kurier aus allererster Hand, wenn Sie hier Ihre Mailadresse eintragen:
[e-mail] und an uns schicken.
Besuchen Sie auch unsere Homepage unter:
www.hotstock-kurier.de.
<!--[if !supportLineBreakNewLine]-->
<!--[endif]-->
Wir freuen uns auf Sie!

Impressum
Camelot Finance Ltd. & Co. KG (In Gründung)
Telefon: [phone]

Kontakt
Chefradaktion: [e-mail]
Abo-Dienst: [e-mail].
Disclaimer
Der HotStock-Kurier dient auf seiner Homepage und als Newsletter ausschließlich Informationszwecken und ist ausdrücklich keine Aufforderung zum Kauf von Wertpapieren. Wir geben ausdrücklich weder Anlageempfehlungen noch Anlageberatung oder sonstige Empfehlungen. Vielmehr geben die Informationen des HotStock-Kuriers persönliche Meinungen wieder.
Der HotStock-Kurier informiert Sie mit seinen Publikationen schwerpunktmäßig über sog. "Pennystocks" (das sind Wertpapiere, die gemäß der Definition der US Securities and Exchange Commission (SEC) unter 5 US$ notieren), die am OTC BB, TSX-V, ASX und AIM und den Pinkssheets gelistet sind. Hierbei handelt es sich um Börsensegmente der höchsten Risikoklasse. Auf Grund der geringer Liquidität, der sich potentiell plötzlich ändernden Nachrichtenlage des jeweiligen Unternehmens während oder nach der Veröffentlichungen unserer entsprechenden Informationen sowie der niedriger Börsenkapitalisierung sind diese Werte höchst spekulativ bzw. extrem volatil und stellen nicht nur eine enorme Chance, sondern auch ein mindestens ebenso hohes Risiko für das vom Anleger eingesetzte Kapital dar, denn Kapitalminderungen bis hin zum Totalverlust des eingesetzten Kapitals können jederzeit eintreten. Hinzu treten politische und wirtschaftliche Risiken sowie mögliche Währungsschwankungen oder Naturkatastrophen, die einen negativen Einfluss auf den Kursverlauf der Aktien haben können und für die wir keine Haftung übernehmen.
Es ist ausgeschlossen, dass die Eigentümer oder Mitarbeiter des HotStock-Kuriers Long oder Short-Positionen in den beschriebenen Wertpapieren halten. Das gilt ebenso für Optionen und Derivate, die auf diesen Wertpapieren basieren. Die auf den Webseiten und in den Newslettern vom HotSTock-Kurier veröffentlichten Interviews und Informationen zu Wertpapieren und Unternehmen werden grundsätzlich von den jeweiligen Unternehmen vergütet. Nach dem geltenden Recht liegt hier ein Interessenkonflikt vor, auf den wir Sie hiermit ausdrücklich hinweisen wollen. Aber auch wenn unsere Informationen und Analysen nicht unabhängig sind, sind sie dennoch von strengen fachmännischen Qualitätskriterien geprägt: Quellenangaben und Risikoeinschätzungen hinsichtlich eines Unternehmens über das wir Sie informieren sind immer Bestandteil aller Informationen des HotStock-Kuriers. Bei aller kritischen Sorgfalt hinsichtlich der Zusammenstellung und Überprüfung der Quellen unserer Informationen übernehmen wir keine Gewähr für Richtigkeit, Genauigkeit und Vollständigkeit der dargestellten Sachverhalte. Auch übernehmen wir keine Garantie oder Haftung dafür, dass die vom HotStock-Kurier vermuteten Kurs- oder Gewinnentwicklungen der jeweiligen Unternehmen erreicht werden.
Jeder Anleger ist immer und zu jeder Zeit selbst verantwortlich für seine Anlageentscheidungen! Wir raten jedem privaten Anleger ausdrücklich sich von professionellen bzw. konzessionierten und unabhängigen Anlageberater Rat auch hinsichtlich unserer Informationen einzuholen.
Sämtliche Urheberrechte und sonstigen Rechte an der Website inklusive an deren Inhalten, Layout und Quelltexten sind vorbehalten. Die Inhalte dürfen nicht verändert und ohne schriftliche Zustimmung vom HotStock-Kurier nicht auf anderen Internetseiten oder vernetzten Rechnern genutzt werden. Ferner dürfen Sie die Inhalte nicht für öffentliche oder kommerzielle Zwecke vervielfältigen, vorführen, verbreiten oder anderweitig verwerten.
Mit Urteil vom 12. Mai 1998 - 312 O 85/98 - "Haftung für Links" hat das Landgericht Hamburg entschieden, dass man durch die Anbringung eines Links die Inhalte der gelinkten Seite ggf. mit zu verantworten hat. Dies kann nur dadurch verhindert werden, dass man sich ausdrücklich von diesen Inhalten distanziert. Hiermit distanzieren wir uns ausdrücklich von den Inhalten aller gelinkten Seiten auf unserer Homepage und machen uns diese Inhalte nicht zu eigen. Diese Erklärung gilt für alle auf unserer Homepage angebrachten Links. Nachdruck (auch auszugsweise), kommerzielle Weiterverbreitung und Aufnahme in kommerzielle Datenbanken nur mit schriftlicher Genehmigung des Herausgebers. Dies gilt insbesondere über Verlinkungen unserer Inhalte auf anderen Internetseiten bzw. die Übernahme unserer Inhalte/Bilder auf anderen Internetseiten.

©Copyright 2006 Camelot Finance Ltd. & Co KG.

[AMERIBULL]

Ihre Chance
AcronGenomics, gegründet 2004 und ehemals selbst ein innovatives Hightechunternehmen aus dem Nanotech-Bereich mit jetzigem Hauptsitz in Genf (Schweiz), versteht sich nunmehr als ein Unternehmen, das sich auf die Finanzierung und Kommerzialisieren neuartiger Technologien im medizinischen Bereich konzentriert. Am 22. Mai 2006 hat man deshalb ein Joint Development Agreement mit Molecular Vision Ltd. im Wert von 6.5 Mio. US$ geschlossen, um medizindiagnostische Produkte basierend auf der sog. BioLED-Technologie, einer Kombination aus Nano- und Biotechnologie, gemeinsam zu entwickeln und zu kommerzialisieren.

das hört sich doch interessant an....

[trading2006]

Antwort auf Beitrag Nr.: 23.036.433 von Cpt_Tenbagger am 25.07.06 11:44:00

das hab ich auch schon gelesen, die haben da wohl was vertauscht

[AMERIBULL]

Also eine Kooperation, welches bis in den NANO- und MEDIZINsektor reicht!

Die Molecular Vision Ltd.
Molecular Vision ist ein noch relativ junges und höchst innovatives Spin-Off-Unternehmen, das sich aus der Imperial Innovations Ltd. heraus entwickelt hat. Die Aufgabe dieser Firma wiederum besteht darin, die zahlreichen Innovationen des auf den Gebieten der Naturwissenschaften, Ingenieurwissenschaften und Medizin überaus renommierten Imperial College in London durch die Bildung entsprechender Firmen zu vermarkten. An der Spitze von Molecular Vision Ltd. steht seit 2001 Prof. Donal Barney, ein international äußerst renommierter Physiker, unter anderem Mitglied der Royal Society, Leiter der physikalischen Abteilung der naturwissenschaftliche Fakultät des Imperial College, Gewinner des Latsis-Preis für Nano-Technologie 2005 als auch im selben Jahr des Jan-Rajchman-Preis für seine Forschungen auf dem Gebiet des Flat Panel Displays (das sind Flachbild-schirme wir etwa das TFT-Display eines Laptops; Anm. d. Red.). Die Enge des Agreements zwischen AcronGenomics und Molecular Vision dokumentiert sich unter anderem darin, dass Donal Barney dem wissenschaftlichen Beratungsgremium von AcronGenomics vorsitzt. Zusammen will man neue und revolutionäre POC-Geräte zur Sofortdiagnose von Diabetes, Geschlechtskrankheiten, kardiovaskulären Krankheiten (Herz und -Gefäße betreffende Kr.; Anm. d. Red.) und Drogenmissbrauch entwickeln. Was ist die BioLED-Technologie? Die BioLED-Technologie bezeichnet das gleiche Konzept wie Lab-On-a-Chip (LOC; Labor auf dem Chip, d.h. vollständige analytische Prozesse von Probenvorbereitung bis zur Auswertung sind auf einem scheckkartengroßen (Computer)Chip integriert, Anm. D. Red.), Point-of-Care (POC; Streifentests und Schnelltestgeräte etwa für Blutalkoholgehalt, Schwangerschaft, Diabetes usw.; Anm. D. Red.) und „miniaturized Total Analysis Systems“ (μTAS; miniaturisierte Komplettanalysesysteme; Anm. d. Red.). Die BioLED ist eine vollkommen neuartige Technologie, bei der durch die patentierte Kombination der Mikroströmungslehre (engl. microfluidics, das Strömungsverhalten von Flüssigkeiten in kleinsten Mengen; Anm. d. Red.) mit optischen Detektoren, basierend auf der organischen pLED (polymer Light Emitting Diode), eine Vielzahl von miniaturisierten tragbaren POC-Diagnose-geräten realisiert werden könne, die das Potential dazu hätten, medizinische Standarttests zu werden.

[trading2006]

Antwort auf Beitrag Nr.: 23.036.436 von AMERIBULL am 25.07.06 11:43:24

zum traden wohl eher nicht glaube ich, es sei denn es stehen news in der pipeline was ich natürlich nicht weiß.

[trading2006]

Antwort auf Beitrag Nr.: 23.036.487 von AMERIBULL am 25.07.06 11:46:46

wenn jemand bereit ist einige mio zu investieren, muss er sich auch was davon versprechen, das ist klar.

[AMERIBULL]

Antwort auf Beitrag Nr.: 23.036.524 von trading2006 am 25.07.06 11:48:53

Nach der aktuellen Lage zu beurteilen, wäre eine Langfristposition wohl eher die interessante Variante, da der Wert charttechnisch sehr tief gefallen ist. Viel falsch könnte man eigentlich nicht machen...hm....

[AMERIBULL]

Die BioLED scheint auch sehr sehr interessant zu sein!!!

[trading2006]

Antwort auf Beitrag Nr.: 23.036.560 von AMERIBULL am 25.07.06 11:50:58

das dachte ich mir auch schon, eher langfristig mit kleinem geld. man bekommt eh kaum was am freien markt

[AMERIBULL]

Die Aufgabe dieser Firma wiederum besteht darin, die zahlreichen Innovationen des auf den Gebieten der Naturwissenschaften, Ingenieurwissenschaften und Medizin überaus renommierten Imperial College in London durch die Bildung entsprechender Firmen zu vermarkten. An der Spitze von Molecular Vision Ltd. steht seit 2001 Prof. Donal Barney, ein international äußerst renommierter Physiker, unter anderem Mitglied der Royal Society, Leiter der physikalischen Abteilung der naturwissenschaftliche Fakultät des Imperial College, Gewinner des Latsis-Preis für Nano-Technologie 2005 als auch im selben Jahr des Jan-Rajchman-Preis für seine Forschungen auf dem Gebiet des Flat Panel Displays (das sind Flachbild-schirme wir etwa das TFT-Display eines Laptops; Anm. d. Red.). Die Enge des Agreements zwischen AcronGenomics und Molecular Vision dokumentiert sich unter anderem darin, dass Donal Barney dem wissenschaftlichen Beratungsgremium von AcronGenomics vorsitzt. Zusammen will man neue und revolutionäre POC-Geräte zur Sofortdiagnose von Diabetes, Geschlechtskrankheiten, kardiovaskulären Krankheiten (Herz und -Gefäße betreffende Kr.; Anm. d. Red.) und Drogenmissbrauch entwickeln.

[trading2006]

Antwort auf Beitrag Nr.: 23.036.521 von AMERIBULL am 25.07.06 11:48:51

nanotech unternehmen werden die nächsten jahre boomen, frage ist nur wer sich durchsetzt am massenmarkt. hier siehts gut aus, weil diagnose im gesundheitsbereich viele mrd verschlingt.

[AMERIBULL]

Antwort auf Beitrag Nr.: 23.036.606 von trading2006 am 25.07.06 11:54:32

Bei solchen Werten ist es immer empfehlenswert kleine Posis aufzubauen, da es ja auch ein Risiko gibt. Wenn es aufgeht, kann man immer noch nachlegen.

[trading2006]

Antwort auf Beitrag Nr.: 23.036.602 von AMERIBULL am 25.07.06 11:54:07

das ist wohl das flagschiff der firma
es wird allerdings noch einige zeit vergehen bis hier umsätze und gewinn erwirtschaftet werden, wie bei so vielen firmen in dem sektor.

[AMERIBULL]

Was ist die BioLED-Technologie?


Die BioLED-Technologie bezeichnet das gleiche Konzept wie Lab-On-a-Chip (LOC; Labor auf dem Chip, d.h. vollständige analytische Prozesse von Probenvorbereitung bis zur Auswertung sind auf einem scheckkartengroßen (Computer)Chip integriert, Anm. D. Red.), Point-of-Care (POC; Streifentests und Schnelltestgeräte etwa für Blutalkoholgehalt, Schwangerschaft, Diabetes usw.; Anm. D. Red.) und „miniaturized Total Analysis Systems“ (μTAS; miniaturisierte Komplettanalysesysteme; Anm. d. Red.). Die BioLED ist eine vollkommen neuartige Technologie, bei der durch die patentierte Kombination der Mikroströmungslehre (engl. microfluidics, das Strömungsverhalten von Flüssigkeiten in kleinsten Mengen; Anm. d. Red.) mit optischen Detektoren, basierend auf der organischen pLED (polymer Light Emitting Diode), eine Vielzahl von miniaturisierten tragbaren POC-Diagnose-geräten realisiert werden könne, die das Potential dazu hätten, medizinische Standarttests zu werden.

[trading2006]

Antwort auf Beitrag Nr.: 23.036.633 von AMERIBULL am 25.07.06 11:56:14

keine frage, oder kennst du ein nanotech unternehmen, welches schon gewinne erwirtschaftet.
hier verhält es sich ähnlich wie bei explorern, erst investieren und bei gelungener innovation/produktion wird geerntet. sowas kann natürlich auch mal schief gehen oder es gibt kurzfristige rückschläge was sich natürlich auch auf den kurs auswirkt. dann ist zeit nachzulegen

[trading2006]

entschuldige bitte rechtschreibfehler, sitze am laptop

[AMERIBULL]

Genauer: Die Reagenzien (Prüfflüssigkeiten oder Indikatoren) einer Feinprobe werden mit der Körperflüssigkeit – Blut, Urin oder Speichel - durch das Mikroflüssigkeitsnetz gemischt.


Diese Mischung wird durch die integrierte, batteriegetriebene pLED dazu angeregt, ein Lichtsignal auszusenden, das wiederum vom integrierten Photodetektor aufgefangen wird und das Lichtsignal umwandelt in einen elektrischen Strom, dessen Spezifik einen medizindiagnostischen Aufschluss über die Struktur der Körperflüssigkeit gibt.

[trading2006]

Börse
Frankfurt

Aktuell
1,44 EUR

Zeit
25.07.06 09:00

Diff. Vortag
+2,13 %

Tages-Vol.
--

Gehandelte Stück
0

Geld
1,46

Brief
1,55

Zeit
25.07.06 11:17

Spread
--

Geld Stk.
1.500

Brief Stk.
685

[trading2006]

das bid wird stärker, gibt wohl erste interessenten

[AMERIBULL]

Nach Angaben von AcronGenomics ist diese Technologie konkurrenzlos. Man ist bestrebt, zukünftig zwei Versionen dieses Chips anzubieten: einmal als Chip, der mit einem handelsüblichen PDA (Personal Digital Assistant) verbunden werden kann, wie sie schon heute zum Beispiel in Krankenhäusern und Arztpraxen eingesetzt werden, und einmal als eine Version, die ohne PDA, stattdessen aber mit Hilfe eines eingebauten minaturisierten LCD-Displays ausgelesen werden kann, was das POC-Gerät auch für den privaten häuslichen Einsatz kostengünstig einsetzbar machen würde.

[AMERIBULL]

Antwort auf Beitrag Nr.: 23.036.676 von trading2006 am 25.07.06 11:58:54

Es gibt keinen NANO, keinen MEDIZINTECHNIK oder EXPLORER Company, die auf anhieb Früchte erntet. Klar muß erst investiert und geforscht werden, aber hier ist man glaube ich schon auf einem guten Wege!


Hier:
Am 22. Mai 2006 hat man deshalb ein Joint Development Agreement mit Molecular Vision Ltd. im Wert von 6.5 Mio. US$ geschlossen, um medizindiagnostische Produkte basierend auf der sog. BioLED-Technologie, einer Kombination aus Nano- und Biotechnologie, gemeinsam zu entwickeln und zu kommerzialisieren.

[AMERIBULL]

Antwort auf Beitrag Nr.: 23.036.686 von trading2006 am 25.07.06 11:59:14

passiert doch jedem, wir wollen doch nicht kleinlich werden

[AMERIBULL]

Fazit
Trotz des bilanziellen Defizits und der erst kurzfristigen geschäftlichen Umorientierung von AcronGenomics erscheint uns das Papier aus folgenden Gründen dennoch als ein hoch interessantes und spekulatives Investment:


Durch die Zusammenarbeit mit Molecular Vision eröffnet sich die Möglichkeit einer sehr engen und Erfolg versprechenden Zusammenarbeit mit höchst renommierten und innovativen Wissenschaftlern – vor allem mit Donal Barney und seinem Team), aus der
höchst innovative Produkte hervorgehen könnten, die auf
einem insgesamt auch zukünftig boomender Mega-Markt für Medizintechnik konkurrenzlos sein könnten.
Aus charttechnischer Sicht könnte sich das Papier in einer Bodenbildungsphase befinden.

Ein Kursziel von 2,30 Euro erscheint uns als möglich auf eine Sicht von zwölf Monaten. Ein StopLoss sollte aber konservativ bei 1,10 Euro gesetzt werden.
Ein sehr spekulativer Kauf!

Ihr Team vom
www.HotStock-Kurier.de

[AMERIBULL]

The global trend towards miniaturization of devices could not leave the Life Sciences sector unaffected. The bringing together of different technologies like microelectronics, optics, mechanics, physics and molecular biology along with the miniaturization of fluidic and sensing devices makes possible the development of fully integrated, miniaturized diagnostic systems.

[AMERIBULL]

Acrongenomics, Inc. and Molecular Vision, Ltd. introduce BioLED Technology, an innovative and patented combination of microfluidics with a state-of-the-art optical detection system based on pLED (polymer Light Emitting Diode) technology to deliver affordable, intelligent and readily portable Point-of-Care Medical Diagnostic devices. Science and technology team up to improve patients’ quality of life.

[AMERIBULL]

Our mission is to provide solutions for:

Faster and accurate diagnosis and treatment decisions
Reduced healthcare costs
Reduced visits to hospitals
Flexibility, versatility and reliability

[AMERIBULL]

Press Release
Acrongenomics, Inc. Announces Closing of $4,000,000 Private Placement to Fund Ongoing Operations

Thursday December 22, 12:40 pm ET

ATHENS, Greece--(BUSINESS WIRE)--Dec. 22, 2005-- Acrongenomics, Inc. (OTCBB:AGNM) a publicly traded research and development nanobiotechnology company pioneering the development of uniquely advanced nano-molecular diagnostics, today announced the closing of the 1,000,000 share private placement financing at $4.00 per share as of Friday December 16th 2005. Acrongenomics will use the net proceeds for the ongoing development of the Nano-JETA platform as well as general corporate purposes.

"The success of this financing illustrates a strong confirmation of our approach, giving us the opportunity to focus on delivering advanced nanotechnology research to the life sciences industry. By putting together our scientific excellence and strong financial base, we have managed to complete this private placement financing earlier than expected," said Constantine Poulios, Acrongenomics' Vice President.
Acrongenomics also announces that it is proceeding to obtain an independent evaluation of its technology from a certified reference laboratory.

About Acrongenomics Inc.
Acrongenomics Inc., is a publicly traded company that focuses on investing and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications.

[AMERIBULL]

Press Release
Acrongenomics Inc. Explores Novel 'Nanoweapons' in Eliminating Hospital-Related Infections

Tuesday February 14, 2:15 pm ET

CALGARY, Alberta-Acrongenomics, Inc. (OTCBB:AGNM) is pleased to announce that it is currently under negotiations in order to complete a collaboration agreement with an International group of experts towards the development of unique "nanoweapons" that exhibit extraordinary properties in eliminating hospital related infections.

Hospital related infections are a major cause of morbidity and mortality around the world. The pathogenesis of hospital-related infections is quite complicated, the virulence of the pathogens is variable, and the host factors have not yet been well defined.

Hospital related infections are one of the 10 leading causes of mortality in developed countries. They often involve bacteria which are resistant to antibiotics, thereby complicating their treatment. Infections involving multi-drug resistant bacteria are a major concern for most hospitals and healthcare establishments, since they contribute to an increase in morbidity and mortality compared to the underlying diseases alone. They also impact the length of stay and the related healthcare costs.

According to the U.S. Centers for Disease Control (CDC) and Prevention, hospital related infections are the fourth leading cause of death in the United States, after heart disease, cancer and stroke.

Among hospital related infections, those caused by Methicillin-resistant Staphylococcus aureus (MRSA) cause particular concern, since they are associated with high morbidity and mortality and are a significant burden on healthcare resources (Clin Infect Dis. 2003). Most frequently cross-transmitted between hospitalized patients through healthcare workers, MRSA is highly contagious and responsible for endemic infections which are very difficult to control.

Antimicrobial resistant infections in healthcare settings are a major threat to patient safety. Each year in the United States an estimated 2 million hospitalized people acquire infections that result in more than 90,000 deaths. More than half of these infections are caused by bacteria that are resistant to at least one of the antimicrobials commonly used to treat those infections, according to CDC.

There are many ways for the infections to spread, from the hands of health care workers, doctors, nurses, nursing aides, and technicians to the patients they encounter. The skin in healthy people provides an every day barrier against germs. But this barrier is routinely breached in hospitals because the skin is opened for operations, because of wounds, and because of the presence of indwelling medical devices such as intravenous catheters or urinary catheters.

Antibiotic resistant infectious diseases impose a significant burden on society, and surpass $30 billion in annual direct treatment costs in the U.S. alone. The high cost stems from several key factors such as: Individuals infected with drug resistant organisms usually have a poor prognosis and are more likely to require hospitalization and drug-resistant infections acquired in hospitals nearly triple the cost of hospital stays. The cost of antibiotic resistance is expected to grow larger as medical experts anticipate record increases of antibacterial resistance in the next decade.
Acrongenomics Inc. strongly believes that such a joint proposal, once adopted would fulfill all current unmet needs in such a thriving market.
Acrongenomics, Inc. also announced today the appointment of Mr. Constantine Poulios, LL.M., as President. Mr. Poulios was holding the position of Vice President at Acrongenomics Inc. as of July 6, 2004. Mr. Poulios succeeds Dr. Eleftherios Georgakopoulos, who retired from the board earlier this week. The leadership change coincides with the transfer of the former president's 4 million shares to the treasury of the company, while the company keeps full title on all its technology developed to date.
Mr. Poulios has extensive experience in serving multinational companies. An attorney by education and profession, he was part of the Corporate and Tax Advisory Services of Ernst & Young before joining Acrongenomics, Inc. Mr. Poulios was managing important accounts including that of Coca Cola, Halliburton, Hewlett Packard, ABN AMRO, Citigroup, Ciments Francais, Pfizer, GlaxoSmithKline and EMI Music for Ernst & Young Southeast Europe, while he has also worked for Ernst & Young in the US. He obtained his Master's of Laws from Northwestern University School of Law in Chicago in 1997, while he is a 1995 graduate from the School of Law at the National University of Athens. Mr. Poulios has also been awarded with a Certificate in Law in 1993 from the School of Law at the University of Bordeaux in France and he has attended graduate courses in management in US universities.

As a corporate executive who has driven business initiative of global corporations for some years, Mr. Poulios is looking forward to bringing in apart from his leadership skills and his business and legal expertise, hands-on knowledge on how to properly conduct business in the rigorous environment of the Sarbanes-Oxley legislation.

Acrongenomics, Inc. also announced today the appointment of Mr. Platon Tzouvalis, MSc., as Vice President. As a Biochemist, Mr. Tzouvalis is an experienced pharmaceutical industry professional. He has been a member of Acrongenomics' Scientific Advisory Board since May 2004. His expertise lies in the areas of Quality Control, Operational Procedures as well as Pharmaceutical Product and Process Improvement. He received his B.S. Degree in Biochemistry from the University of Illinois in 1990 and his Master's Degree in the same field from DePaul University at Chicago in 1995.

Mr. Tzouvalis' earlier career includes working as a Research Chemist in collaboration with the University of Illinois at Chicago, holding the position of Research and Development Chemist at SynQuest, Inc. and as Advanced Quality Assurance Specialist of Organic Operations and then Project Manager in Bioanalytical Quality Assurance for Abbott Laboratories. Mr. Tzouvalis has also been awarded with the Abbott Diagnostics Division Science Award of 2002 as part of the Organic Operation Remediation Team.

About Acrongenomics Inc.
Acrongenomics Inc., is a publicly traded company that focuses on investing and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications.

[AMERIBULL]

Press Release
Acrongenomics, Inc. Appoints Chief Technology Officer

Friday February 24, 9:35 am ET

ATHENS, Greece--(BUSINESS WIRE)--Acrongenomics, Inc. announced today the appointment of Dr. Manos Topoglidis to its Board of Directors & Scientific Advisory Board as Chief Technology Officer.

In his new role, Dr. Topoglidis will be responsible for providing Acrongenomics' management team with a solid scientific and technical vision. This includes understanding and translating Acrongenomics' science and technology-based capabilities into competitive advantages, implementing a compelling R&D pipeline and collaborating with government, academia and industry leaders in the life sciences industry. Dr. Topoglidis will also play a significant role in leading the Company's research team to define and assess viable opportunities for Acrongenomics, with particular interest in the realm of biosensors.

Dr. Topoglidis has impressive experience leading international research teams in academia to unlock nanotechnology solutions. He ranks among the first to extensively research the use of nanoporous surfaces for biosensing applications and has written numerous original nanotechnology-related publications which have been cited worldwide.
"In this new, ever-changing field of nanobiotechnology, it is paramount for our team to stay on top of the pioneering technologies, trends and unmet needs in the medical community," states Constantine Poulios, President of Acrongenomics. "Dr. Topoglidis' unique and in-depth background in the fields of nanotechnology and biology made him the ideal candidate to direct our technological vision. He provides invaluable experience relating to the intricacies of our current nanotechnology projects and will also set the tone in determining Acrongenomics' future biotechnology solutions."

Acrongenomics also announces new headquarters in Geneva, Switzerland to accommodate its forthcoming expansion phase, grow its collaborative network and centrally position itself in a first-rate European market. In addition to its rank as the leading financial center of Europe, Switzerland is a global leader in scientific and life sciences research, making it an excellent location. With a bustling biotechnology sector, Switzerland exhibits a solid cluster of world-class Universities, pharmaceutical giants, burgeoning biotech companies, key government organizations and industry associations. Acrongenomics is thrilled to explore the opportunities offered by the dynamic European economy.

About Acrongenomics, Inc.
Acrongenomics Inc., is a publicly traded company that focuses on investing and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications. The company has its international headquarters in Geneva, Switzerland.

[AMERIBULL]

Acrongenomics Inc. Enters Into Memorandum of Understanding with Molecular Vision, an Imperial Innovations Spin-Out Company

Wednesday March 29, 12:09 pm ET

GENEVA, Switzerland--(BUSINESS WIRE)--March 29, 2006--Acrongenomics Inc. (OTCBB:AGNM) and Molecular Vision Ltd -- an Imperial Innovations spin-out company -- today signed a Memorandum of Understanding (MOU) to embark on joint R&D to develop and commercialize a line of low-cost, easy-to-use and readily portable point-of-care (POC) diagnostic devices for medical testing that will greatly extend the tools available to the medical community.

The devices will allow for on-the-spot quantitative/qualitative diagnosis for diabetes, drug abuse, STDs and cardiovascular diseases. The ability to perform accurate and fast diagnosis at first consultation will eliminate the need for patients to make repeat visits, thereby bringing forward the initiation of treatment, freeing up clinical time, and lowering treatment costs.

Furthermore, the technology offers potential outside the diagnostics market and will be of use to many specialists lacking access to on-site laboratory facilities. The global POC testing market is estimated to reach US$18 billion by 2010 (BCC Research).

Molecular Vision's patented diagnostic chips have the potential to become a de-facto standard for medical testing. They are based on a novel technology platform that will allow the development of readily portable POC devices for a broad range of medical applications. They incorporate two powerful technologies: microfluidics and organic semiconductor devices (light emitting diodes and photodetectors).

Organic polymer light emitting diodes have been the subject of intense scientific and commercial interest since their discovery at Cambridge University in 1989 by Molecular Vision co-founder Professor Donal Bradley and his colleagues. This early development led Professor Bradley and colleagues to found Cambridge Display Technology Ltd (NASDAQ:OLED). Professor Bradley is now the head of the Physics Department at Imperial College London and enjoys an international reputation for his organic semiconductor research. In 2005 he was awarded the prestigious Jan Rajchman Prize by the Society for Information Displays for outstanding scientific and technical research in the field of flat-panel displays. He also received the 2005 European Latsis Prize for Nano-Engineering, awarded by the European Science Foundation, for research on molecular-level control of the performance of organic semiconducting materials and devices.
Professor Andrew deMello -- Molecular Vision-co-founder -- is a professor of Chemical Nanosciences in the Department of Chemistry at Imperial College. He is a pioneer in the field of microfluidics. In 2002 he was awarded the SAC Silver Medal by the Royal Society of Chemistry.
Dr John deMello -- Molecular Vision-co-founder -- is a senior lecturer in nanomaterials in the Department of Chemistry at Imperial College. His primary research interests include organic semiconductors, miniaturized devices for chemical and biological diagnostics, and intelligent synthesis techniques for the controlled production of nanoparticles.
"There is a great demand for accurate quantitative and qualitative portable testing devices, and the POC market is still at an embryonic stage. Acrongenomics Inc. looks forward to working with leading research academics from Imperial College London," said Constantine Poulios, President of Acrongenomics. "We believe that this collaborative effort between Acrongenomics and Molecular Vision in advancing medical diagnostics will be fruitful and rewarding for both companies."
About Acrongenomics Inc.

Acrongenomics Inc., is a publicly traded company that focuses on investing and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications. The company has its international headquarters in Geneva, Switzerland.

About Molecular Vision Ltd
Molecular Vision is a spin-out company of Imperial Innovations Ltd. The company was founded in 2002 in order to meet a clearly defined demand in the medical diagnostics, biosensors and analytical instrumentations markets: the need for miniaturized chemical and biological detectors offering high sensitivity and functionality at low cost. The company has directly addressed this market demand by inventing a novel method for optical detection based on recent advances in organic electronics and light emitting diodes combined with microfluidics technology. The company has mainly focused on applying its technology to the medical diagnostics markets.

About Imperial Innovations Ltd
Imperial Innovations is one of the UK's leading technology commercialization companies with a strong value creation record having already generated revenues in excess of GBP 30 million from spin-outs and licenses since 1997. The company, together with Imperial's academic inventors, has established equity holdings in more than 54 spin-out companies and completed over 100 commercial agreements. Over 1,000 jobs have been created through the spin-out companies.

Imperial Innovations commercializes technology emanating from Imperial College and external sources. Technologies range across software, micro and nano devices, power electronics, renewable energy, mechanical tools, medical imaging and devices, therapeutics and drug discovery tools.

[AMERIBULL]

Press Release
Acrongenomics Inc., signs a £3.45 Million (US $6.5 Million) Joint Development Agreement with Molecular Vision Ltd., to offer novel Point-Of-Care solutions through the unique BioLED technology.

Monday May 22, 2006

GENEVA, Switzerland--(BUSINESS WIRE)—May 22, 2006—Acrongenomics, Inc. (OTCBB:AGNM) and Molecular Vision, Ltd. -- an Imperial Innovations spin-off company -- today announced a joint collaboration intended to accelerate the development and commercialization of low-cost, easy-to-use and readily portable Point-of-Care (POC) diagnostic devices for personalized medical testing that will greatly extend the tools available to the medical community.

The project outlined in the collaboration is intended to support the development of novel POC devices for on-the-spot diagnosis of diabetes management, STDs (Sexually Transmitted Diseases), cardiovascular diseases and substances of abuse, based on the BioLED technology developed by the Molecular Vision’s founders.

“With diagnostics and therapeutics converging in today’s healthcare market, Acrongenomics and Molecular Vision embark on a promising partnership to tackle the tough technical challenges associated with personalized medicine,” said Constantine D. Poulios, president of Acrongenomics Inc. “Through the combined strength of our teams, we will be able to deliver revolutionary POC diagnostics to market and provide sophisticated tools demanded by the global medical community.”

“We look forward to working closely with Acrongenomics to develop a new generation of point-of-care diagnostic devices.” said Donal Bradley co-founder of Molecular Vision Ltd. “This collaboration enables us to progress towards our first products in a timely fashion”

Collaboration Details

The contract signed by both parties, describes the relationship, fields of practice and actions that each party undertakes for the technology’s development through this collaboration. Specific joint projects are to be carried out under a disease-focused technology project agreement describing the milestones and the sharing of values. The parties will share tasks associated with research and development, as well as potential revenues from commercial products resulting from the project.

About POC and Personalized Medicine

Advanced POC technologies are shaping a new era of personalized diagnosis, in which predisposition to a disease is detected at an earlier stage and treatment is tailored to the patient’s individual needs. Personalized medicine encompasses in vitro diagnostics to assess disease risk, identify and characterize disease, monitor patients for disease onset and progression, select therapy and evaluate therapeutic response. The ability offered by BioLED technology to perform accurate and fast diagnosis at first consultation will reduce the need for patients’ repeated visits to hospitals/GP’s, thereby bringing forward the initiation of treatment, freeing up clinical time and lowering treatment costs.

[AMERIBULL]

BioLED Technology

Molecular Vision's patented diagnostic chips have the potential to become a de-facto standard for medical testing. They are based on its novel BioLED technology which allows for the development of readily portable POC devices for a broad range of medical applications. They incorporate two powerful technologies: microfluidics and organic semiconductor devices (light emitting diodes and photodetectors).

Conjugated polymer light emitting diodes have been the subject of intense scientific and commercial interest since their discovery at Cambridge University in 1989 by Molecular Vision co-founder Professor Donal Bradley and his colleagues. This early development led Professor Bradley and colleagues to found Cambridge Display Technology, Ltd. (NASDAQ:OLED).

Professor Bradley is the head of the Physics Department at Imperial College London and enjoys an international reputation for his organic semiconductor research. In 2005, he was awarded the prestigious Jan Rajchman Prize by the Society for Information Displays for outstanding scientific and technical research in the field of flat-panel displays. He also received the 2005 European Latsis Prize for Nano-Engineering, awarded by the European Science Foundation, for research on molecular-level control of the performance of organic semi-conducting materials and devices. This year he was a runner-up in the inaugural European Inventor of the Year Awards.


Professor Andrew de Mello -- Molecular Vision’s co-founder -- is a professor of Chemical Nanosciences in the Department of Chemistry at Imperial College. He is a pioneer in the field of microfluidics. In 2002, he was awarded the SAC Silver Medal by the Royal Society of Chemistry for his contribution to the Analytical Sciences.

Dr John de Mello -- Molecular Vision’s co-founder -- is a senior lecturer in nanomaterials in the Department of Chemistry at Imperial College. His primary research interests include organic semiconductors, miniaturized devices for chemical and biological diagnostics, and intelligent synthesis techniques for the controlled production of nanoparticles.

Professor Donal Bradley, Professor Andrew de Mello and Dr John de Mello have joined Acrongenomics’ Scientific Advisory Board.

"The addition of these three noted scientists to our Scientific Advisory Board is a tremendous gain for our company. Their insight will be invaluable in moving forward towards our strategic goals" said Platon Tzouvalis, Acrongenomics’ Vice President & Chief Operating Officer

About Acrongenomics, Inc.

Acrongenomics Inc., is a publicly traded company that focuses on investing and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-oriented applications. The company has its international headquarters in Geneva, Switzerland.

About Molecular Vision, Ltd.

Molecular Vision is a spin-off company of Imperial Innovations Ltd. The company was founded to meet a clearly defined demand in the medical diagnostics, biosensors and analytical instrumentations markets: the need for miniaturized chemical and biological detectors offering high sensitivity and functionality at low cost. The company has directly addressed this market demand by inventing a novel method for optical detection based on recent advances in organic electronics and light emitting diodes combined with microfluidics technology. The company has mainly focused on applying its technology to the medical diagnostics markets.


Important Information About Forward-Looking Statements

All statements in this news release that are other than statements of historical facts are forward-looking statements which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates", "believes", "could", "expects", "intends", "may", "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.

A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions.

For further information concerning risks and uncertainties that may affect our future results, please review the disclosures contained in our latest filings with the SEC, including our most recent annual report on Form 10-KSB, and subsequent quarterly reports on Form 10-QSB. Other than as required by federal securities laws, we undertake no obligation to publicly update or revise any of our forward-looking statements, whether as a result of changed circumstances, new information, future events, or for any other reason occurring after the date of this news release.

[AMERIBULL]

http://www.acrongen.com/files/agnm_in_clinica_p18_b.pdf

[AMERIBULL]

OUTSTANDINGS nur 13.824.123

[AMERIBULL]

Acrongenomics, Inc.
At-a-Glance
Headquarters: Geneva,Switzerland

OTC.BB: AGNM

Deutsche Borse AG: EQ9.F

Fiscal year ends: Dec. 31

Market cap (mm)*: ~ 35
Common shares outstanding
(mm)*: 13,824,123
*(as of May 19, 2006)

[AMERIBULL]

Market Opportunity: POC Diagnostics
The worldwide POC market reached US$9.1 billion in 2005 and is estimated to reach US$18.2 billion by 2010 (report: RB-209 Point-Of-Care Diagnostics from Business Communications Company, Inc.). According to this report, United States is the world’s leader, with POC Testing (POCT) revenues of US$5.07 billion in 2005 and is expected to yield sales of nearly US$9.68 billion in 2010. In the
future, the POC market will not be segmented by testing discipline (i.e. wet and dry chemistry, clinical chemistry, hematology, etc.), but will be divided by need and convenience. Undoubtedly, POCT is a vital component for patient care since it can provide fast and accurate diagnosis.

[AMERIBULL]

Meeting All Market Expectations
BioLED technology

�� is the only technology that uses pLEDs as an innovative optical detection system.

�� gives clear result in 2-3 minutes.

�� offers portable devices with very low manufacturing cost < $1.

�� offers simple, easy to use devices that do not require expert personnel,ideal as Over-The-Counter (OTC) product.

�� is designed to handle drops of complex materials (blood, urine and saliva).

�� has the ability to run multiple diagnostic tests on the same microchip.

�� has the potential to go beyond POC devices.

[AMERIBULL]

Board of Directors
Acrongenomics’ board of directors has been extensively involved in creating and implementing the Company’s successful business model, essential for its future financial growth and development.

• Constantine Poulios LL.M., President and member of the Board of
Directors. Mr. Poulios has extensive experience in serving multinational companies in the rigorous environment of the Sarbanes-Oxley legislation. Mr.Poulios was managing important accounts including that of Coca Cola,Halliburton, Hewlett Packard, ABN AMRO, Citigroup, Ciments Francais, Pfizer,GlaxoSmithKline and EMI Music for Ernst & Young Southeast Europe, while he
has also worked for Ernst & Young LLP in the US.

• Platon Tzouvalis, M.Sc., Vice President and member of the Board of Directors and Scientific Advisory Board. Mr. Tzouvalis expertise lies in the areas of Quality Control, Operational Procedures as well as Pharmaceutical Product and Process mprovement.

• Ron Lizée B.Comm. CGA. CFP, Chief Financial Officer. Mr. Lizée has over 25 years experience in the fields of tax, accounting and auditing.

• Manos Topoglidis, Ph.D., member of the Board of Directors and Scientific Advisory Board. Mr. Topoglidis received his Ph.D. in Chemistry from Imperial College London in 2001. His research interests and expertise lie in the areas of Biosensors, Nanomaterials, Biotechnology and Nanotechnology.

[AMERIBULL]

Arch Investment Conference Thursday, June 15, 2006 in New York for Small and Micro-cap Companies Thursday June 8, 4:49 pm ET NEW YORK--(BUSINESS WIRE)--June 8, 2006--

Arch Investment Conferences, Inc. is proud to announce its 2006 conference series continues as a dynamic set of small- and micro-cap companies present to the investment community on Thursday, June 15 in New York at the Hotel Plaza Athenee. Featured guest panelists include Josh Levine of ChangeWave.com and Peter Leeds of PeterLeeds.com. Presenting companies include:

Baldwin Technology Co. Inc. (AMEX:BLD - News) Synergetics USA (NASDAQ:SURG - News)

NeoGenomics Inc. (OTCBB:NGNM - News) China Digital Communication Group (OTCBB:CHID - News)

Acrongenomics, Inc. (OTCBB: AGNM - News)

The Hotel Plaza Athenee is located at 37 East 64th Street (at Madison Ave.), New York, N.Y. 10021. Breakfast and registration begin at 8:00 a.m. The entire event will be webcast and available for 90 days through Vcall at http://www.informedinvestors.com/VC/ClientPage.asp?ID=45356 and at www.investrend.com. Attendance at Arch conferences is open only to qualified investment professionals, and by invitation only. We encourage institutional investors as well as buy-side money managers, small/micro cap analysts, and portfolio managers to inquire about attending Arch conferences as our guests. For more information, or to request an invitation, please contact German de la Roche at [e-mail] or call 866-707-7920. This event is sponsored by: Tobin Smith and ChangeWave, Charles Payne and Wall Street Strategies, PeterLeeds.com, Wall Street Calendar, Investrend Research, Business Wire, and ArchInsight.com About Arch Investment Conferences, Inc. Arch Investment Conferences was founded in 2005 by German de la Roche. Arch's audience has grown substantially and more than 1,600 investors, primarily institutional, have attended or been part of the conference and webcasts. With eight conferences in 2006 in New York City and three West Coast conferences beginning in September 2006, Arch plans to continue delivering on its promise to be a bridge to the companies of tomorrow.

For more information, visit http://www.archconferences.com. Companies interested in presenting please contact German de la Roche. Contact: Arch Investment Conferences, Inc. German de la Roche, 866-707-7920 [e-mail]

[trading2006]

Antwort auf Beitrag Nr.: 23.037.061 von AMERIBULL am 25.07.06 12:25:49

dann stimmt die info von comdirect ja mal. sind sonst nicht immer so aktuell

[trading2006]

Antwort auf Beitrag Nr.: 23.036.790 von AMERIBULL am 25.07.06 12:05:29

[trading2006]

Börse
Frankfurt

Aktuell
1,44 EUR

Zeit
25.07.06 09:00

Diff. Vortag
+2,13 %

Tages-Vol.
--

Gehandelte Stück
0

Geld
1,46

Brief
1,55

Zeit
25.07.06 11:17

Spread
--

Geld Stk.
1.500

Brief Stk.
685

taxe unverändert.

[trading2006]

Antwort auf Beitrag Nr.: 23.037.248 von AMERIBULL am 25.07.06 12:38:43

kannst du etwas über die aktionärsstruktur herausfinden? es werden so wenige shares gehandelt, dass das nur daran liegne kann, das viele shares in festen händen sind. oder das teil kannte einfach nur keine sau vorher, aber glaub ich nicht so wirklich

[trading2006]

Kurshistorie Frankfurt
Datum Erster Hoch Tief Letzter Umsatz
24.07.2006 1,52 1,52 1,41 1,41 2.0k
21.07.2006 1,52 1,52 1,52 1,52 0
20.07.2006 1,53 1,53 1,53 1,53 0
19.07.2006 1,58 1,58 1,58 1,58 0
18.07.2006 1,50 1,50 1,50 1,50 0
17.07.2006 1,49 1,49 1,49 1,49 0
14.07.2006 1,48 1,48 1,48 1,48 0
13.07.2006 1,52 1,52 1,52 1,52 0
12.07.2006 1,51 1,51 1,51 1,51 0
11.07.2006 1,51 1,51 1,51 1,51 0
10.07.2006 1,62 1,62 1,62 1,62 0
07.07.2006 1,80 1,80 1,80 1,80 0
06.07.2006 1,78 1,78 1,78 1,78 0
05.07.2006 1,80 1,80 1,80 1,80 0
04.07.2006 1,81 1,81 1,81 1,81 0
03.07.2006 1,80 1,80 1,80 1,80 0
30.06.2006 1,74 1,74 1,74 1,74 250
29.06.2006 1,77 1,87 1,77 1,87 1.5k
28.06.2006 1,84 1,84 1,84 1,84 0

[trading2006]

Kurshistorie NASDAQ
Datum Erster Hoch Tief Letzter Umsatz
24.07.2006 1,80 1,89 1,80 1,89 82
21.07.2006 1,90 1,90 1,90 1,90 71
20.07.2006 2,00 2,00 2,00 2,00 5
19.07.2006 2,00 2,00 2,00 2,00 5
18.07.2006 1,95 2,05 1,95 2,05 105
17.07.2006 1,90 1,95 1,95 1,95 3.5k
14.07.2006 1,90 1,95 1,80 1,95 3.5k
13.07.2006 2,05 2,05 1,88 1,95 82
12.07.2006 1,85 2,16 1,85 2,00 28
11.07.2006 2,02 2,03 1,90 2,00 108
10.07.2006 2,00 2,00 1,80 2,00 11.9k
07.07.2006 2,25 2,25 2,10 2,15 60
06.07.2006 2,20 2,38 2,20 2,38 2.3k
05.07.2006 2,30 2,40 2,25 2,35 51
04.07.2006 2,45 2,45 2,31 2,40 2.1k
03.07.2006 2,45 2,45 2,31 2,40 2.1k
30.06.2006 2,22 2,40 2,22 2,40 77
29.06.2006 2,22 2,30 2,22 2,30 26
28.06.2006 2,39 2,45 2,30 2,30 11.4k

[AMERIBULL]

Interviewed On: Tue, May 30 2006 Interview Link: http://www.ceocast.com/(bnfqsz45nnyyxz55odl53055)/company.as…
Interview Transcript: Good day.

This is Michael Wax with CEO cast. I am here today with Dr. Manos Topoglidis. Dr. Topoglidis is the Chief Technology Officer and Angela Vernadaki who is the Director of Business Development for Acrongenomics, Inc., a company that trades on the bulletin board under the symbol AGNM and it recently entered into a Memorandum of Understanding with Molecular Vision.

Thanks for joining CEO cast today.

Angela Vernadaki: Thank you very much for giving us the opportunity to introduce you our new collaboration with Molecular Vision, a spin-off company of Imperial Innovations at Imperial College London. We have just signed the final Joint Development Agreement on the 22nd of May 2006 and we look forward to actually exploring the Point-Of-Care Diagnostics market.

Michael Wax: Perhaps you can begin with a brief overview of Acrongenomics and its business strategy.

Angela Vernadaki: Yes, Acrongenomics, Inc. was founded in 2004 and our primary focus was on the Nanotechnology area introducing the Nano-JETA technology platform. On the way to the development of this platform, we faced problems with the nanoparticles and their instability. That is why the Nano-JETA project has now been our second priority and we have now signed a Joint Development agreement with Molecular Vision of Imperial College London. They offer a unique technology that combines microfluidics with polymer Light Emitting Diodes. The development of Point-Of-Care (POC) diagnostic devices that can analyze complex substances like blood urine or saliva, for the management of diabetes, for the detection of sexually transmitted diseases, of cardiovascular diseases and of substances of abuse.

Michael Wax: As you look at now the technology itself how does the technology work and what are some of its applications? Dr. Topoglidis: I would like to thank you also for inviting us and I would like to tell you that so far the realization of readily portable diagnostic devices for POC testing has been hampered by the lack of suitable miniaturized, low-power consumption, optical detection systems. Therefore our BioLED technology platform is able to fill this gap by introducing low cost, organic semiconductor polymers (pLEDs) with tunable optical properties for the development of POC devices.
Our BioLED technology platform consists of the unique combination of microfluidics and semiconducting polymer technology towards of course the development of novel POC devices for the quantitative and qualitative diagnosis of medical conditions. I would like to explain you what Microfluidics are. They refer to fluid flow in a network of microchannels which can be integrated on disposable and low cost Lab-On-a-Chip (LOC) cartridges. The other part of our technology is the pLEDs. A typical pLED comprises of one or more layers of polymer sandwiched between two electrodes, of which at least one must be transparent. That is why the combination of these two technologies offers us a strong market position since our novel patented technology does not face any immediate competition. Therefore, our BioLED technology's prototypes will consist of a LOC cartridge and an (optional) commercially available Personal Digital Assistant (PDA) data collector. Two configurations will be offered: �� The first one regarding the PDA which will supply the power needed, display the result on screen and offer data management and enhanced networking possibilities. This is of course ideal for hospital and physician’s office use. �� The second configuration we will offer is fully autonomous chips that do not require a PDA, with an integrated display and powered by lithium batteries. And this is of course ideal for home-care environment. Like Ms Vernadaki said before the applications of our technology will be for Diabetes Management (Kidney Markers), detection of Sexually Transmitted Diseases (STDs), Cardiovascular Diseases (Cardiac Markers) and Substances of Abuse. Such POC devices can be used in:

�� Hospitals (e.g. emergency or operating rooms) �� Physicians' offices

�� Remote areas or even patient's home (e.g. being able to buy them from the pharmacy) The benefits to end users will be: �� Reduced healthcare costs

�� Reduced visits to hospitals

�� Physicians’ ability for better control of disease diagnosis and monitoring

�� Improved patients' quality of life by offering greater independence from organized sites of care

Michael Wax: What about now your R&D pipeline? What are some of your projects you actively working on? Like I have said before, we are focusing at the moment on the project regarding Molecular Vision for the development of the BioLED technology, but because our BioLED technology has also many other applications this allows us to decide on further BioLED technology developments, once the 4 prototypes mentioned before have been completed.

The first one will be:

�� Pharmaceutics Drug discovery, drug testing (high throughput screening) �� Environmental technology Soil (also agriculture), water and air quality measurements

�� Veterinary Medicine Early disease detection in animals and location of the source of pathogens of public health threats such as mad cow disease and avian flu

�� Biodefense - Homeland Security Portable devices which sample the air for bio-warfare agents e.g. anthrax spores etc.

�� Forensics Automated processing of crime scene forensic evidence

�� Food industry Food diagnostics, packaging (smart sensors), functional food testing, etc. Michael Wax: Where do you see the company going in the next few years?

Angela Vernadaki: The global trend for miniaturization has fueled research and development for novel, POC testing devices. Such technological advancements are necessary to progress and promote quality, on-the spot and non-invasive healthcare, making the POC testing market a compelling and lucrative opportunity in the medical diagnostics sector. The global market is estimated to reach US$18billion by 2010. While estimated to be a US$5.07 billion market (U.S.) in 2005, we know from market research that only an average of 15% of hospitals use POC testing to facilitate bedside patient diagnosis whereas large, off-site laboratories handle the remaining 85%. As you can understand this ratio is predicted to reverse as physicians and hospitals adapt to the next generation POC technologies which are more desired and cost-effective than central laboratory testing. We have to mention that Heart Disease, Diabetes Management and STDs dominate the medical diagnostics market promising exceptionally high annual growth rates over the next 5 years. We therefore endeavor to gain a substantial market share since our unique technology faces no direct competition. The two scenarios of commercialization that we have are: Either all the way by ourselves meaning we will manufacture the POC cartridges, or we could license the technology to a major market player and we actually endeavor to catch more than 50% market penetration from the first year of introducing the first prototype for diabetes management in the market.

Michael Wax: What are some of the key advances now investors should look in the coming quarters?

Angela Vernadaki: Actually, we have an agreement with Molecular Vision that we will be able to bring the first prototype to the market in 12 months time. And then in 6 months intervals, we will actually bring in the market the other three prototypes for the rest of the diseases.

Michael Wax: Speaking to executives from Acrongenomics, the company that trades on the bulleting board under the symbol AGNM and when it recently signed a US$6.5 million Joint Development Agreement with Molecular Vision Limited, to offer unique POC solutions through the BioLED technology.

Thanks for joining CEO cast today. Dr. Topoglidis: Thank you for having us.

Angela Vernadaki: Thank you.

[trading2006]

Kursdaten NASDAQ
Kurs:
00:40:42 1,89 -0,53%
-0,01
Taxe Stück
Bid: 18:41:55 1,80 5
Ask: 21:56:18 1,89 5
Tief Hoch
Jahr: 1,80 4,70
52 Wochen: 1,80 5,90

[trading2006]

handel minimal in usa/brd noch weniger
taxe bid und ask sind ok, wenigstens recht eng beinander in amiland

[trading2006]

Antwort auf Beitrag Nr.: 23.037.347 von AMERIBULL am 25.07.06 12:44:52

gut recherchiert

[AMERIBULL]

Antwort auf Beitrag Nr.: 23.037.254 von trading2006 am 25.07.06 12:39:02

ja, von comdirekts Outstandings kann man nicht immer ausgehen

[AMERIBULL]

Antwort auf Beitrag Nr.: 23.037.368 von trading2006 am 25.07.06 12:46:02

Danke !

[trading2006]

Wertpapiertyp
Auslandsaktie

Marktsegment
Freiverkehr

Branche
--

Geschäftsjahr
--

Marktkapital.
19,91 Mio. EUR

Streubesitz
--

Nennwert
--

Stücke
14 Mio.

Symbol
EQ9.FSE

ISIN
--

WKN
A0B9TS

[AMERIBULL]

Press Release Source: EQUITIES Magazine


EQUITIES Magazine's Summer Conference 2006 to Be Held at Yale Club in NYC on June 15
Tuesday June 13, 2:20 pm ET


NEW YORK, NY--(MARKET WIRE)--Jun 13, 2006 -- EQUITIES Magazine, the industry's most trusted source of business and financial news of promising public companies, announces its upcoming corporate conference -- Summer Conference 2006. This exciting event is to be held on Friday, June 15, at the Yale Club (50 Vanderbilt Ave) in New York City. Presenting at the conference will be some of the small-cap market's most undervalued growth companies. Three of the 10 companies presenting will be:
Immune Response Corp. (OTC BB:IMNR.OB - News), an immuno-pharmaceutical company, focuses on the development of various products to treat autoimmune and infectious diseases. It offers NeuroVax, which is based on T-cell receptor peptide technology for the treatment of multiple sclerosis; and IR103 and Remune for the treatment of Human Immunodeficiency Virus (HIV).

Acrogenomics, Inc (OTC BB:AGNM.OB - News) focuses on the development of novel technology in the life sciences field such as its patented BioLED Technology, which will help advance Point-of-Care (POC) devices for rapid diagnosis of STDs and cardiovascular diseases, as well as detecting substances of abuse and diabetes management (Kidney Markers). BioLED has the potential for other uses in various markets as well.

MidasTrade.com, Inc (Other OTC:MIDS.PK - News) an online securities trading company committed to the deployment of the Midas Global Direct Access Network (GDAN) that allows investors to trade securities, options and futures in real time via their online trading account through the MidasTrade network of participating exchanges, all over the world.

ADVERTISEMENT


PLUS: Master of the market, stock guru and author Fred Kobrick kicks off the conference with how investors can "Yield the Big Money" while building character at the same time.

For over 25 years EQUITIES Magazine has been sponsoring corporate conferences -- the longest running record in the industry. And, after a quarter of a century, we believe that this might be the most exciting line-up of emerging growth companies we've had to date! Don't let the market pass you by, come and discover some of the most undervalued companies in the market today!

Safe Harbor -- This press release includes forward-looking statements that involve risks and uncertainties, including, but not limited to, product delivery, the management of growth, market acceptance of certain products and other risks. These forward-looking statements are made in reliance on the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that forward-looking statements are not guarantees of performance. Actual results may differ materially from management expectations.



Contact:
Contact:
EQUITIES Global Communications, LLC
Jonathan Bernard
Director of Communications
310-575-4400
Email Contact



--------------------------------------------------------------------------------
Source: EQUITIES Magazine

[trading2006]

Antwort auf Beitrag Nr.: 23.037.400 von AMERIBULL am 25.07.06 12:48:20

was du immer so auskramst

[AMERIBULL]

Financial Information

AUDITORS
Amisano Hanson · Vancouver BC
LEGAL COUNSEL
Clark Wilson LLP, Vancouver, Canada
BANKERS
HSBC Bank Canada · Calgary, Alberta
REGISTRAR AND TRANSFER AGENT
Pacific Stock Transfer Company · Las Vegas, Nevada
STOCK EXCHANGE LISTING
AGNM · OTCBB
EQ9.F · Deutsche Borse AG
FULLY DILUTED
13,722,536 (As of April 13th 2005)
PRICE RANGE 52 WEEK
AGNM · OTCBB $ 2.40 - $ 6.16
EQ9.F · Deutsche Borse AG €2.08 - €4.80

[trading2006]

Börse
XETRA

Aktuell
4,10 EUR

Zeit
24.10.05 13:29

Diff. Vortag
+17,14 %

das waren noch zeiten

[trading2006]

Fazit
Trotz des bilanziellen Defizits und der erst kurzfristigen geschäftlichen Umorientierung von AcronGenomics erscheint uns das Papier aus folgenden Gründen dennoch als ein hoch interessantes und spekulatives Investment:


Durch die Zusammenarbeit mit Molecular Vision eröffnet sich die Möglichkeit einer sehr engen und Erfolg versprechenden Zusammenarbeit mit höchst renommierten und innovativen Wissenschaftlern – vor allem mit Donal Barney und seinem Team), aus der
höchst innovative Produkte hervorgehen könnten, die auf
einem insgesamt auch zukünftig boomender Mega-Markt für Medizintechnik konkurrenzlos sein könnten.
Aus charttechnischer Sicht könnte sich das Papier in einer Bodenbildungsphase befinden.

Ein Kursziel von 2,30 Euro erscheint uns als möglich auf eine Sicht von zwölf Monaten. Ein StopLoss sollte aber konservativ bei 1,10 Euro gesetzt werden.
Ein sehr spekulativer Kauf!

d
as kursziel erscheint durchaus realistisch wenn weitere fortschritte gemacht werden. bis zur vermarktung ist es ja nicht mehr weit, wenn das produkt fertig gestellt ist. wo ein markt ist, sind auch leute die es verkaufen wollen

[AMERIBULL]

A summary of the status of the stock option plan as of March 31, 2006 and changes during the period is presented below:




Weighted

Average

Shares
Exercise Price






Options outstanding and exercisable at December 31, 2005 and March 31, 2006



200,000



$3.00





At March 31, 2006, 200,000 share purchase options were outstanding to consultants entitling the holders thereof the right to purchase one common share of the Company at $3.00 per share for each share purchase option held. These share purchase options expire on August 31, 2007.

[trading2006]

Antwort auf Beitrag Nr.: 23.037.491 von AMERIBULL am 25.07.06 12:54:15

optionen zu 3 usd?

[trading2006]

wären so 2,3 euro. dann kommt das kz ja gut hin

[AMERIBULL]

Antwort auf Beitrag Nr.: 23.037.439 von trading2006 am 25.07.06 12:51:00

[AMERIBULL]

Non-cash Transaction




Investing and financing activities that do not have an impact on current cash flows are excluded from the statements of cash flows. During the three months ended March 31, 2006, the Company issued 180,668 common shares between $2.30 and $2.40 pursuant to the receipt of proceeds of $426,329 from stock subscriptions received during the year ended December 31, 2004. This transaction was excluded from the statements of cash flow

[AMERIBULL]

Vision and Goals

Acrongenomics' goal is to advance the Medical Diagnostics industry and accomplish industry-leading growth by establishing our technology platform worldwide. Through innovative and advanced medical diagnostic applications, we aim to provide the most efficient and sustainable means of delivering new value to the marketplace.

We are also committed to contribute to the human health and quality of life by exploring new scientific approaches and continuously considering:

Business
By sponsoring new innovative ideas and transforming them into commercial opportunities.

Social Welfare
By providing the market with superior technology designed to serve the common good.

Our People
By expanding our qualified team of business professionals to further support our technology pipeline.

Acrongenomics is dedicated to sustain a code of contact that is defined by a list of values like:

ACHIEVEMENT: We value the active pursuit of excellence, demonstrated by continuous improvement in standards, quality, speed and timeliness. Our collective ability to get results and accomplish our goals adds priceless value to the Company. We are committed to winning in today's competitive market.

INNOVATION: Innovation is fundamental for Acrongenomics’ success. We value creativity—the ability of people to develop new ways to identify opportunities and solve problems. We utilize our skills to search for and apply new technologies, approaches and business solutions which will contribute to the development of new diagnostic platforms.

INTEGRITY: At Acrongenomics we insist on applying the highest ethical standards and adherence to Company values. All employees have the responsibility to conduct their business relationships with the highest level of professionalism and integrity.

SCIENCE: We invest on ground-breaking technologies. We are committed to nurturing breakthrough technological platforms within our framework of focused strategic directions.

[AMERIBULL]

Antwort auf Beitrag Nr.: 23.037.525 von trading2006 am 25.07.06 12:55:00

Heftig oder zu 3 USD

[trading2006]

Antwort auf Beitrag Nr.: 23.037.608 von AMERIBULL am 25.07.06 12:59:32

ja, schon. mußt aber auch bedenken, das die damals auch höher standen. aber die müssen sich ja dabei was gedacht haben. warum der wert so gefallen ist, weiß ich nicht. ist auf jeden fall nichts ersichtlich negativesder firma widerfahren. liegt wohl mit am derzeitigen umfeld

[AMERIBULL]

Strategic Alliances

Acrongenomics utilizes its extensive international network and qualified management team to scout out and invest in dynamic research projects. To that extent Acrongenomics has established a Strategic Alliance with the UK based Molecular Vision Ltd.


Molecular Vision is a spin-out company of Imperial Innovations Ltd. The company was founded in 2002 in order to meet a clearly defined demand in the medical diagnostics, biosensors and analytical instrumentations markets: the need for miniaturized chemical and biological detectors offering high sensitivity and functionality at low cost. The company has directly addressed this market demand by inventing a novel method for optical detection based on recent advances in organic electronics and light emitting diodes combined with microfluidics technology. The company has mainly focused on applying its technology to the medical diagnostics markets.

[AMERIBULL]

BioLED Technology

Terms like Lab-On-a-Chip (LOC), Point-of-Care (POC) testing and miniaturized Total Analysis Systems (μTAS) describe the same concept; specialized, light weight, readily portable and easy to use devices, designed to perform complex biological tests at the site where they are most needed. These tests normally require specialized laboratories equipped with bulky and expensive instruments. POC testing constitutes a “stand alone” new market with impressive growth potential that may/or may not complement the already established laboratory testing. The main market driving force is the enhanced portability and networking capabilities that lead to improved patient’s quality of life and increased independence from organized healthcare facilities.

So far, the realization of readily portable diagnostic devices for POC testing has been hampered by the lack of suitable miniaturized, low-power consumption, optical detection systems.

Low cost, organic semiconductor polymers with tunable optical properties is the answer provided by Acrongenomics and Molecular Vision. Optical detection is provided by polymer Light Emitting Diodes (pLEDs) which are fully compatible with microfluidic chip technology. The combination of the two technologies is used for the development of a "readily portable" microfluidic and pLED platform (BioLED technology) that is initially applied to the development of POC microchips for the quantitative and qualitative analysis of medical conditions with high sensitivity and functionality at low cost.

Acrongenomics’ and Molecular Vision’s BioLED technology operates with two interdependent components that combine to form a Lab-On-a-Chip cartridge:

Microfluidics - Processing and Reaction component
pLED (polymer Light Emitting Diode) - Detection Component

[trading2006]

nichts im aks drüben?

Börse
NASDAQ OTC BB

Aktuell
1,89 USD

Zeit
24.07.06 21:57

Diff. Vortag
-0,53 %

Tages-Vol.
14.849,00

Gehandelte Stück
8.200

Geld
1,80

Brief
1,89

Zeit
24.07.06 21:56

Spread
4,76%

Geld Stk.
500

Brief Stk.
--

[trading2006]

ask

[AMERIBULL]

How does it work?

Under electrical excitation the polymer emits light via radiative combination of injected electrons and holes and therefore may be used as a light source. The same structure can then be used in reverse as a photodetector by illuminating the polymer in order to generate a measurable electrical current.

The reagents of an assay will be mixed with the body fluid through the microfluidic network. The resulting mixture will be excited by the integrated, battery driven pLED and the resulting light-signal will be detected by the integrated photodetector which will generate an electrical current (electronic readout).

We endeavor to possess a strong market position since our novel and patented technology does not face any immediate competition.

BioLED technology's prototypes will consist of a Lab-On-a-Chip cartridge and an (optional) commercially available PDA (Personal Digital Assistant) data collector. Two configurations will be offered:

The chip will plug into a PDA which will supply the power needed, display the result on screen and offer data management and enhanced networking possibilities (ideal for hospital + physician's office use).
Fully autonomous chips that do not require a PDA, with an integrated display and powered by lithium button batteries (ideal for a home-care environment).

[trading2006]

Schluss Vortag
1,90

Eröffnung
1,80

Hoch
1,89

Tief
1,80

52W Hoch
5,70

52W Tief
1,85

[AMERIBULL]

BioLED Technology
Meets Market Requirements

Market Demands…
We provide…

Fast, Unambiguous diagnosis
Electronic readout gives clear answer in 2-3 minutes. Quantitative and qualitative analysis with accuracy comparable to standard lab tests. Data management and networking possibilities.

Miniaturized analysis of complex materials (blood, urine and saliva)
Microfluidics are designed to handle drops of such materials. Detection at the submicromolar level, aiming to increase sensitivity to picomolar levels.

Multiple testing
Ability to run multiple diagnostic tests on the same microchip at marginal additional cost compared to a single-test microchip.

Low unit cost
Components manufactured by in-house printing technologies; total cost of each microchip < $1

Ease of use
Simple device; no expert personnel required; ideal as over the counter (OTC) product.

Miniaturized biochemical reactors
Technology platform with potential applications that go beyond POC devices.


References

Lab Chip, 2005, 5, 863-868.
Lab Chip, 2004, 4, 136-140
Sensors and Actuators B, 2005, 106, 878-884.

[trading2006]

der wert steht nahe an seinem tief. könnte einen rebound geben, wie weit weiß nur der liebe herrgott

[trading2006]

ACRONGENOMICS INC
Börse: NASDAQ OTC BB
Datum: 24.07.06
Tickliste Zeit Kurs Volumen
21:57:26 1,8900 100
21:57:07 1,8000 2500
21:56:15 1,8000 2000
21:56:12 1,8500 500
21:56:12 1,8000 500
21:54:50 1,8500 100
21:45:53 1,8000 100
18:53:04 1,8500 1000
18:52:50 1,8000 0
18:52:50 1,8000 1400

[trading2006]

Antwort auf Beitrag Nr.: 23.037.728 von trading2006 am 25.07.06 13:05:41

8k sind schon eine menge handel im vergleich zu den letzten wochen. wüßte wirklich gerne deren aktionärsstruktur, aber weiß echt nicht wo ich die herkriegen könnte

[AMERIBULL]

Antwort auf Beitrag Nr.: 23.037.630 von trading2006 am 25.07.06 13:00:51

Seit Januar/Februar 2006 hat sich der Kurs der Aktie von ca. 4 US$ bis auf aktuell ca. 1,90 US$ halbiert. Grund hierfür dürfte der Rücktritt von Dr. Leftheris Georgakopoulos als Präsident und Chefwissenschaftler von AcronGenomics am 13.02.2006 gewesen sein. Dr. Georgakopoulos stand für die viel versprechende Nano-JETA-Technologie. Mit dem Wechsel an der Firmenspitze hat sich auch das Geschäftsmodell verändert. Am 13.02.2006 wurde zwischen AcronGenomics und dem ausgeschiedenen Präsidenten ein Agreement geschlossen, die 4 Mio. Stammaktien von Dr. Georgakopoulos gegen 50 Prozent der Einnahmen aus dem Nano-Jeta Patent zu tauschen. Demnach werden alle möglichen zukünftigen Gewinne aus diesem Patent durch das Agreement geschmälert.
Darüber hinaus wies AcronGenomics im März 2006 ein akkumuliertes bilanzielles Defizit von insgesamt ca. 16 Mio. US$ für 2005 aus, von dem ein Löwenanteil auf Entwicklungskosten zurück zu führen ist. Am 22.05.2006 wies AcronGenomics einen Cashbestand von ca. US$ 1,279 Mio. US$ aus, der für die Finanzierung des operativen Geschäfts der nächsten sechs Monate ausreiche. Eine Kapitalerhöhung von US$ 1.12 Mio. zur Deckung der Betriebskosten in 2006 ist geplant und erscheint von Firmenseite als notwendig; vor allem im Hinblick auf die Finanzierung der Entwicklungskosten in der Zusammenarbeit mit Molecular Vision, die das einzige aktuelle Standbein von AcronGenomics zu sein scheint.
Hinzu kommt, dass bisher noch keine Umsätze generiert wurden und noch nicht abgesehen werden kann, wann das der Fall sein wird. Alles in allem keine ungewöhnliche finanzielle Situation für ein Early–Stage-Unternehmen, die einmal mehr das extreme Chance-Risiko-Verhältnis der am OTC BB gelisteten Firmen dokumentiert.

Fazit
Trotz des bilanziellen Defizits und der erst kurzfristigen geschäftlichen Umorientierung von AcronGenomics erscheint uns das Papier aus folgenden Gründen dennoch als ein hoch interessantes und spekulatives Investment:


Durch die Zusammenarbeit mit Molecular Vision eröffnet sich die Möglichkeit einer sehr engen und Erfolg versprechenden Zusammenarbeit mit höchst renommierten und innovativen Wissenschaftlern – vor allem mit Donal Barney und seinem Team), aus der
höchst innovative Produkte hervorgehen könnten, die auf
einem insgesamt auch zukünftig boomender Mega-Markt für Medizintechnik konkurrenzlos sein könnten.
Aus charttechnischer Sicht könnte sich das Papier in einer Bodenbildungsphase befinden.

Ein Kursziel von 2,30 Euro erscheint uns als möglich auf eine Sicht von zwölf Monaten. Ein StopLoss sollte aber konservativ bei 1,10 Euro gesetzt werden.
Ein sehr spekulativer Kauf!

Ihr Team vom
www.HotStock-Kurier.de

[trading2006]

Antwort auf Beitrag Nr.: 23.037.751 von AMERIBULL am 25.07.06 13:07:07

ok, das könnte der grund für den wertverlust an der börse sein, auch wieder wahr. aber die forschung schreitet sicher gut voran, sonst hätten die kein JV bekommen und einige mio. die aussichten auf ange sicht sind mehr als gut im diagnosebereich

[MaatMod]

@AMERIBULL
@trading2006

da hier anscheinend im Minutentakt alte Meldungen gepostet werden
wird eine Diskussion, wenn ihr sie wirklich wollt, unmöglich


Gebt doch einfach interessierten Usern die Möglichkeit
sich minimal einzulesen

Sollte dies nicht möglich sein
werde ich den Thread sperren


MfG
MaatMOD

[trading2006]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[AMERIBULL]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[trading2006]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[trading2006]

Antwort auf Beitrag Nr.: 23.037.832 von AMERIBULL am 25.07.06 13:11:14

ah, gute idee. schaue sowas selten nach als trader. danke

[AMERIBULL]

Das Oderbuch in USA ist aber sehr explosiv auf der ASK-Seite !!!

[AMERIBULL]

Orderbuch OTCBB:
VERT 1.80 500 UBSS 1.89 500
ETRD 1.80 500 JEFF 1.90 500
HDSN 1.75 500 ETRD 2.00 500
UBSS 1.65 500 HDSN 2.00 500
JEFF 1.61 500 HILL 2.50 500
NITE 1.61 500 VERT 3.00 500
HILL 1.55 500 NITE 3.00 500
DOMS 1.51 500 DOMS 3.14 500
SACM 1.50 500 SACM 3.15 500
TDCM 1.50 500 PERT 3.20 500
ABLE 1.50 500 TDCM 3.20 500
BEST 1.50 500 BEST 3.20 500
PERT 1.01 500 ABLE 3.96 500
VFIN 1.01 500 MERI 3.98 500
MERI 0.98 2500 VFIN 10.01 200

[trading2006]

Antwort auf Beitrag Nr.: 23.037.929 von AMERIBULL am 25.07.06 13:15:19

unter 2 liegt nicht viel, das wäre ja schonmal was

[trading2006]

wo ist mein posting mit der geplanten KE geblieben?

[AMERIBULL]

Antwort auf Beitrag Nr.: 23.037.811 von MaatMod am 25.07.06 13:10:05

Alles klar, Kein Problem...

Obwohl es keine alte Meldungen sondern Informationen über die Company und deren Geschäftsfeld sind , die für jeden nützlich sein können!

AMERIBULL

[trading2006]

"Eine Kapitalerhöhung von US$ 1.12 Mio. zur Deckung der Betriebskosten in 2006 ist geplant und erscheint von Firmenseite als notwendig; vor allem im Hinblick auf die Finanzierung der Entwicklungskosten in der Zusammenarbeit mit Molecular Vision, die das einzige aktuelle Standbein von AcronGenomics zu sein scheint."


ein schnitt von etwa 2,5 USD die letzten 3 monate macht etwa 500k neue shares

[trading2006]

Antwort auf Beitrag Nr.: 23.037.929 von AMERIBULL am 25.07.06 13:15:19

bei 1,5 ist wohl eine größere unterstützung, aber ist auch tief genug. ask bis 3 usd sehr dünn, aber das würde sich sicher füllen ab kursen jenseits der 2

[AMERIBULL]

Antwort auf Beitrag Nr.: 23.038.033 von trading2006 am 25.07.06 13:20:09

Bei bei enstprechender Newslage könnte der Wert schnell auf die 3 USD laufen...

[AMERIBULL]

What is Microfluidics?

Microfluidics refers to a set of technologies that control the flow of minute amounts of liquids or gases- typically measured in nano- and picoliters- in a miniaturized system. Designed in the nanometer scale, microfluidic chips incorporate pumps, valves, microchambers and microchannels (usually less than 100 nanometers wide) that direct samples from one compartment to the next on the chip.

Although the laws of physics do not change, as the scale at which fluids are studied decreases the effects driving and controlling fluid motion changes radically. This is because properties such as surface forces, surface tension, capillary effect, electronic charges, heat and mass transfer become dominant altering the system’s behavior dramatically. Microfluidics not only enable the very precise manipulation of minute amounts of fluids but may perform functions such as mixing, separating handling different components efficiently, rapidly and with little human intervention.

"Microfluidics is one of the 10 technologies
that will change the world"
(Microfluidics Technologies, BCC, March 2004)

Contrary to microelectronics, where miniaturization is achieved mainly by reducing in the size of the transistors, microfluidic devices require construction and design that differ from macroscale devices. More complex systems of channels with more sophisticated fluid-handling capabilities are necessary.

The advantages of such systems include:

Reduced size of devices ("readily portable" microfluidic chips)
Reduced fabrication cost.
Efficient use of expensive reagents.
Reduced volumes of rare samples.
Low fabrication cost allows disposability of the chips.
Multifuncionality and speed.
Ease of use and enhanced safety.
Precise volumetric control of samples and reagents leading to higher sensitivities in analytical applications.
High throughput biological screening made possible by faster sampling times through parallel processing of samples.
Low power consumption.
Can be combined or integrated with other systems like MEMS (Micro-Electro-Mechanical Systems), NEMS (Nano-Electro-Mechanical Systems) to produce highly efficient μTAS (Miniaturized Total Analysis Systems), LOC (Lab-On-a-Chip) or POC (Point-of-Care) devices to form portable "all-in-one" devices able to perform complex functions.
Applications

"As the number of experiments has grown, the devices used to carry them out have shrunk, and the strategy of "smaller is better" has begun to transform the world of fluidics as it transformed the world of electronics."
(G. Whitesides, Mallinckrodt Professor of Chemistry and Chemical Biology at Harvard University -The Industrial Physicist, Aug/Sept 2003)

Microfluidics, due to recent advances in fluidics, microelectronics and integrated system technologies has penetrated to a number of diverse markets including printing, industrial automation, power management systems and life sciences.

The Life Science segment of the microfluidics market demonstrates the largest and fastest growth rate and is divided into:

Drug Discovery (Combinatorial Chemistry, High Throughput Screening, Quality Control)
Medicine (Diagnostics, Therapeutics)
Biotechnology (Genomics, Proteomics, Cell Sorting and counting)
Ecology (Food, Air/Water)
Microfluidics delivers advanced flexibility. A conventional diagnostic test follows a protocol that involves a series of processes and utilizes a number of bulky and expensive instruments that may take up the space of an entire bench. Moreover, specialized laboratory technicians are needed to perform the test.

A microfluidics-based assay can perform the same diagnostic test in a space smaller than the size of a credit card, requiring minimum human intervention. The advantages of such systems are the reason for the continuous penetration of microfluidics in markets that were traditionally driven by other technologies.

Links:
MIFLUS – Microfluidics Terminology Tree

[AMERIBULL]

What is pLED

Successful Point-Of-Care (POC) device design has to incorporate 2 major components. A reaction component, responsible for the chemical/biological reactions of an assay and a detection component, that will sense and report the outcome of the assay. The development of novel optical detection techniques are crucial in modern day chemical and biological analysis due to a recognised need for rapid, on-line measurements at low concentrations in fields such as chemical production, DNA analysis, drug discovery, pharmaceutical screening medical diagnostics and environmental analysis.

A Light-Emitting Diode (LED) is a semiconductor device that emits light under electrical excitation. This phenomenon is called electroluminescence. The color of the emitted light is determined by the chemical composition of the semi-conducting material used, and may therefore be controlled using standard synthetic chemistry. If the light-emitting semi-conducting layer material of a LED is organic then the device is known as Organic Light Emitting Diode (OLED). The OLED’s emitting material can be small organic molecules in crystalline phase or flexible polymers (plastics), which are basically long chains of organic molecules. Such LEDs are known as polymer LEDs or pLEDs.

A typical OLED or pLED consists of one or more organic layers sandwiched between two electrodes. Application of an electric field between these two electrodes results in emission of light from the organic layers. At the same time, the organic layers can generate a measurable current when illuminated; therefore, OLEDs and pLEDs exhibit dual functionality (photoemittors and photodetectors).

OLED Technologies
There are currently 3 OLED technologies:

Light Emitting Polymers have been the subject of intense scientific and commercial interest since their discovery in 1990 by Molecular Vision co-founder Professor Donal Bradley and his colleagues (Dr Jeremy Burroughes and Professor Richard Friend) at the Cambridge University Cavendish Laboratory. The emissive materials can be applied on the substrate by a technique derived from inkjet printing making manufacturing flexible and inexpensive. Light Emitting Polymers are set to revolutionize the display market, allowing for wafer-thin television and computer screens at very low cost. The diagnostics market represents a new and important application of this disruptive technology.
Small Molecule OLED technology was developed by Easman-Kodak, usually referred to as "small-molecule" OLED or SM-OLED. The production of this type of devices requires vacuum deposition making manufacturing expensive and inflexible.
A third hybrid light emitting layer technology has been developed recently. This technology uses nonconductive polymers doped with light-emitting, conductive molecules.
Applications

To date, interest in semi-conducting polymers has been driven primarily by their applications in thin film displays and – to a lesser extent – as solar cells and transistors. One of the great benefits of OLED displays compared to traditional LCD displays is that OLEDs do not require a backlight to function. This means that they draw far less power and, when powered from a battery can operate longer on the same charge. However the favourable processing properties of polymeric semiconductors make them highly attractive for a broad range of additional applications.

Owing to their simple design, OLEDs have great potential for integration into microfluidic systems at marginal additional costs delivering state-of-the-art and inexpensive POC devices. The integration of such sensing systems within microfluidic devices is the area of particular interest for Acrongenomics and Molecular Vision.

[trading2006]

Antwort auf Beitrag Nr.: 23.038.066 von AMERIBULL am 25.07.06 13:22:13

keine frage, viel umsatz ist dazu nicht notwendig. dennoch sehe ich das hier eher als langfristanlage mit wenig einsatz. geld, welches man nicht wirklich braucht und das man 2-3 jahren liegen lassen kann. bis dahin könnte es ein kleiner vervielfacher werden, wen ndie entwicklung der produkte entsprechend fortschreitet

[AMERIBULL]

Antwort auf Beitrag Nr.: 23.038.139 von trading2006 am 25.07.06 13:26:21

so gesehen ist es korrekt...

[trading2006]

die produkte haben eine große zukunft vor sich. immer mehr jugendliche erkranken an diabetes, traurig. was uns alleine diese risikogruppe ide nächsten jahrzehnte kostet....

[trading2006]

Antwort auf Beitrag Nr.: 23.038.166 von AMERIBULL am 25.07.06 13:27:47

aber da haben wir eh keinen einfluss drauf. dem aktionär bleibt da nur die hoffnung das alles seinen geregelten weg geht

[AMERIBULL]

What is POC/LOC?

The new trends in healthcare dictate the provision of laboratory testing at the point where patient care is rendered or what is commonly called Point-Of-Care (POC) testing. Initially, diagnostic tests used to require well organized laboratory facilities, staffed with experienced personnel. Over the past few years, however, technological advances have driven the development of Lab-On-a-Chip (LOC) technology and POC testing which in turn have revolutionised the way medical diagnostic tests are performed. New technological attributes have added speed, simplicity, automation and accessibility to the in vitro diagnostics sector. Large and expensive laboratory facilities, well trained personnel and time consuming procedures are no longer necessary.

LOC technology involves the performance of complex biological functions on a very small chip-like device, able to perform automated biological protocols with minimal human intervention. This technology has been implemented in both laboratory testing instrumentation and POC testing devices.

As the POC testing market evolves two main types of technology have been adopted:

a) Small bench top analysers (e.g., blood gas and electrolyte systems) and
b) Hand held devices, usually accompanied by disposable cassettes, cartridges or sticks.

Both types exhibit significant advantages over laboratory testing. The bench top systems are smaller versions of laboratory analysers in which vulnerable operator dependent steps have been automated. Hand held devices (internally complex devices) have been developed using microfabrication techniques, which makes medical testing more immediate and accessible even for less ideal situations.

The benefits of POC testing can be assessed in terms of the benefit to the diagnostic and/or treatment outcome, as well as the economic outcome. Some examples benefits to the clinical outcome are the faster treatment decision making, improved adherence to treatment, reduce incidence of complications, quicker optimization of treatment and patient satisfaction. The economic benefits involve reduced number of clinic visits and hospitalisation, earlier discharge from hospital, better optimized drug treatment, less inappropriate use of drugs, reduced requirements in staff, equipment and estate and improved quality of life.

[AMERIBULL]

Antwort auf Beitrag Nr.: 23.038.187 von trading2006 am 25.07.06 13:28:55

Targeted Diseases
Diabetes

Diabetes mellitus (DM) is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin secretion, insulin action, or both. Diabetes can be associated with serious complications, such as:

Cardiovascular disease- a major complication and the leading cause of premature death among people with diabetes (about 75 percent of people with diabetes die from heart disease or stroke).
Kidney disease- also called Nephropathy is a condition that affects one-third or more of people who have had Type 1 (juvenile) diabetes for at least 20 years. About 10 to 40 percent of people with Type 2 (adult onset) diabetes also have kidney disease.
Blindness- diabetes is a major cause of blindness in the U.S. Diabetic retinopathy alone accounts for at least 12 percent of new cases of blindness each year in the U.S. People with diabetes are 25 times more at risk for blindness than the general population.
Nervous system disease- around 60 to 70 percent of diabetics have some type of nervous system damage or neuropathy, which includes decrease sensation in feet or hands, slowed digestion in the stomach, or carpal tunnel syndrome.
Dental disease- almost one third of people with diabetes has severe periodontal or gum diseases with loss of attachment of the gums to the teeth measuring 5 millimeters or more.
There are currently more than 194 million people with diabetes worldwide according to the World Health Organization (WHO). The National Information Clearinghouse estimates that DM costs the United States US$132 billion every year.

Sexually Transmitted Diseases (STDs)

Sexually transmitted diseases (STDs) -also called Sexually Transmitted Infections (STIs) - are a major global cause of acute illness, infertility, long term disability and death, with severe medical and psychological consequences for millions of men, women and children. The general term sexually transmitted disease (STD) is applied to any of the group of diseases that can be spread by sexual contact. STDs are caused by viruses, bacteria and parasites. There are at least 25 different STDs. The most common ones are the Acquired Immune Deficiency Syndrome (AIDS), Herpes Virus, Chlamydia, Syphilis, Human Papillomavirus (HPV), Hepatitis and Gonorrhea. The Medical Institute for Sexual Health in Texas estimates that 1 in 5 Americans between the ages of 15 and 55 are currently infected with one or more STDs, and 12 million Americans are newly infected each year. Also, the World Health Organization (WHO) states that in developing countries, STDs and their complications are amongst the top five disease categories for which adults seek health care. Direct medical costs associated with STDs in the United States are estimated at US$ 13 billion annually.

Cardiovascular disease

Cardiovascular disease (CVD) refers to diseases of the heart and blood vessel system (arteries, capillaries, veins). CVD claims more lives each year that the next 4 leading causes of deaths combined, which are cancer, chronic lowers respiratory diseases, accidents and diabetes mellitus. According to the World Health Organization (WHO), 16.7 million of people around the globe die of CVD each year. This is over 29 percent of all deaths globally. Today, men, women and children are at risk, and 80 percent of the burden is in low- and middle income countries. It is estimated that by 2010, CVD will be the leading cause of death in developing countries, whereas by 2020 heart diseases and strokes will be the leading cause of death and disability worldwide, increasing fatalities to more than 20 million yearly and to more than 24 million by 2030. (Atlas of Heart Disease and Stroke, WHO, September 2004). In U.S. the direct and indirect cost of CVD for 2006 is estimated to be US$ 403.1 billion, according to the American Social Health Association.

Drug abuse

Drug abuse refers to the use of illegal drugs or the inappropriate use of legal drugs. There are many reasons for drug abuse, including producing pleasure, alleviating stress, altering or avoiding reality. The negative impacts of the illicit drug trade touch every society in the world. This year's World Drug Report estimates that 200 million people, or 5% of the global population age 15-64, have consumed illicit drugs at least once in the last 12 months. The medical cost of drug abuse was estimated by the National Centre for Health Statistics to be nearly $60 billion worldwide.

[trading2006]

Antwort auf Beitrag Nr.: 23.038.278 von AMERIBULL am 25.07.06 13:34:21

da ist auch was für den häuslichen gebrauch. das ist optimal, da man sich somit den endkunden-markt sichert und jede menge umsatzpotential

[trading2006]

Antwort auf Beitrag Nr.: 23.038.292 von AMERIBULL am 25.07.06 13:35:01

diabetes wird wohl bald zu einer art "epedemie" in europa. wir esse neinfach zuviel zucker in der heutigen zeit.

hoffe ich habs richtig geschrieben

[trading2006]

bin jetzt mal weg, bis später

[AMERIBULL]

Antwort auf Beitrag Nr.: 23.038.368 von trading2006 am 25.07.06 13:39:56

bis später...

[AMERIBULL]

RT 1,89 USD

[AMERIBULL]

ASK 1,80
BID 1,65

recht groß der Spread muß man ehrlicherweiße dazu sagen

[AMERIBULL]

RT 1,79 USD

[trading2006]

Börse
Frankfurt

Aktuell
1,44 EUR

Zeit
25.07.06 09:00

Diff. Vortag
+2,13 %

Tages-Vol.
--

Gehandelte Stück
0

Geld
1,46

Brief
1,56

Zeit
25.07.06 16:11

Spread
--

Geld Stk.
1.500

Brief Stk.
500

[trading2006]

Börse
Berlin-Bremen

Aktuell
1,49 EUR

Zeit
25.07.06 09:09

Diff. Vortag
+4,20 %

Tages-Vol.
--

Gehandelte Stück
0

Geld
1,36

Brief
1,50

Zeit
25.07.06 16:44

Spread
9,33%

[trading2006]

Wertpapiertyp
Auslandsaktie

Marktsegment
Freiverkehr

Branche
--

Geschäftsjahr
--

Marktkapital.
19,91 Mio. EUR

Streubesitz
--

Nennwert
--

Stücke
14 Mio.

Symbol
EQ9.FSE

ISIN
--

WKN
A0B9TS

[trading2006]

Antwort auf Beitrag Nr.: 23.042.571 von AMERIBULL am 25.07.06 17:31:42

kein wunder bei der geringen nachfrage bzw umsatz

[trading2006]

Antwort auf Beitrag Nr.: 23.042.906 von trading2006 am 25.07.06 17:51:28

taxe seit heute morgen leicht verändert aber keine käufe

[trading2006]

Antwort auf Beitrag Nr.: 23.042.906 von trading2006 am 25.07.06 17:51:28

taxe seit heute morgen leicht verändert aber keine käufe

[trading2006]

24.07.2006 1,80 1,89 1,80 1,89 82
21.07.2006 1,90 1,90 1,90 1,90 71
20.07.2006 2,00 2,00 2,00 2,00 5
19.07.2006 2,00 2,00 2,00 2,00 5
18.07.2006 1,95 2,05 1,95 2,05 105
17.07.2006 1,90 1,95 1,95 1,95 3.5k
14.07.2006 1,90 1,95 1,80 1,95 3.5k
13.07.2006 2,05 2,05 1,88 1,95 82
12.07.2006 1,85 2,16 1,85 2,00 28
11.07.2006 2,02 2,03 1,90 2,00 108
10.07.2006 2,00 2,00 1,80 2,00 11.9k
07.07.2006 2,25 2,25 2,10 2,15 60
06.07.2006 2,20 2,38 2,20 2,38 2.3k
05.07.2006 2,30 2,40 2,25 2,35 51
04.07.2006 2,45 2,45 2,31 2,40 2.1k
03.07.2006 2,45 2,45 2,31 2,40 2.1k
30.06.2006 2,22 2,40 2,22 2,40 77
29.06.2006 2,22 2,30 2,22 2,30 26
28.06.2006 2,39 2,45 2,30 2,30 11.4k

[trading2006]

Die Molecular Vision Ltd.
Molecular Vision ist ein noch relativ junges und höchst innovatives Spin-Off-Unternehmen, das sich aus der Imperial Innovations Ltd. heraus entwickelt hat. Die Aufgabe dieser Firma wiederum besteht darin, die zahlreichen Innovationen des auf den Gebieten der Naturwissenschaften, Ingenieurwissenschaften und Medizin überaus renommierten Imperial College in London durch die Bildung entsprechender Firmen zu vermarkten. An der Spitze von Molecular Vision Ltd. steht seit 2001 Prof. Donal Barney, ein international äußerst renommierter Physiker, unter anderem Mitglied der Royal Society, Leiter der physikalischen Abteilung der naturwissenschaftliche Fakultät des Imperial College, Gewinner des Latsis-Preis für Nano-Technologie 2005 als auch im selben Jahr des Jan-Rajchman-Preis für seine Forschungen auf dem Gebiet des Flat Panel Displays (das sind Flachbild-schirme wir etwa das TFT-Display eines Laptops; Anm. d. Red.). Die Enge des Agreements zwischen AcronGenomics und Molecular Vision dokumentiert sich unter anderem darin, dass Donal Barney dem wissenschaftlichen Beratungsgremium von AcronGenomics vorsitzt. Zusammen will man neue und revolutionäre POC-Geräte zur Sofortdiagnose von Diabetes, Geschlechtskrankheiten, kardiovaskulären Krankheiten (Herz und -Gefäße betreffende Kr.; Anm. d. Red.) und Drogenmissbrauch entwickeln. Was ist die BioLED-Technologie? Die BioLED-Technologie bezeichnet das gleiche Konzept wie Lab-On-a-Chip (LOC; Labor auf dem Chip, d.h. vollständige analytische Prozesse von Probenvorbereitung bis zur Auswertung sind auf einem scheckkartengroßen (Computer)Chip integriert, Anm. D. Red.), Point-of-Care (POC; Streifentests und Schnelltestgeräte etwa für Blutalkoholgehalt, Schwangerschaft, Diabetes usw.; Anm. D. Red.) und „miniaturized Total Analysis Systems“ (μTAS; miniaturisierte Komplettanalysesysteme; Anm. d. Red.). Die BioLED ist eine vollkommen neuartige Technologie, bei der durch die patentierte Kombination der Mikroströmungslehre (engl. microfluidics, das Strömungsverhalten von Flüssigkeiten in kleinsten Mengen; Anm. d. Red.) mit optischen Detektoren, basierend auf der organischen pLED (polymer Light Emitting Diode), eine Vielzahl von miniaturisierten tragbaren POC-Diagnose-geräten realisiert werden könne, die das Potential dazu hätten, medizinische Standarttests zu werden.

[trading2006]

AcronGenomics, gegründet 2004 und ehemals selbst ein innovatives Hightechunternehmen aus dem Nanotech-Bereich mit jetzigem Hauptsitz in Genf (Schweiz), versteht sich nunmehr als ein Unternehmen, das sich auf die Finanzierung und Kommerzialisieren neuartiger Technologien im medizinischen Bereich konzentriert. Am 22. Mai 2006 hat man deshalb ein Joint Development Agreement mit Molecular Vision Ltd. im Wert von 6.5 Mio. US$ geschlossen, um medizindiagnostische Produkte basierend auf der sog. BioLED-Technologie, einer Kombination aus Nano- und Biotechnologie, gemeinsam zu entwickeln und zu kommerzialisieren.

[trading2006]

Targeted Diseases
Diabetes

Diabetes mellitus (DM) is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin secretion, insulin action, or both. Diabetes can be associated with serious complications, such as:

Cardiovascular disease- a major complication and the leading cause of premature death among people with diabetes (about 75 percent of people with diabetes die from heart disease or stroke).
Kidney disease- also called Nephropathy is a condition that affects one-third or more of people who have had Type 1 (juvenile) diabetes for at least 20 years. About 10 to 40 percent of people with Type 2 (adult onset) diabetes also have kidney disease.
Blindness- diabetes is a major cause of blindness in the U.S. Diabetic retinopathy alone accounts for at least 12 percent of new cases of blindness each year in the U.S. People with diabetes are 25 times more at risk for blindness than the general population.
Nervous system disease- around 60 to 70 percent of diabetics have some type of nervous system damage or neuropathy, which includes decrease sensation in feet or hands, slowed digestion in the stomach, or carpal tunnel syndrome.
Dental disease- almost one third of people with diabetes has severe periodontal or gum diseases with loss of attachment of the gums to the teeth measuring 5 millimeters or more.
There are currently more than 194 million people with diabetes worldwide according to the World Health Organization (WHO). The National Information Clearinghouse estimates that DM costs the United States US$132 billion every year.

Sexually Transmitted Diseases (STDs)

Sexually transmitted diseases (STDs) -also called Sexually Transmitted Infections (STIs) - are a major global cause of acute illness, infertility, long term disability and death, with severe medical and psychological consequences for millions of men, women and children. The general term sexually transmitted disease (STD) is applied to any of the group of diseases that can be spread by sexual contact. STDs are caused by viruses, bacteria and parasites. There are at least 25 different STDs. The most common ones are the Acquired Immune Deficiency Syndrome (AIDS), Herpes Virus, Chlamydia, Syphilis, Human Papillomavirus (HPV), Hepatitis and Gonorrhea. The Medical Institute for Sexual Health in Texas estimates that 1 in 5 Americans between the ages of 15 and 55 are currently infected with one or more STDs, and 12 million Americans are newly infected each year. Also, the World Health Organization (WHO) states that in developing countries, STDs and their complications are amongst the top five disease categories for which adults seek health care. Direct medical costs associated with STDs in the United States are estimated at US$ 13 billion annually.

Cardiovascular disease

Cardiovascular disease (CVD) refers to diseases of the heart and blood vessel system (arteries, capillaries, veins). CVD claims more lives each year that the next 4 leading causes of deaths combined, which are cancer, chronic lowers respiratory diseases, accidents and diabetes mellitus. According to the World Health Organization (WHO), 16.7 million of people around the globe die of CVD each year. This is over 29 percent of all deaths globally. Today, men, women and children are at risk, and 80 percent of the burden is in low- and middle income countries. It is estimated that by 2010, CVD will be the leading cause of death in developing countries, whereas by 2020 heart diseases and strokes will be the leading cause of death and disability worldwide, increasing fatalities to more than 20 million yearly and to more than 24 million by 2030. (Atlas of Heart Disease and Stroke, WHO, September 2004). In U.S. the direct and indirect cost of CVD for 2006 is estimated to be US$ 403.1 billion, according to the American Social Health Association.

Drug abuse

Drug abuse refers to the use of illegal drugs or the inappropriate use of legal drugs. There are many reasons for drug abuse, including producing pleasure, alleviating stress, altering or avoiding reality. The negative impacts of the illicit drug trade touch every society in the world. This year\\'s World Drug Report estimates that 200 million people, or 5% of the global population age 15-64, have consumed illicit drugs at least once in the last 12 months. The medical cost of drug abuse was estimated by the National Centre for Health Statistics to be nearly $60 billion worldwide.


das verspricht das größte umsatzpotential: diabetes, eine immer weiter fortschreitende krankheit, die sogar schon jugendliche trifft.

[trading2006]

Future

BioLED Technology has the potential for the development of a vast spectrum of applications that may include:

Pharmaceutics
Drug discovery, drug testing (high throughput screening)
Environmental technology
Soil (also agriculture), water and air quality measurements
Veterinary Medicine
Early disease detection in animals and location of the source of pathogens of public health threats such as mad cow disease and avian flu
Biodefense - Homeland Security
Portable devices which sample the air for biowarfare agents e.g. anthrax spores etc.
Forensics
Automated processing of crime scene forensic evidence
Food industry
Food diagnostics, packaging (smart sensors), functional food testing


das ist doch mal was, schafft große umsatzerwartungen. leider erst in einigen jahren so wie ich das sehe

[trading2006]

What is Microfluidics?

Microfluidics refers to a set of technologies that control the flow of minute amounts of liquids or gases- typically measured in nano- and picoliters- in a miniaturized system. Designed in the nanometer scale, microfluidic chips incorporate pumps, valves, microchambers and microchannels (usually less than 100 nanometers wide) that direct samples from one compartment to the next on the chip.

Although the laws of physics do not change, as the scale at which fluids are studied decreases the effects driving and controlling fluid motion changes radically. This is because properties such as surface forces, surface tension, capillary effect, electronic charges, heat and mass transfer become dominant altering the system’s behavior dramatically. Microfluidics not only enable the very precise manipulation of minute amounts of fluids but may perform functions such as mixing, separating handling different components efficiently, rapidly and with little human intervention.

"Microfluidics is one of the 10 technologies
that will change the world"
(Microfluidics Technologies, BCC, March 2004)

Contrary to microelectronics, where miniaturization is achieved mainly by reducing in the size of the transistors, microfluidic devices require construction and design that differ from macroscale devices. More complex systems of channels with more sophisticated fluid-handling capabilities are necessary.

The advantages of such systems include:

Reduced size of devices ("readily portable" microfluidic chips)
Reduced fabrication cost.
Efficient use of expensive reagents.
Reduced volumes of rare samples.
Low fabrication cost allows disposability of the chips.
Multifuncionality and speed.
Ease of use and enhanced safety.
Precise volumetric control of samples and reagents leading to higher sensitivities in analytical applications.
High throughput biological screening made possible by faster sampling times through parallel processing of samples.
Low power consumption.
Can be combined or integrated with other systems like MEMS (Micro-Electro-Mechanical Systems), NEMS (Nano-Electro-Mechanical Systems) to produce highly efficient μTAS (Miniaturized Total Analysis Systems), LOC (Lab-On-a-Chip) or POC (Point-of-Care) devices to form portable "all-in-one" devices able to perform complex functions.
Applications

"As the number of experiments has grown, the devices used to carry them out have shrunk, and the strategy of "smaller is better" has begun to transform the world of fluidics as it transformed the world of electronics."
(G. Whitesides, Mallinckrodt Professor of Chemistry and Chemical Biology at Harvard University -The Industrial Physicist, Aug/Sept 2003)

Microfluidics, due to recent advances in fluidics, microelectronics and integrated system technologies has penetrated to a number of diverse markets including printing, industrial automation, power management systems and life sciences.

The Life Science segment of the microfluidics market demonstrates the largest and fastest growth rate and is divided into:

Drug Discovery (Combinatorial Chemistry, High Throughput Screening, Quality Control)
Medicine (Diagnostics, Therapeutics)
Biotechnology (Genomics, Proteomics, Cell Sorting and counting)
Ecology (Food, Air/Water)
Microfluidics delivers advanced flexibility. A conventional diagnostic test follows a protocol that involves a series of processes and utilizes a number of bulky and expensive instruments that may take up the space of an entire bench. Moreover, specialized laboratory technicians are needed to perform the test.

A microfluidics-based assay can perform the same diagnostic test in a space smaller than the size of a credit card, requiring minimum human intervention. The advantages of such systems are the reason for the continuous penetration of microfluidics in markets that were traditionally driven by other technologies.

Links:
MIFLUS – Microfluidics Terminology Tree

References:

"A New Wave of Microfluidic Devices" by Jennifer Ouellette, The Industrial Physicist, August/September 2003.
Global Watch Technology Partnering, Information Technology, Electronics & Communications Sector Report (November 2005)
"Microfluidics", P. Kallio and J. Kuncova, TEKES, National Technology Agency, Technological Review 158/2004.

[trading2006]

Current - POC Diagnostics

Following a primary market research, a number of potential POC diagnostic device applications were evaluated in terms of feasibility, market needs, revenue generating potential, market growth rate and competition. Among these, four disease areas were chosen to be our primary targets for BioLED device development. These POC devices will enable on-the-spot quantitative and qualitative diagnosis from a few drops of blood, urine or saliva for:

Diabetes Management (Kidney Markers):
The prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030 (Global Prevalence of Diabetes. Diabetes Care 27:1047-1053, 2004). Microalbuminuria (MAU), a well known diabetic nephropathy marker, is defined by increased urinary Human Serum Albumin (HSA) excretion. If diagnosed at an early stage, MAU can be treated before its progression to the development of diabetic nephropathy (kidney failure). Approximately 25 – 30% of all diabetics develop evidence of nephropathy.

Sexually Transmitted Diseases (STDs):
STDs remain a major public health challenge in both developed and developing countries. According to the World Health Organization (WHO), more than 340 million new cases of sexually transmitted infections occur every year, worldwide, in people aged 15-49 years.
These infections can be a major cause of illness, infertility and even death. Most of them, however, can be treated and cured easily and with low cost, if diagnosed early enough.

Cardiovascular Diseases (Cardiac Markers):
Cardiovascular diseases are responsible for the deaths of 17 milion people worldwide each year, making them the developed world’s leading cause of death according to the World Health Organization. 32 million heart attacks and strokes per year demonstrate the need for the development of accurate, cost efficient and accessible diagnostics. Conventional diagnostic techniques, however, are costly, time consuming and of limited predictive potential. A smarter diagnostic approach is the in vitro measurement of various cardiac biomarkers of high preventive value, using a POC device.

Substances of Abuse:
According to the World Drug Report 2005, 5% of the global population have consumed illicit drugs at least once in the last 12 months. This number (about 200 million people) illustrates the severity of substance abuse as a major healthcare and socioeconomic problem. Diagnosis of substances of abuse is imperative to the judicial system, professional, professional sports, large corporations and healthcare. Easy, fast, simple and on-site diagnosis has considerable commercial value and huge revenue generating potential.

[trading2006]

Strategic Alliances

Acrongenomics utilizes its extensive international network and qualified management team to scout out and invest in dynamic research projects. To that extent Acrongenomics has established a Strategic Alliance with the UK based Molecular Vision Ltd.

Molecular Vision is a spin-out company of Imperial Innovations Ltd. The company was founded in 2002 in order to meet a clearly defined demand in the medical diagnostics, biosensors and analytical instrumentations markets: the need for miniaturized chemical and biological detectors offering high sensitivity and functionality at low cost. The company has directly addressed this market demand by inventing a novel method for optical detection based on recent advances in organic electronics and light emitting diodes combined with microfluidics technology. The company has mainly focused on applying its technology to the medical diagnostics markets.

[trading2006]

Vision and Goals

Acrongenomics\\' goal is to advance the Medical Diagnostics industry and accomplish industry-leading growth by establishing our technology platform worldwide. Through innovative and advanced medical diagnostic applications, we aim to provide the most efficient and sustainable means of delivering new value to the marketplace.

We are also committed to contribute to the human health and quality of life by exploring new scientific approaches and continuously considering:

Business
By sponsoring new innovative ideas and transforming them into commercial opportunities.

Social Welfare
By providing the market with superior technology designed to serve the common good.

Our People
By expanding our qualified team of business professionals to further support our technology pipeline.

Acrongenomics is dedicated to sustain a code of contact that is defined by a list of values like:

ACHIEVEMENT: We value the active pursuit of excellence, demonstrated by continuous improvement in standards, quality, speed and timeliness. Our collective ability to get results and accomplish our goals adds priceless value to the Company. We are committed to winning in today\\'s competitive market.

INNOVATION: Innovation is fundamental for Acrongenomics’ success. We value creativity—the ability of people to develop new ways to identify opportunities and solve problems. We utilize our skills to search for and apply new technologies, approaches and business solutions which will contribute to the development of new diagnostic platforms.

INTEGRITY: At Acrongenomics we insist on applying the highest ethical standards and adherence to Company values. All employees have the responsibility to conduct their business relationships with the highest level of professionalism and integrity.

SCIENCE: We invest on ground-breaking technologies. We are committed to nurturing breakthrough technological platforms within our framework of focused strategic directions.

[trading2006]

Board of Directors

Constantine Poulios LL.M
President

Mr. Poulios, 36, was appointed to the Board of Directors as Vice President on July 7, 2004 and as President on February 14, 2006. He has extensive experience in serving multinational companies in the rigorous environment of the Sarbanes-Oxley legislation. An attorney by education and profession, he was part of the Corporate and Tax Advisory Services of Ernst & Young before joining Acrongenomics, Inc. Mr. Poulios was managing important accounts including that of Coca Cola, Halliburton, Hewlett Packard, ABN AMRO, Citigroup, Ciments Francais, Pfizer, GlaxoSmithKline and EMI Music for Ernst & Young Southeast Europe, while he has also worked for Ernst & Young LLP in the US. He obtained his Master\\'s of Laws from Northwestern University School of Law in Chicago in 1997, while he is a 1995 graduate from the School of Law at the National University of Athens. Mr. Poulios has also been awarded with a Certificate in Law in 1993 from the School of Law at the University of Bordeaux in France and he has attended graduate courses in management from top US universities.


Platon Tzouvalis MSc
Vice President, Chief Operating Officer

Mr. Tzouvalis, 41, was appointed Vice President of Acrongenomics, Inc. on February 14th, 2006. As a Biochemist and ex-Abbott Laboratories Associate, he is an experienced pharmaceutical industry professional. He has been a member of Acrongenomics\\' Scientific Advisory Board since May 2004. His expertise lies in the areas of Quality Control, Operational Procedures as well as Pharmaceutical Product and Process Improvement. He received his B.Sc. Degree in Biochemistry from the University of Illinois in 1990 and his Master\\'s Degree in the same field from DePaul University at Chicago in 1995. Mr. Tzouvalis\\' earlier career includes working as a Research Chemist in collaboration with the University of Illinois at Chicago, holding the position of Research and Development Chemist at SynQuest, Inc. and as Advanced Quality Assurance Specialist of Organic Operations and then Project Manager in Bioanalytical Quality Assurance for Abbott Laboratories. Mr. Tzouvalis has also been awarded with the Abbott Diagnostics Division Science Award of 2002 as part of the Organic Operation Remediation Team.


Ron Lizèe B.Comm. CGA. CFP
Chief Financial Officer

Mr. Lizèe, 52, was appointed Chief Financial Officer of Acrongenomics in 2004. Mr. Lizèe has over 25 years experience in the fields of tax, accounting and auditing.


Manos Topoglidis PhD
Chief Technology Officer

Dr. Topoglidis, 32, was appointed to the Board of Directors and Scientific Advisory Board on February 24, 2006 as Chief Technology Officer. He received his Bachelor’s of Science from King’s College (University of London) in 1996, his MSc in Biochemistry from Imperial College London in 1997 and his Ph.D. in Chemistry (Biosensors and Nanomaterials) from Imperial College London in 2001. His research interests and expertise lie in the areas of Biosensors, Nanomaterials, Biotechnology and Nanotechnology. He has worked as a research fellow at the Center of Electronic Materials and Devices of Imperial College London and as manager of European and National programs at the MESL laboratory of the National Centre for Scientific Research, Demokritos in Athens. He is a member of the Electrochemical and British Biochemical Societies. Dr. Topoglidis has impressive experience leading international research teams in academia to unlock nanotechnology solutions. He ranks among the first to extensively research the use of nanoporous surfaces for biosensing applications and has written numerous original nanotechnology-related publications, which have been cited worldwide.

[AMERIBULL]

RT 1,80 USD !

[AMERIBULL]

Bid zieht an...

[AMERIBULL]

ASK 1,80 USD
BID 1,70 USD

[AMERIBULL]

[trading2006]

Börse
NASDAQ OTC BB

Aktuell
1,80 USD

Zeit
25.07.06 20:11

Diff. Vortag
-4,76 %

Tages-Vol.
24.909,30

Gehandelte Stück
13.659

Geld
1,65

Brief
1,80

Zeit
25.07.06 16:44

Spread
8,33%

Geld Stk.
500

Brief Stk.
--

[trading2006]

war ja mal richtig umsatz in der bude

[trading2006]

Börse
Frankfurt

Aktuell
1,55 EUR

Zeit
26.07.06 09:19

Diff. Vortag
+7,64 %

Tages-Vol.
1.550,00

Gehandelte Stück
1.000

Geld
1,43

Brief
1,53

Zeit
26.07.06 09:20

Spread
--

Geld Stk.
750

Brief Stk.
750

[trading2006]

werde den wert mal in meiner WL beobachten.

[trading2006]

Börse
Berlin-Bremen

Aktuell
1,50 EUR

Zeit
26.07.06 09:19

Diff. Vortag
+0,67 %

Tages-Vol.
1.500,00

Gehandelte Stück
1.000

Geld
1,36

Brief
1,50

Zeit
26.07.06 09:19

Spread
9,33%

[Inspektor_Clouseau]

+++NEWS+++NEWS++++++NEWS+++NEWS++++++NEWS+++NEWS++++++NEWS+++NEWS+++

Acrongenomics Inc. and Molecular Vision Ltd. Take Further Steps towards the First Milestone for Diabetes Monitoring

Thursday October 5

GENEVA--(BUSINESS WIRE)--Acrongenomics, Inc. (OTCBB:AGNM) and Molecular Vision, Ltd. -- an Imperial Innovations spin-out company -- today present a second R&D update of their joint collaboration, following the meeting that took place on 27th September 2006 at Acrongenomics' headquarters in Geneva. The ultimate goal of the partnership is to develop and commercialize smart Point-of-Care (POC) diagnostic devices based on the innovative technology platform offered by Molecular Vision's experts.

The devices, being developed upon mutually set milestones, will enable personalized on-the-spot analysis for:

diabetes monitoring through albumin/creatinine detection in urine
detection of cardiac markers
detection of STDs (Sexually Transmitted Diseases), and
detection of substances of abuse
Both parties are working towards a generic research prototype to be delivered at the beginning of 2007. Development steps include the design and fabrication of stand-alone product models based around chemiluminescence detection. The products will comprise a microfluidic substrate, an organic photodetector, a printed circuit board, a display and a battery.

Dr. Jingsong Huang, a principal research scientist at Molecular Vision Ltd, presented our technology's latest results at the OEC 2006 conference that took place in Frankfurt, in a talk entitled "Application of polymer electronic devices in miniaturized diagnostic detection systems". Dr. Huang reported on the fabrication on a chip-based diagnostic device by integration of a pLED and a polymer photodetector with a microfluidic analysis system. Details of the integration process and the optimization of the components were also presented.

In the coming months a series of microfluidic devices, able to handle blood samples, will be tested and the most suitable blood pretreatment methods and assays will be determined. This work, which is being partially funded by the UK Government's Health Technology Devices (HTD) Scheme, will provide the basis for the development of the next POC diagnostic devices capable of detecting cardiovascular markers.

The company also announces that Mr. Platon Tzouvalis MSc Vice President of Acrongenomics, Inc. has been appointed President of Acrongenomics, Inc., replacing Constatine Poulios who has stepped down from the company to pursue other opportunities.

About Acrongenomics, Inc.

Acrongenomics Inc., is a publicly traded company that focuses on investing and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-oriented applications. The company's headquarters are located at Geneva, Switzerland.

About Molecular Vision, Ltd.

Molecular Vision is a spin-off company of Imperial Innovations Ltd. The company was founded to meet a clearly defined demand in the medical diagnostics, biosensors and analytical instrumentations markets. The technology emerged for covering the need for miniaturized chemical and biological detectors offering high sensitivity and functionality at low cost. The company has directly addressed this market demand by inventing a novel method for optical detection based on recent advances in organic electronics and light emitting diodes combined with microfluidics technology. The company has mainly focused on applying its technology to the medical diagnostics markets.

[Inspektor_Clouseau]

Totgesagte leben eben länger.

Und Acrongenomics entwickelt sich offenbar nicht schlecht.

Auch der Chart stimmt wieder sehr zuversichtlich:

[Inspektor_Clouseau]

Nach der Bereinigung nun endlich ein Boden!!
Und was das Schönste ist: die Umsätze ziehen ganz offensichtlich richtig an!!!

[Inspektor_Clouseau]

+++NEWS+++NEWS++++++NEWS+++NEWS++++++NEWS+++NEWS++++++NEWS+++NEWS++++++NEWS+++NEWS++++++NEWS+++NEWS+++

"Molecular Vision, Pearson Matthews, Acrongenomics and Imperial College London Secure GBP 440,000 (US $825,000) Award from the UK National Health Service
Friday September 15, 10:26 am ET

GENEVA--(BUSINESS WIRE)--Sept. 15, 2006--Molecular Vision Ltd in partnership with Acrongenomics, Inc. (OTCBB:AGNM - News), Pearson Matthews Ltd, and Imperial College London has today been awarded GBP 440,000 (US $825,000) by the UK Government's Health Technology Devices (HTD) Scheme for the development of a line of low cost, easy-to-use and portable point-of-care diagnostic devices for testing of cardiovascular health. The HTD scheme, which provides 50% funding, aims to stimulate new and innovative health care technologies designed to improve significantly the quality of healthcare in the United Kingdom.
ADVERTISEMENT

Molecular Vision's patented diagnostic devices will allow for accurate on-the-spot qualitative and quantitative diagnosis of cardiovascular diseases at first consultation, eliminating the need for patients to make repeat visits and so bringing forward the initiation of treatment, thereby freeing up clinical time, and lowering treatment costs.

The proposed devices have the potential to become a de-facto standard for medical testing and are based on the novel BioLED technology platform, which Molecular Vision is commercializing in partnership with Acrongenomics, Inc. (OTCBB:AGNM - News). BioLED technology will allow the development of readily portable POC devices for a broad range of medical applications by exploiting two powerful technologies: microfluidics and organic semiconductor devices (light emitting diodes and photodetectors).

Organic polymer light emitting diodes have been the subject of intense scientific and commercial interest since their discovery at Cambridge University in 1989 by Molecular Vision co-founder Professor Donal Bradley -- now Head of the Department of Physics at Imperial -- and his colleagues. This early development led Professor Bradley and colleagues to found Cambridge Display Technology Ltd (NASDAQ: OLED - News).

Commenting on the HTD award, Professor Bradley said, "This is a tremendous step forward for our company. This new consortium brings together wide ranging expertise in the development and commercialisation of medical technologies, and will allow us to dramatically accelerate our product development plans."

About Molecular Vision Ltd

Molecular Vision is a spin-out company of Imperial Innovations Ltd. The company was founded by three Imperial College London researchers -- Prof. Donal Bradley, Prof. Andrew de Mello and Dr. John de Mello -- in 2002 in order to meet a clearly defined demand in the medical diagnostics, biosensors and analytical instrumentations markets: the need for miniaturized chemical and biological detectors offering high sensitivity and functionality at low cost. The company has directly addressed this market demand by inventing a novel method for optical detection based on recent advances in organic electronics and light emitting diodes combined with microfluidics technology. The company has mainly focused on applying its technology to the medical diagnostics markets. Molecular Vision recently signed a GBP 3.45 million (US $6.5 million) development contract with Acrongenomics Inc. to jointly exploit and commercialise the technology.

About Imperial College London

Consistently rated in the top three UK university institutions, Imperial College London is a world leading science-based university whose reputation for excellence in teaching and research attracts students (11,000) and staff (6,000) of the highest international quality. Innovative research at the College explores the interface between science, medicine, engineering and management and delivers practical solutions that enhance the quality of life and the environment -- underpinned by a dynamic enterprise culture.

About Pearson Matthews Ltd

Pearson Matthews is a specialist design development company with 20 years experience specifically in the healthcare sector for companies in the UK, US and Europe. Started in 1983 by Mike Pearson, they have built a reputation around innovation and the development of breakthrough products. Pearson Matthews is ISO9001 accredited, giving it the ability to handle major projects from early R&D through to manufacture.

About Acrongenomics Inc.

Acrongenomics Inc. is a publicly traded company that focuses on investing in and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications. The company has its headquarters in Geneva, Switzerland.

About the Health Technology Devices Scheme

The Health Technology Devices Scheme was set up by the UK National Health Service (NHS) to stimulate, commission and monitor collaborative R&D on innovative new health technology devices that would improve the health and wealth of the UK. The aim of the scheme is to facilitate links between companies, science-based researchers, NHS professionals and patient consumer groups in order to deliver innovative medical and technological devices that assist implementation of the NHS."

[Inspektor_Clouseau]

Schaut es euch mal an!!!

[Inspektor_Clouseau]

Hier ein Paar Infos auf Deutsch:

http://www.hotstock-kurier.de/Text/Archiv/HotStock-Kurier7_2…

[Inspektor_Clouseau]

Noch haben wir eine Seitwärtsbewegung bei relativ hohen Umsätzen drüben.

Ich persönlich glaube, dass der Chart am Boden ist!
Meine Meinung

[Inspektor_Clouseau]

Es geht Vorwärts:

"Acrongenomics Inc. and Molecular Vision Ltd. Take Further Steps towards the First Milestone for Diabetes Monitoring
Thursday October 5, 1:30 pm ET

GENEVA--(BUSINESS WIRE)--Acrongenomics, Inc. (OTCBB:AGNM - News) and Molecular Vision, Ltd. -- an Imperial Innovations spin-out company -- today present a second R&D update of their joint collaboration, following the meeting that took place on 27th September 2006 at Acrongenomics' headquarters in Geneva. The ultimate goal of the partnership is to develop and commercialize smart Point-of-Care (POC) diagnostic devices based on the innovative technology platform offered by Molecular Vision's experts.

The devices, being developed upon mutually set milestones, will enable personalized on-the-spot analysis for:

* diabetes monitoring through albumin/creatinine detection in urine
* detection of cardiac markers
* detection of STDs (Sexually Transmitted Diseases), and
* detection of substances of abuse

Both parties are working towards a generic research prototype to be delivered at the beginning of 2007. Development steps include the design and fabrication of stand-alone product models based around chemiluminescence detection. The products will comprise a microfluidic substrate, an organic photodetector, a printed circuit board, a display and a battery.

Dr. Jingsong Huang, a principal research scientist at Molecular Vision Ltd, presented our technology's latest results at the OEC 2006 conference that took place in Frankfurt, in a talk entitled "Application of polymer electronic devices in miniaturized diagnostic detection systems". Dr. Huang reported on the fabrication on a chip-based diagnostic device by integration of a pLED and a polymer photodetector with a microfluidic analysis system. Details of the integration process and the optimization of the components were also presented.

In the coming months a series of microfluidic devices, able to handle blood samples, will be tested and the most suitable blood pretreatment methods and assays will be determined. This work, which is being partially funded by the UK Government's Health Technology Devices (HTD) Scheme, will provide the basis for the development of the next POC diagnostic devices capable of detecting cardiovascular markers.

The company also announces that Mr. Platon Tzouvalis MSc Vice President of Acrongenomics, Inc. has been appointed President of Acrongenomics, Inc., replacing Constatine Poulios who has stepped down from the company to pursue other opportunities."

[Inspektor_Clouseau]

Und schaut euch mal den Chart an:
abgesehen von den letzten Kursanstiegen nehmen die Umsätze rasant zu

[Inspektor_Clouseau]

UNd drüben haben wir wieder HAmmerumsätze!!

[Inspektor_Clouseau]

Es geht weiter: noch ein Schritt und der Abwärtstrend ist gebrochen!

[Inspektor_Clouseau]

Und die Umsätze sind noch immer heftig!!

[Inspektor_Clouseau]

[Inspektor_Clouseau]

Na also: Schaut euch mal den Chart an. ICh hab´s Euch ja gesagt

[Inspektor_Clouseau]

Vor allem scheint der Aufwärtstrend überhaupt kein Ende zu kennen!

[Inspektor_Clouseau]

Da ist jetzt echt Musik drin!

[Inspektor_Clouseau]

Und dabei sehen wir gerade einmal eine Erholung.
Mehr ist das noch nicht.

Da kommt noch was!

[Inspektor_Clouseau]

Und heute drüben schon wieder +7 Prozent bei guten Umsätzen!!
Super!

[spiritrob]

ja inspektor, das freut auch mich.
und wenn sie noch mal 100% steigt bin ich auch wieder pari

schönen abend

[Inspektor_Clouseau]

Antwort auf Beitrag Nr.: 28.154.601 von spiritrob am 06.03.07 20:34:57

Ich bin es längst, denn ich habe nachgekauft!!

[Inspektor_Clouseau]

Und jetzt noch einmal +30 Prozent. Ha! Heute knallen die Sektkorken!

[Inspektor_Clouseau]

So sieht eine Kerze aus!

[spiritrob]

bioled erfolgreich demonstriert
http://biz.yahoo.com/bw/070312/20070312005751.html?.v=1

[Inspektor_Clouseau]

Und der Kurs steigt und steigt und steigt.

HIer wie drüben!!

[Inspektor_Clouseau]

Und schon wieder +13 Prozent!!!

[spiritrob]

clouseau, ich glaube du verfolgst ja schon länger die spur von acrongen, nicht wahr?
kennst du deren pläne, ich meine, wann haben die mal vor, umsätze zu machen, und wenn, wie viel?